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The estrogen receptor-binding fragment-associated gene 9 (EBAG9) has received increased 
attention as an independent prognostic marker for disease-specific survival since in some 
human tumor entities high expression levels correlate with tumor progression and poor 
clinical prognosis. Interestingly, EBAG9 was identified as an ubiquitously expressed Golgi 
protein. Recent data demonstrate an involvement in regulated exocytosis in secretory cells and 
the cytotoxic functions of lymphocytes. However, EBAG9 is expressed in essentially all 
mammalian tissues, and in epithelial cells it has been identified as a modulator of tumor-
associated O-linked glycan expression, a hallmark of many carcinomas.  
This thesis addresses the pathogenetic link between EBAG9 expression and the alteration of 
the cellular glycome. To gain further insights into the cellular functions of EBAG9 in 
epithelial cells, tumor-associated EBAG9 overexpression was mimicked in living cells. It was 
demonstrated that EBAG9 associates with anterograde COPI-coated carriers and shuttles 
between the ER-Golgi intermediate compartment and cis-Golgi stacks. EBAG9 
overexpression imposes a delay in anterograde ER-to-Golgi transport and mislocalizes 
components of the ER quality-control and glycosylation machinery. Conversely, EBAG9 
downregulation accelerates glycoprotein transport through the Golgi and enhances 
mannosidase activity. Functionally, EBAG9 impairs ArfGAP1 recruitment to membranes and 
consequently, interferes with the disassembly of the coat lattice at the cis-Golgi prior to 
fusion. 
Thus, EBAG9 acts as a negative regulator of a COPI-dependent ER-to-Golgi transport 
pathway in epithelial cells and represents a novel pathogenetic principle in which interference 
with intracellular membrane trafficking results in the emergence of a tumor-associated 
glycome. 
 
Keywords: anterograde transport, COPI, EBAG9, glycosylation, immunomodulation, 





EBAG9 (estrogen receptor-binding fragment-associated gene 9) hat als unabhängiger prog-
nostischer Marker viel Aufmerksamkeit erregt, da in einigen Tumoren hohe Expressionsraten 
und Tumorentwicklung korrelieren. In diesen Fällen ist eine hohe EBAG9 Expression häufig 
mit einer schlechten klinischen Prognose verbunden. EBAG9 ist ein ubiquitär exprimiertes 
Golgi Protein. Aktuelle Daten demonstrieren, dass es in sekretorischen Zellen an der regulier-
ten Exozytose und an der zytotoxischen Funktion von Lymphozyten beteiligt ist. In epithelia-
len Zellen führt es zur Generierung von Tumor-assoziierten O-Glykanen, welche ein Erken-
nungsmerkmal vieler Krebsarten sind.  
In dieser Arbeit wurde der pathogenetische Zusammenhang zwischen EBAG9 Expression und 
der Veränderung des zellulären Glykoms untersucht. Um einen tieferen Einblick in die zellu-
läre Funktion von EBAG9 in epithelialen Zellen zu gewinnen, wurden Zellen mit tumor-
ähnlicher EBAG9 Expression verwendet. Innerhalb dieser Arbeit wurde demonstriert, dass 
EBAG9 mit anterograden COPI Vesikeln assoziiert und zwischen dem ER-Golgi intermediä-
ren Kompartiment und cis-Golgi pendelt. EBAG9 verursacht eine Verzögerung des anterogra-
den Transportes vom ER zum Golgi und verändert die Lokalisation von Komponenten der ER 
Qualitätskontrolle und des Glycosylierungsapparates. Auf der anderen Seite beschleunigt die 
verminderte Expression von  EBAG9 den Proteintransport durch den Golgi und verstärkt die 
Aktivität von Mannosidase II. Mechanistisch betrachtet verhindert EBAG9 die Rekrutierung 
von ArfGAP1 an die Membran. Dies beeinträchtigt das Auflösen der COPI Vesikelhülle und 
somit die Fusion von Vesikeln am cis-Golgi. 
Damit agiert EBAG9 in epithelialen Zellen als negativer Regulator des COPI-abhängigen ER-
Golgi Transportes und stellt damit ein neues phatogenetisches Prinzip dar, bei dem die Beein-
flussung des intrazellulären Transportes zu der Entstehung von Tumor-assoziierten Glykanen 
führt. 
 
Schlagwörter: anterograder Transport, COPI, EBAG9, Glykosylierung, Immunmodulation, 






1.1 The tumor associated antigen EBAG9 
Estrogen receptor-binding fragment-associated antigen 9 (EBAG9), which was isolated by the 
use of the CpG-genomic binding site cloning method (Watanabe, et al., 1998), was reported to 
be identical to RCAS1 (receptor-binding cancer antigen expressed on SiSo cells) (Ikeda, et 
al., 2000). RCAS1 was initially defined by the 22.1.1 monoclonal antibody (mAb), which was 
raised by immunization of mice with the human uterine cervical adenocarcinoma cell line 
SiSo (Sonoda, et al., 1996). Cell surface staining with mAb 22.1.1 was shown 
immunohistochemically in a large number of different tumor tissues, and in some tumor 
entities 22.1.1, staining correlated well with poor clinical prognosis (Izumi, et al., 2001; 
Nakakubo, et al., 2002). A soluble form of the 22.1.1 antigen was purified from the 
supernatant of cultured SiSo cells (Sonoda, et al., 1996). Expression cloning led to the 
isolation of a cDNA apparently encoding the 22.1.1 antigen (Nakashima, et al., 1999). 
However, recent studies demonstrated that the EBAG9 gene-product and the 22.1.1 defined 
antigen are structurally and functionally separate antigens (Reimer, et al., 2005). In fact, it 
was shown that EBAG9 is not recognized by the 22.1.1 mAb. Instead, the 22.1.1 mAb 
recognizes the Tn-glycan antigen, which appears upon EBAG9 overexpression on the cell 
surface of HEK293 cells (Engelsberg, et al., 2003).  
 
1.1.1 Features of EBAG9 protein 
EBAG9 is highly conserved in phylogeny, and data bank screens revealed that there are no 
homologies to any other known genes or proteins. The predicted amino acid sequences of 
murine and canine EBAG9 showed 98 % and 96 % homologies with those of human EBAG9, 
respectively (Sonoda, et al., 2008). Furthermore, evolutionary highly conserved proteins 
orthologous to EBAG9 are found in rat (Rattus norvegicus), canine (Canis familiaris), 
Xenopus (Xenopus laevis) und Zebrafish (Danio rerio). However, no homolog exists in yeast. 
Ikeda et al. (2000) discovered that the human EBAG9 gene is located at chromosome 8q23 
and is frequently amplified in breast tumors. The EBAG9 cDNA sequence is 1060 bp long 
and includes a coding region of 639 bp. The protein itself consists of 213 amino acids and has 
a predicted molecular weight of 24 kDa. Using a polyclonal serum against recombinant 




32 kDa (Tsuchiya, et al., 2001). This difference can not be explained either by N- or O-
glycosylation of the protein (Engelsberg, et al., 2003). Additionally, Sonoda et al. (1996) 
showed that mAb 22.1.1 immunoprecipitates generated a 78-kDa signal in SDS-PAGE gels 
under reducing and non-reducing conditions. Here, a homodimerization via the C-terminal 
coiled-coil region was suggested (Nakashima, et al., 1999). According to sequence 
predictions, EBAG9 has been postulated to be a type II transmembrane (TM) protein with an 
N-terminal TM region (amino acids 8–27) and an extracellular C-terminal coiled-coil region 
(amino acids 179–206), which is also highly conserved in human EBAG9 (Fig. 1-1). 
  
 
Fig. 1-1: Protein structure of EBAG9. Sequence prediction was carried out by „TMbase Server“ (Hofmann 
and Stoffel 1993) and „Coiledcoil prediction Server“ (Lupas, et al., 1991). TM = transmembrane domain; CC = 
coiled-coil domain. 
 
EBAG9 mRNA as well as protein is ubiquitously expressed, but expression levels vary among 
tissues. The protein can be detected in the brain, spleen, lung, liver kidney, and testis as well 
as in the embryo at day 12, 14 and 16 dpc (days post coitus). Furthermore, relatively low 
expression levels were observed in the heart, uterus, and ovary, and at negligible levels in 
skeletal muscle (Tsuchiya, et al., 2001). Engelsberg et al. (2003) demonstrated that EBAG9 is 
predominantly localized in the Golgi. From deletion mutant studies it was concluded that the 
transmembrane domain of EBAG9 is responsible for its localization and sorting to the Golgi 
complex. Furthermore, Ruder et al. (2005) revealed that palmitoylation contributes to 
membrane association of EBAG9 and suggested that this anchor facilitates dynamic 
redistribution of EBAG9 in neuroendocrine cells.  
 
1.1.2 EBAG9 and cancer 
EBAG9 has been identified as a primary estrogen-responsive gene from a cDNA library of 
MCF-7 human breast cancer cell line (Watanabe, et al., 1998). Estrogen plays important roles 
in many biological processes, including the regulation of growth development and cell-type-
specific gene expression in the reproductive tract (Couse and Korach, 1999), central nervous 




Garcia, 1997). These diverse functions are mediated by the estrogen receptors (ERα and β) 
which are members of the steroid-thyroid hormone receptor superfamily (Evans, 1988). The 
estrogen receptors bind to an estrogen responsive element (ERE) located in the promoters of 
responsive genes in a ligand-dependent manner and directly regulates their transcription 
(Nilsson, et al., 1998; Nilsson, et al., 2001). Furthermore, the estrogen receptors regulate gene 
expression by associating with other promoter-bound transcription factors. In MCF-7 cells it 
has been shown that EBAG9 mRNA is upregulated by estrogen and that its promoter responds 
to estrogen through the complete palindromic ERE, located in the 5´-upstream region of the 
gene. This binding increases the transcription rate by 0.5-3.2 times (Ikeda, et al., 2000; 
Watanabe, et al., 1998). Additionally, there might be estrogen-independent regulatory 
mechanisms of EBAG9 transcription, since putative binding motifs (GC-boxes and E-boxes) 
exist as well (Ikeda, et al., 2000). Alterations in the response to estrogen are associated with a 
variety of hormone-dependent diseases such as breast cancer, endometrial cancer, 
cardiovascular disease, and osteoporosis (Henderson and Feigelson, 2000; Ikeda, et al., 2000; 
Park, et al., 2005; Suzuki, et al., 2004; Tsuchiya, et al., 2001; Watanabe, et al., 1998). 
EBAG9 overexpression has been recorded in a multitude of human epithelial cancers and has 
been proposed to correlate with tumor progression. Accordingly the molecule was introduced 
as an independent prognostic marker for disease-specific survival (Akahira, et al., 2004; 
Ogushi, et al., 2005; Suzuki, et al., 2004; Takahashi, et al., 2003; Tsuneizumi, et al., 2001). 
Interestingly, EBAG9 was shown to induce the surface deposition of the truncated O-linked 
glycans Tn (GalNAc) and the closely related TF (Thomsen-Friedenreich, Galβ1-3GalNAc) 
antigen at the cell surface in non-secretory cells (Engelsberg, et al., 2003). Using an Tn-
antigen reactive antibody, elevated amounts of the truncated O-glycan Tn were detected in 
several tumor entities correlating with poor prognosis (Akashi, et al., 2003; Enjoji, et al., 
2002; Okada, et al., 2003; Sonoda, et al., 1996). These results pointed towards an indirect, 
modulatory role of EBAG9 in the process of Tn antigen generation. Functionally, TF and Tn 
antigens were suggested to contribute to the pathogenesis of tumors through mediation of 
adhesion, invasion, and metastasis (Baldus, et al., 2000; Cavallaro and Christofori, 2001; 
Hakomori, 2002; Tsuiji, et al., 2003). Such glycan epitopes are normally cryptic in healthy 
and benign tissues, except in early embryonic stages (Springer, 1984). One conclusion has 
been that EBAG9 contributes indirectly to the antigenicity of tumor cells by modulating Tn 




1.1.3 Biological functions of EBAG9 
Despite its putative role in tumor progression, the pathophysiological function of EBAG9 has 
not yet been well defined. Recombinantly expressed EBAG9 was suggested to bind to a yet 
unidentified receptor, which was supposed to be expressed on activated immune cells. Cell 
culture supernatant from SiSo cells inhibited proliferation of activated T cells and induced 
apoptotic cell death in receptor-bearing cells. Therefore, EBAG9 was proposed as a new death 
receptor ligand involved in tumor immune escape (Nakashima, et al., 1999). Moreover, it has 
been suggested that EBAG9 is involved in down-regulation of the maternal immune response 
during pregnancy (Ohshima, et al., 2001). Matsushima et al. (2001) demonstrated that 
EBAG9 expression by bone marrow macrophages is important in the regulation of 
erythropoiesis by induction of apoptosis in erythroid progenitor cells. Thereby the role of 
EBAG9 was extended to a general cell death-inducing system according to the Fas/Fas ligand 
system (Matsushima, et al., 2001). These studies mainly used the 22.1.1 antibody or the cell 
culture supernatant from SiSo cells. However, as already indicated, recent studies 
demonstrated that the EBAG9 gene-product and the 22.1.1 defined antigen are structurally 
and functionally separate antigens (Reimer, et al., 2005). This discrepancy sheds doubt on the 
proposed function of EBAG9 as an apoptosis-inducing death receptor ligand. 
On the other hand, a recent study in neuroendocrine PC12 cells demonstrated that EBAG9 
induces a downregulation of [Ca
2+
] regulated secretion, but essentially no glycan alteration 
(Ruder, et al., 2005). Together with the identification of Snapin, a SNARE (soluble N-
ethylmaleimide-sensitive factor attachment protein receptors) associated molecule as an 
interaction partner, these results pointed to a role for EBAG9 in the secretory pathway. 
Mechanistically, the phosphorylation of Snapin, which is a modulator of synaptotagmin-
associated regulated exocytosis, was reduced. This in turn decreased the association of Snapin 
with the synaptosome-associated proteins of 23 and 25 kDa (SNAP23 and SNAP25), 
followed by a decrease in synaptotagmin recruitment. Enhancing the interaction between 
EBAG9 and Snapin inhibited the secretion of neuropeptide Y from PC12 cells in vitro, 
whereas constitutive secretion of α1-antitrypsin in HepG2 cells remained unaffected. From 
these data it was suggested that EBAG9 is a novel modulator of regulated exocytosis that acts 




However, a modulation of neurotransmitter release in cells equipped with a regulated 
exocytosis machinery could not be reconciled with the effects observed in epithelial cell lines, 
including O-linked glycan generation. This raises the question what physiological function 
EBAG9 in epithelial cells has, and whether this function relates to its proposed tumor 
association. Therefore, further analysis of the physiological role of EBAG9 in normal tissues 
and in tumor formation might be essential in order to understand general principles of 
oncogenic transformation. 
 
1.2 The secretory pathway 
1.2.1 From the endoplasmic reticulum to the cell exterior 
In the biosynthetic secretory pathway of eukaryotic cells newly synthesized proteins are 
transported from the endoplasmic reticulum (ER), via the intermediate compartment (IC) and 
the Golgi apparatus to the plasma membrane (PM), or via late endosomes to lysosomes (Fig. 
1-2) (Harter and Wieland, 1996; Saraste, et al., 2009). Between these compartments, vesicles 
continuously bud off from one membrane and fuse with another. There are three major classes 
of vesicles involved in protein trafficking, identified by their electron-dense “coats” COPI and 
COPII-coated vesicles (where COP stands for coat protein complex), and clathrin-coated 
vesicles (CCV). Each type is used for different transport steps in the cell and will be defined 
in detail in chapter 1.2.3.1 (Barlowe, 2000). During the stepwise transport of proteins through 
the secretory pathway, they are successively modified by means of glycosylation (Nilsson, et 
al., 2009). Transfer from one compartment to the next involves a delicate balance between 
forward (anterograde) and backward (retrograde) transport pathways. Here, transport vesicles 
select cargo molecules and move them to the next compartment in the pathway, while others 
retrieve escaped proteins and return them to a previous compartment where they usually 
function (Harter and Reinhard, 2000; Jackson, 2009). 
1.2.1.1 Transport from the trans-Golgi-network 
In general, the biosynthetic-secretory pathway allows the cell to modify the molecules it 
produces in a series of steps, store them until needed, and then deliver them to the exterior 
through a specific cell-surface domain in a process called exocytosis. At the trans-Golgi 




signal-mediated sorting into lysosomes, constitutive exocytosis and signal-dependent-
regulated exocytosis (Gu, et al., 2001). 
 
 
Fig. 1-2: The biosynthetic secretory pathway based on the stable compartment model. Newly synthesized 
proteins are transported from the endoplasmic reticulum (ER), via the intermediate compartment (IC) and the 
Golgi apparatus to the plasma membrane (PM) in an anterograde direction. They are first incorporated into 
COPII vesicles which bud from the ER and move towards the IC where a switch from COPII to COPI vesicles 
takes place (Scales, et al., 1997). From here tubulo-vesicular ER-to-Golgi carriers (EGCs) might move towards 
the cis Golgi in a COPI-dependent manner (Appenzeller-Herzog and Hauri, 2006). The sorting of mature 
proteins destined for lysosomes, constitutive or signal-mediated-regulated secretion takes place at the trans-
Golgi-Network (TGN). In the retrograde direction Golgi resident and premature proteins that possess the C-
terminal signal KDEL are retrieved from the IC/Golgi by KDEL-Receptor (KDELr) recycling back to the ER via 
retrograde COPI vesicles (Martinez-Menarguez, et al., 2001). The dual function of COPI might be made possible 
by the existence of different COPI vesicle sub-populations (Orci, et al., 1997). 
The constitutive secretory pathway operates in all cells. Many soluble proteins are continually 
secreted from the cell by this pathway, which also supplies the plasma membrane with newly 
synthesized lipids and proteins. In contrast, specialized secretory cells also have a regulated 
secretory pathway, by which selected proteins at the TGN are diverted into secretory vesicles. 
In these vesicles, proteins are concentrated and stored until an extracellular signal induces a 
rise of cytoplasmic Ca
2+
. This is followed by their fusion with the target membrane and 
finally, secretion (Burgoyne and Morgan, 2003). Although major differences between 
regulated and constitutive exocytosis have been established, a few regulatory molecules have 
been suggested to function in the switch between both processes. More specifically, the small 
Ras-like GTPase Rab11b has been demonstrated to function as a GTP-dependent switch 




cell lines (Khvotchev, et al., 2003). This observation suggested that the organization of the 
secretory pathway differs fundamentally between cells in which regulated and constitutive 
secretion coexist and, on the other hand, cells that are equipped only with a constitutive 
machinery. 
One prominent example for regulated secretion is the cytotoxic response of cytotoxic T-
lymphocytes (CTLs), which plays an important role in the killing of malignant and virally 
infected cells. Upon contact of T cells with antigen-presenting cells (APCs), a multimolecular 
assembly of receptors and adhesion molecules on both cells is induced, termed the 
immunological synapse (IS) (Friedl, et al., 2005). The antigen-specific cytotoxic response can 
be divided into three stages: 1. recognition and attachment of a CTL to a target cell, which is 
mediated through adhesion molecules and causes relocalization of the microtubule-organizing 
center (MTOC), the Golgi and lytic granules towards the IS (Kupfer and Singer, 1989; 
Stinchcombe, et al., 2001); 2. interaction of the T-cell receptor (TCR) with the peptide/MHC 
complex; 3. induction of target cell apoptosis via release of cytotoxic enzymes from lytic 
granules such as granzyme A and B and the pore-forming molecule perforin or Fas-L/Fas 
interaction (Montoya, et al., 2002; Reichardt, et al., 2007).  
Multiple pathways to the endosomal system arise from the TGN and mediate delivery of 
essential components to various endosomal intermediates and finally, the lysosomes. Thus, 
proteins can reach lysosomes by both biosynthetic and endocytic pathways. Generally, 
membrane proteins are sorted by signals in their cytoplasmic tails recognized by the 
appropriate sorting machinery, including the adaptor complexes (AP) (Boehm and 
Bonifacino, 2001; Duffield, et al., 2008; Robinson and Bonifacino, 2001). However, some 
proteins do not possess a sorting signal; instead they are modified during biosynthesis by the 
addition of a mannose-6phosphate moiety, which is recognized by mannose-6-phosphate 
receptors (MPR). These transmembrane receptors cycle between the TGN and late endosomes 
and carry soluble proteins to lysosomes (Blott and Griffiths, 2002; van Meel and 
Klumperman, 2008). 
1.2.1.2 Polarized transport 
Many cell types of multicellular organisms are polarized and have two functionally distinct 
membrane domains to which different types of vesicles must be directed by the polarized 




often has specialized features such as cilia or a brush border of microvilli. Such a cell also has 
a basolateral domain, which covers the rest of the cell (Huet, et al., 2003). The two domains 
are separated by a ring of tight junctions which prevent proteins and lipids from diffusing 
between the two domains, so that the compositions of the two domains are different (Tanos 
and Rodriguez-Boulan, 2008). The transport routes of apically and basolaterally destined 
cargo diverge at the TGN in polarized cells (Ikonen and Simons, 1998; Rodriguez-Boulan and 
Powell, 1992; Schuck and Simons, 2004). From the TGN, cargo can be transported directly to 
the apical or basolateral membrane. Additionally, basolateral cargo can reach the plasma 
membrane through endosomes, whereas apical cargo can also be sorted to the apical 
membrane via the transcytotic route following initial transport to the basolateral membrane 
(Polishchuk, et al., 2004). 
Basolateral sorting signals are confined to the cytosolic tails of membrane proteins. These 
signals are often tyrosine- or dileucine-based amino acid motifs that may be related to clathrin 
coated pit endocytic signals or PDZ-domain binding motifs (Duffield, et al., 2008; Rodriguez-
Boulan, et al., 2005). Apical sorting signals are more variable, whereas basolateral 
determinants seem to dominate over apical ones (Schuck and Simons, 2004). The most 
notable difference between the apical and basolateral sorting principles seems to be that apical 
recognition is based not only on cytosolic protein-protein interactions, but also cooperative 
inter-lipid and protein-lipid affinities as well as carbohydrate recognition (Ikonen and Simons, 
1998; Schuck and Simons, 2004). Both N- and O-glycosylation of the extracellular domain 
have been implicated in apical targeting (Scheiffele, et al., 1995). Here, 1-benzyl-2-
acetamido-2-deoxy-α-D-galactopyranoside (GalNAc-α-O-bn), an inhibitor of O-
gylcosylation, blocked cargo delivery to the apical surface in polarized cells (Delacour, et al., 
2003). Mechanistically, GalNAcα-O-bn is converted into the benzyldisaccharide Galβ1–
3GalNAcα-O-bn, which acts as a potent competitive inhibitor of α2,3-sialyltransferase 
(ST3Gal I) and is involved in the terminal elongation of O-linked glycans. However, there is 
also evidence that GalNAc-α-O-bn inhibits glycosylation in a cell-specific manner (Leteurtre, 
et al., 2003). Interestingly, GalNAc-α-O-bn was also shown to induce Tn and TF generation 
(Huet, et al., 2003).  
Defects in trafficking pathways which maintain epithelial polarity can cause disease in organs 
in which epithelial cell polarity is crucial, such as the liver, kidney and intestines (Stein, et al., 




remains unclear whether this is a consequence of or a prerequisite for oncogenic 
transformation (Fransen, et al., 1991; Hanahan and Weinberg, 2000; Moolenaar, et al., 1997; 
Tanos and Rodriguez-Boulan, 2008). Since EBAG9 is overrepresented in tumors of epithelial 
origin and an induction of tumor-associated glycans was observed, the question arose whether 
EBAG9 influences polarized transport. 
 
1.2.2 Mechanisms of biosynthetic protein transport from the ER 
towards the Golgi 
Currently, different models regarding the transport of anterograde and retrograde cargo 
through the secretory pathway are being considered. In general, cargo molecules move from 
the ER in vesicular or tubular shaped-transport intermediates, also called Vesicular Tubular 
Clusters (VTCs), to the Golgi complex, which involves the passage through an ER-Golgi 
intermediate compartment (ERGIC) or IC, the marker of which is the lectin ERGIC-53 (Fig. 
1-2) (Polishchuk, et al., 2009; Presley, et al., 1997; Scales, et al., 1997; Schweizer, et al., 
1991; Stephens and Pepperkok, 2001). Recent reports argue against mobile transport 
complexes but favour a stationary IC where anterograde and retrograde sorting of proteins 
occurs (Appenzeller-Herzog and Hauri, 2006). Furthermore, the IC also contributes to the 
concentration, folding, and quality control of newly synthesized proteins (Hauri, et al., 2000; 
Hebert, et al., 2005).  
Subsequently, a secretory cargo arrives at the cis side of a Golgi stack and then travels across 
the stack to the opposite, trans side before being exported from the trans-Golgi network 
(TGN). It is still uncertain how the Golgi apparatus achieves and maintains its polarized 
structure and how molecules move from one cisterna to another. One view is that vesicles 
might transport proteins between the cisternae, budding from one cisterna and fusing with the 
next. According to this vesicular transport model, the Golgi apparatus is a relatively static 
structure, with its enzymes held in place, while the molecules in transit are moved through the 
cisternae in sequence, carried by transport vesicles (Nickel, et al., 1998; Orci, et al., 1997; 
Palade, 1975; Pepperkok, et al., 1993; Volchuk, et al., 2000). Retrograde flow retrieves 
escaped ER and Golgi proteins and returns them to preceding compartments. Directional flow 
is achieved as forward-moving cargo molecules are selectively packaged into forward-moving 




However, the cisternal maturation mode of cargo transport is now the favoured model (Barr, 
2002). This cisternal maturation model assumes that Golgi cisternae form de novo, 
progressively mature, and ultimately dissipate (Bonfanti, et al., 1998; Glick, et al., 1997; 
Martinez-Menarguez, et al., 1999; Stephens, et al., 2000). In a stacked Golgi, vesicular tubular 
clusters that arrive from the ER would fuse with one another to become a cis-Golgi network. 
This new cisternae would progress through the stack, and peel off from the trans face. 
Secretory cargo proteins are thought to be carried forward by this process of cisternal 
progression. Meanwhile, the progressing cisternae would mature by the recycling of resident 
Golgi proteins from older to younger cisternae via retrograde vesicle flow (Rabouille and 
Klumperman, 2005; Storrie and Nilsson, 2002; Ungar, et al., 2006). A combination of both 
models, the percolating vesicle model, integrates the advantages of rapid anterograde 
transport mediated by vesicles, as opposed to the higher capacity of cisternal maturation that 
accounts for the transport of large cargo (Bethune, et al., 2006; Pelham and Rothman, 2000). 
 
1.2.3 From budding to fusion: components of the secretory 
pathway 
1.2.3.1 Coat proteins 
Coat proteins play a key role in intracellular transport by coupling vesicle formation with 
cargo sorting. This process involves coat binding to specific sequences in the cytoplasmic 
domains of cargo proteins for their proper packaging into nascent vesicles. Most transport 
vesicles form from specialized, coated regions of membranes. They bud off as coated vesicles 
(COPI, COPII or CCV) that have a distinctive cage of proteins covering their cytosolic 
surface. Before the vesicle fuses with a target membrane, the coat is discarded. This is 
required to allow the two cytosolic membrane surfaces to interact directly and fuse (Barlowe, 
et al., 1994; Malhotra, et al., 1989). 
Clathrin-coated vesicles (CCV) have been demonstrated to mediate transport from the Golgi 
apparatus and from the plasma membrane (Hanover, et al., 1984). Here, clathrin as a central 
organiser concentrates cargo adaptor protein (AP) complexes such as AP1, AP2 and AP3 
(Robinson, 2004). Most AP complexes link clathrin to selected membrane cargo and lipids 
and bind accessory proteins that regulate coat assembly and disassembly. It has been shown 




coats (Fig. 1-3) (Boehm and Bonifacino, 2001; Bonifacino and Lippincott-Schwartz, 2003; 
Hoffman, et al., 2003; McMahon and Mills, 2004; Robinson and Bonifacino, 2001; Serafini, 
et al., 1991).  
 
Fig. 1-3: Schematic representation of adaptins and coatamer protein I. (A) N and C indicate the amino- and 
carboxy-termini of the proteins, respectively; γ-adaptin earhomology domain; MHD, µ-homology domain 
(Boehm and Bonifacino, 2001). (B) The structure of the coatomer protein (COPI) βγδζ subcomplex is based on 
the model of AP2 because of the homology of their subunits. The arrangement of the other COPI subunits has 
not been elucidated (Bonifacino and Lippincott-Schwartz, 2003). 
 
In contrast, COPI- and COPII-coated vesicles commonly mediate transport from the ER and 
the Golgi cisternae (Fig. 1-2). COPI is composed of seven conserved subunits 
(α, β, β´, δ, γ, ε and ζ) divided into two subcomplexes: the F subcomplex (β δ, γ and ζCOP), 
and the B subcomplex (α, β´, ε). The former subcomplex probably has a topology similar to 
the AP complex and the latter is likely to be the functional equivalent of clathrin (Fig. 1-3) 
(McMahon and Mills, 2004; Schledzewski, et al., 1999; Takatsu, et al., 2001; Waters, et al., 
1991). Coatomer subunits recruit cargo by directly binding to dilysine motifs (KKXX, 
KXKXX) or to a motif containing two arginine and phenylalanine moieties, both located at 
the carboxy terminus (Cosson and Letourneur, 1994; Letourneur, et al., 1994). Moreover, 
cargos are captured by adaptor transmembrane proteins, such as the KDEL receptor (KDELr), 
that communicate with the COPI coat at their cytosolic site. KDELr recognizes the K(H)DEL 
sequence at the carboxy terminus of many ER-resident proteins and thus retrieves them from 
the Golgi (Lewis and Pelham, 1992; Semenza, et al., 1990). The COPII coat structure was 
found to consist of the subcomplexes Sec23/24p and Sec13/31p. For cargo proteins a DxE-
type motif was found to interact with COPII subunits (Bonifacino and Lippincott-Schwartz, 
2003; Harter and Wieland, 1996; Nishimura, et al., 1999).  
While COPII functions in ER export in the anterograde transport direction (Budnik and 
Stephens, 2009; Hughes and Stephens, 2008), the interpretation of the role of COPI-coated 




Their distribution is statistically significantly segregated within the Golgi complex (Beck, et 
al., 2009; Malsam, et al., 2005; Moelleken, et al., 2007; Orci, et al., 1997). COPI acts 
primarily in the retrieval of ER-derived resident proteins from later compartments. More 
recent studies have revealed that mammalian cells contain at least three distinct isoforms of 
coatomers that appear to assemble separately and regionally within the Golgi (Moelleken, et 
al., 2007). These findings suggested that COPI may carry traffic in both the anterograde and 
retrograde direction within a stack, depending on the COPI population involved (Lee, et al., 
2004). This second function of COPI transport carriers was proposed because they were 
shown to serve the anterograde route as well. Using vesicular stomatitis virus G protein 
(VSVG) as anterograde transport marker, it was demonstrated that COPII is lost rapidly after 
vesicle budding from ER exit sites. At the boundary between ER exit sites and the IC, the 
COPII coat is replaced by COPI coat components. Depending on the COPI population, these 
vesicular tubular clusters move either towards the Golgi, or recycle back to the ER (Bannykh 
and Balch, 1997; Beck, et al., 2009; Griffiths, et al., 1995; Scales, et al., 1997; Stephens, et al., 
2000). Direct evidence for a role of coatomer in ER-to-Golgi transport was provided by the 
demonstration that VSVG transport to the Golgi is inhibited by antibodies directed against the 
βCOP subunit of coatomer (Pepperkok, et al., 1993; Peter, et al., 1993). Furthermore, in 
Saccharomyces cerevisiae, a block of anterograde transport is observed in mutants of COPI 
subunits (Hosobuchi, et al., 1992). Additionally, COPI has also been implicated in post-Golgi 
trafficking steps such as the maintenance of endosomal/lysosomal function (Aniento, et al., 
1996; Razi, et al., 2009).  
However, many reports point toward a more complex structure of the secretory pathway, since 
an additional pathway for Golgi-to-ER transport has been discovered (Girod, et al., 1999; 
Storrie, et al., 2000; White, et al., 1999). Girod et al. (1999) provided evidence for a COPI-
independent transport pathway which is specifically regulated by Rab6 and is used by Golgi 
glycosylation enzymes and Shiga toxin.   
1.2.3.2 The vesicle machinery: from Arfs to SNAREs 
Targeting of COPI vesicles to a particular destination in the Golgi or ER is a multistep process 
in which tethers and members of the Rab- and Adenosine diphosphate-ribosylation factor 




ultimately a SNARE-dependent membrane fusion event (Bonifacino and Glick, 2004; Cai, et 
al., 2007).  
In general, each vesicle transport reaction can be divided into four essential steps (Fig. 1-4) 
(Bonifacino and Glick, 2004). First, the assembly of protein coats which are dynamic 
structures that cycle on and off membranes. Recruitment of the coat components from the 
cytosol onto donor membranes is regulated by the small guanosine triphosphatases (GTPases) 
ADP-Ribosylation Factor 1 (ARF1) for COPI vesicles and Sar1 for COPII vesicles (Cai, et 
al., 2007; Donaldson, et al., 1992). These in turn are activated by Guanine-nucleotid-exchange 
factors (GEFs) which replace GDP by GTP (Chardin, et al., 1996; Jackson and Casanova, 
2000; Peyroche, et al., 1996). Coatomer-Arf1-GTP complexes then undergo low affinity 
interactions to generate a membrane-deforming lattice capable of budding-coated carriers 
(Bremser, et al., 1999; Goldberg, 2000). 
 
Fig. 1-4: From budding to fusion. 
Each vesicle transport reaction can be 
divided into four essential steps that 
include coatomer recruitment, vesicle 
budding, vesicle transport, tethering 
and fusion. Briefly, proteins and lipids 
are sorted to specific sites on the 
donor membrane, transport vesicles 
bud with the aid of cytosolic 
complexes of coat proteins and 
vesicles move along cytoskeletal 
tracks. The vesicle is tethered and 
docked near the target membrane and 
subsequently fuses with the acceptor 
bilayer, releasing its contents (after 




Second, after budding, vesicles are transported to their final destination by diffusion or by 
motor-mediated transport along a cytoskeletal track (microtubules or actin). The molecular 
motors kinesin, dynein, and myosin have all been implicated in this process (Lippincott-
Schwartz, 1998; Mermall, et al., 1998). Prior to vesicle tethering, ARF1 or Sar1, respectively, 
are inactivated by GTPase activating proteins (GAPs), which hydrolyze GTP on Arf1 leading 
to release of Arf1-GDP and disassembly of the coatomer complex (Bigay, et al., 2003; 
Cukierman, et al., 1995; Liu, et al., 2005; Makler, et al., 1995; Randazzo and Kahn, 1994; 
Reinhard, et al., 2003; Tanigawa, et al., 1993). 
Third, the Rab proteins of the ras superfamily of small GTPases, are key regulators of 
tethering and fusion by facilitating docking of vesicles at the target membrane (Zerial and 
McBride, 2001). They bind to GEFs and are activated by the exchange of GDP to GTP. 
Finally, Rab binds to Rab effectors at the target membrane and facilitates the attachment of 
SNARE proteins (Ohya, et al., 2009). The complexity of the Rab protein family in 
mammalian cells correlates with the diversity of vesicle transport routes displayed in a variety 
of mammalian cell types (Simons and Zerial, 1993). Individual Rab proteins are localized to 
distinct, characteristic organelles, suggesting that each type regulates a particular membrane 
traffic step (de Renzis, et al., 2002; Rink, et al., 2005).  
The last step in vesicle-mediated transport is the fusion of the vesicle with its target 
membrane. The fusion of two lipid bilayers is catalyzed by the assembly of the SNARE 
complex. Here a SNARE molecule on a transport vesicle (v-SNARE) pairs with its cognate 
SNARE-binding partner (t-SNARE) on the appropriate target membrane (Sollner, et al., 1993; 
Sollner, et al., 1993). However, recent findings indicate that it is not the pairing of SNAREs 
that drives the specificity of vesicle targeting, but rather tethers like Rab proteins, which act 
further upstream (Burgoyne and Morgan, 2003; Cai, et al., 2007; Chavrier, et al., 1990; Jahn 
and Scheller, 2006; Olkkonen and Ikonen, 2000; Sudhof, 1995). 
SNAREs are a family of membrane proteins that are related to three different neuronal 
proteins: Syn1 (syntaxin 1), VAMP (vesicle-associated membrane protein)/synaptobrevin, and 
SNAP25 (synaptosome-associated protein-25) (Bennett, et al., 1992; Cai, et al., 2007; Oyler, 
et al., 1989; Trimble, et al., 1988). Individual family members function in distinct vesicular 
trafficking pathways. Thus, Syn1, VAMP2 and SNAP25 are required for synaptic vesicle 




Here, Snapin has been reported to be a neuron-specific component of synaptic vesicles that 
interacts with isolated SNAP25 as well as with the assembled synaptic SNARE complex to 
modulate the interactions between SNAREs and synaptotagmin (Buxton, et al., 2003; Ilardi, 
et al., 1999; Sudhof, 1995). Synaptotagmin plays a crucial role in regulated exocytosis by 
binding Ca
2+
 and functions as a Ca
2+
 sensor that triggers neurotransmitter release (Andrews 
and Chakrabarti, 2005; Chapman, 2002). As has been described in chapter 1.1.3, this step was 
shown to be regulated by EBAG9. 
 
1.2.4 Retrograde transport 
Control of membrane traffic has a major role in maintaining the composition of various cell 
membranes. To maintain the composition of each membrane-enclosed compartment in the 
secretory pathway at a constant size, the balance between the “forward” and “backward” flow 
needs to be precisely regulated. Thus, simultaneously to the anterograde transport, there is a 
constant retrograde flow of proteins and membrane lipids which are either taken up at the 
plasma membrane by endocytosis, or of Golgi resident proteins which need to be retrieved 
(Sannerud, et al., 2003).  
The intracellular retrograde transport routes between the plasma membrane and the 
endoplasmic reticulum have been insufficiently explored. Bacterial toxins, such as the Shiga 
toxin subunit B (STB) produced by Shigella dysenteriae, have become a powerful tool to 
study this pathway. STB enters the cell through clathrin-independent endocytosis and is 
transported directly to the Golgi via the retrograde pathway, which is distinct from the well-
known route used by the MPR (chapter 1.2). However, the Golgi-to-ER transport route 
appears to be independent of classic recycling markers, such as the KDELr and COPI. 
Instead, it was demonstrated that the STB reaches the ER via a Rab6-dependent retrograde 
pathway, which is also used by several Golgi glycosylation enzymes (Girod, et al., 1999; 
Johannes, 2002; Mallard, et al., 1998). 
On the other hand, proteins can also bind directly to COPI coats by signals, such as the 
KKXX sequence, at C-terminus forming retrograde directed vesicles. In contrast, soluble ER 
resident proteins containing the lysine-aspartate-glutamate-leucine (KDEL) or related 
sequences bind to specialized receptor proteins such as the KDEL receptor (Lewis and 




transmembrane protein that binds to the KDEL sequence and packages any protein displaying 
this residue into COPI-coated retrograde transport vesicles. To accomplish this task, the 
KDEL receptor itself cycles between the ER and the cis-Golgi apparatus via the IC, where it 
is mainly localized (Majoul, et al., 1998; Martinez-Menarguez, et al., 2001; Orci, et al., 1997). 
The receptor has a high affinity for the KDEL sequence in vesicular tubular clusters and the 
Golgi apparatus. There it captures escaped ER resident proteins that are present in VTC and 
the Golgi at low concentration. Subsequently, in the ER the KDELr has a low affinity for the 
KDEL sequence to unload its cargo in spite of the very high concentration of KDEL-
containing resident proteins. This is accomplished by different pH values established in the 
different compartments, regulated by H
+
 pumps in their membranes. The KDELr could bind 
the KDEL sequence under the slightly acidic conditions in vesicular tubular clusters and the 
Golgi compartment, but could release it at the neutral pH in the ER. Such pH-sensitive 
protein-protein interactions form the basis for many protein sorting steps in the cell (Harter 
and Wieland, 1996; Pelham, 1996). 
So far, three KDEL receptor proteins with a significant degree of conservation have been 
identified, suggesting that they might have some redundant functions (Capitani and Sallese, 
2009; Raykhel, et al., 2007). In addition, the retrieval of KDEL-tagged proteins contributes to 
the protein quality-control (Yamamoto, et al., 2001). Quality control checkpoints exist in 
many organelles along the secretory pathway. In the ER, proteins deemed defective by the 
quality control process are sorted for degradation by the cytosolic 26S proteasome through a 
process termed ER-associated protein degradation (ERAD). Properly folded proteins are 
directed to ER exit sites for export. Once in the IC or cis-Golgi, aberrant proteins that have 
escaped earlier checkpoints can also be selectively returned to the ER. Here, proteins that fail 
the quality control test can be retained and prevented from traversing the secretory pathway. 
The ER retention of a substrate is mediated by its binding to resident ER proteins that possess 
ER retention signals, such as the KDEL sequence. Thus, retrieval from the IC or Golgi is 
mediated by the recycling of the KDELr back to the ER. These substrate-KDELr complexes 
are selectively included in COPI coated vesicles, which bud from the cis-Golgi (Beck, et al., 
2009; Daniels, et al., 2004; Ellgaard, et al., 1999).  
Moreover, recent literature suggests that KDELr exhibits properties of a signalling protein 
(Pulvirenti, et al., 2008; Sallese, et al., 2009; Yamamoto, et al., 2003). Here, ER chaperones 




Src family kinases (SFKs), which control intra-Golgi trafficking (Asp and Nilsson, 2008; 
Pulvirenti, et al., 2008; Sallese, et al., 2009; Yamamoto, et al., 2003). 
On the other hand, KDELr was also demonstrated to regulate the secretory pathway through 
its interaction with ARFGAP1. Aoe et al. (1997) could show that KDELr oligomerizes and 
interacts with ARFGAP1, which in turn recruits cytosolic GAP to membranes and induces 
ARF1 inactivation (Inoue and Randazzo, 2007; Liu, et al., 2005). 
 
1.3 Biosynthetic transport and glycosylation  
The Golgi complex is a major site of carbohydrate synthesis. The oligosaccharide processing 
steps occur in a correspondingly organized sequence in the Golgi stack, with each cisterna 
containing a characteristic abundance of processing enzymes. Proteins are modified in 
successive stages as they move from cisterna to cisterna across the stack, so that the stack 
forms a multistage processing unit. This compartmentalization might seem unnecessary, since 
each oligosaccharide processing enzyme can accept a glycoprotein as a substrate only after it 
has been properly processed by the preceding enzyme. Nonetheless, it is clear that processing 
occurs in a spatial as well as a biochemical sequence: enzymes catalyzing early processing 
steps are concentrated in the cisternae toward the cis face of the Golgi stack, whereas 
enzymes catalyzing later processing steps are concentrated in the cisternae toward the trans 
face. To generate such ordered distribution, enzymes must first be transported to specific 
Golgi cisternae, and subsequently their localization must be maintained through a 
combination of retention, retrieval or replacement (Brockhausen, 2006; Rabouille and 
Klumperman, 2005; Sannerud, et al., 2003; Ungar, et al., 2006). 
 
1.3.1 N- and O-glycosylation 
Two types of glycan modifications can be distinguished. Firstly, in N-linked glycosylation 
oligosaccharides are uniquely added to asparagines found in Asn-X-Ser/Thr recognition 
sequences in proteins. Secondly, in O-linked glycosylation, carbohydrates are attached to 
hydroxyl groups of mainly serine or threonine residues. The latter begins in the cis-Golgi, 
whereas N-glycosylation takes place throughout the ER and the Golgi (Brockhausen, 1999; 




The processing pathway of both is highly ordered so that each step is dependent on the 
previous one. Processing of N-glycans is initiated in the ER with the attachment of N-linked 
oligosaccharide onto the protein, which is then trimmed while the protein is still in the ER 
(Molinari, 2007). Further modifications and additions occur in the Golgi apparatus. Here, the 
last enzyme in the sequential action of three enzymes, Mannosidase II, removes two 
mannoses to yield the final core of three mannoses that is present in a complex 
oligosaccharide (Tulsiani, et al., 1982). At this stage, the bond between the two N-
acetylglucosamines in the core becomes resistant to attack by a highly specific 
endoglycosidase (Endo H) (Fig. 1-5). Since all later structures in the pathway are also Endo 
H-resistant, treatment with this enzyme can be used as a marker for intra-Golgi transport 
(Matlin and Simons, 1983). Finally, additional N-acetylglucosamines, galactoses, and sialic 
acids are added depending on the protein and tissue. Sialic acids are negatively charged and 
can be cleaved by the enzyme neuraminidase (Kornfeld and Kornfeld, 1985; Moremen, 2002; 
Roth, 2002; Zhang, 2006). 
 
Fig. 1-5: Selected steps of N-glycosylation in eukaryotic cells. The sequential action of enzymes in the ER and 
Golgi, including Mannosidase II (Man II), yields the final core of three mannoses of complex oligosaccharides. 
These are further processed in the Golgi and glycosylation is terminated by addition of sialic acids. GlcNAc = N-
acetylglucosamine, Man = mannose, Gal = galactose, sialic acid = N-acetylneuraminic acid [modified after 
(Alberts, 2002)].  
O-Glycans are assembled by a series of reactions catalyzed by glycosyltransferases and 
sulfotransferases in the Golgi. Depending on the nature of the amino acid residue and sugar 
group involved in the carbohydrate-protein linkage, O-glycans can be divided into multiple 
subgroups: (1) in mucin-type O-glycoproteins, GalNAc is linked to serine or threonine 
residues; mucins are defined as cell surface or secreted glycoproteins with large numbers of 
clustered O-glycans; (2) for intracellular-glycoproteins, N-acetylglucosamine is linked to 
serine or threonine; and (3) for proteoglycans, xylose is linked to serine or threonine (Zhang, 




similar to the termini of N-glycans. Usually, processing of O-glycans is initiated in the cis-
Golgi by the addition of N-acetylgalactosamine (GalNAc) by polypeptide GalNAc-
transferases (GalNAcT), expressed in a tissue-specific fashion. Altogether, eight O-glycan 
core structures can then be synthesized. The most common O-glycan core structures are cores 
1 and 2. Core structures 1 to 4 in particular are elongated by Gal- and GlcNAc-transferase 
and/or terminated by Fucose-, sialyl-, Galactose-, N-acetylglucosamine-, GalNAc- and/or 
sulfo-transferases in many different ways to form functional carbohydrate structures 
(Brockhausen, 1999).  
 
1.3.2 Functional role of glycosylation 
Glycans have been shown to play a pivotal role in the folding, oligomerization, sorting, and 
transport of proteins. In addition, they influence cell-cell adhesion, cell-surface signalling, 
protein quality control and immune system functions including the mediation of cell death 
and antitumor responses (Bax, et al., 2007; Fukuda, 2002; Helenius and Aebi, 2001; Julien, et 
al., 2007; Priatel, et al., 2000; Rudd, et al., 2001; Toscano, et al., 2007; Tsuboi and Fukuda, 
1998; Zhang, 2006).  
The most important indirect effect of glycans on folding involves the quality control 
checkpoints, where N-linked carbohydrates act as maturation tags (Helenius and Aebi, 2001). 
Quality control in the ER is mediated via the Calnexin-calreticulin cycle, whereas quality 
control in the IC or Golgi depends on efficient retention of immature proteins primarily 
mediated by recycling of the KDELr as described in chapter 1.2.4 (Hebert, et al., 1995; 
Helenius and Aebi, 2004; Ou, et al., 1993; Peterson, et al., 1995).  
On the other hand, glycosylation is also involved in the selective anterograde trafficking of 
glycoproteins. Hauri, Appenzeller et al. (2000) suggested that the mannose-binding lectin 
ERGIC-53 serves as a cargo capture and transport receptor for trafficking from the ER to the 
IC. In this study, ERGIC-53 has been shown to associate with human cathepsin C and 
accelerate its transport to the Golgi in a glycan-dependent fashion (Hauri, et al., 2000; Hauri, 
et al., 2000; Hebert, et al., 2005). 
Furthermore, increasing evidence has been provided for an important role of glycosylation in 




regulation of the innate and adaptive immune response are glycoproteins. Glycans and 
glycopeptides not only influence the structure and function of immune molecules, but also 
influence the immune response leading to tumor immunity (Bax, et al., 2007; Irimura, et al., 
1999; Rudd, et al., 2001; Toscano, et al., 2007; Tsuboi and Fukuda, 1998; Zhang, 2006). Thus, 
O-glycans as well as N-glycans have been demonstrated to affect T and B cell functions, but 
also the complement pathway. More specifically, glycans have been shown to modulate ligand 
binding to the CD8αβ coreceptor of T cells (Moody, et al., 2001) and play an important role 
in the differentiation of T lymphocytes as demonstrated in ST6Gal I-deficient mice (Alvarez, 
et al., 1999; Marino, et al., 2008). Additionally, it has been established that glycans play a role 
in the generation and loading of antigenic peptides onto MHC class I molecules. Thus, 
Calnexin and ERp57 assist in the early folding events of the MHC class I heavy chain (HC). 
Here, unassembled HCs interact with membrane-bound Calnexin through a monoglycosylated 
N-linked glycan at Asn86 of the MHC class I HC (Peaper and Cresswell, 2008; Wearsch, et 
al., 2004). Moreover, glycans also influence the range of antigenic peptides generated in the 
endosomal pathway for presentation by MHC class II (Bax, et al., 2007; Rudd, et al., 2001; 
Toscano, et al., 2007; Tsuboi and Fukuda, 1998; Zhang, 2006). 
 
1.4 The secretory pathway and disease 
The biosynthetic secretory pathway is an essential processes for the correct localization and 
function of molecules within the cell. Disturbances in the function of the biosynthetic 
transport pathway can lead to a variety of diseases, including cancer (Aridor and Hannan, 
2000; Olkkonen and Ikonen, 2000). One example linking exocytosis and tumor development 
is the EWS-WT1 gene-fusion (Palmer, et al., 2002). The EWS-WT1 product in desmoplasmic 
small round cell tumors induces the overexpression of the Munc13-1-related molecule 
BAIAP3. Since BAIAP3 has been implicated in regulated exocytosis and tumor growth, it has 
been assumed that modulation of exocytosis per se might play a role in tumor development. 
However, the process by which cancer is linked to the modulation of the secretory pathway is 
still poorly understood and might provide a novel pathogenetic principle. 
Targeting the function of biosynthetic transport often causes interference with the coordinated 
spatial and functional arrangement of the glycosylation machinery, which has global effects 




glycosylation pathways is associated with deregulated expression of naturally occurring 
glycans, abnormal branching of glycoproteins and glycolipids, and neoexpression of sugars 
normally restricted to embryonic tissue (Dube and Bertozzi, 2005; Hakomori, 1989; Newsom-
Davis, et al., 2009). Changes of the resulting glycome are a hallmark of cancer cells; 
functional consequences may include modulation of metastasis and evasion from 
immunosurveillance (Cavallaro and Christofori, 2001; Ohtsubo and Marth, 2006; Rudd, et al., 
2001; Toscano, et al., 2007; Tsuboi and Fukuda, 1998; Zhang, 2006). Many tumor cells have 
altered biosynthetic pathways of glycans and aberrant mRNA expression levels or activities of 
glycosyltransferases, leading to the disturbance of the cellular glycome (Brockhausen, 2006; 
Brockhausen, et al., 1998; Brockhausen, et al., 1995; Dennis, et al., 1999; Field and 
Wainwright, 1995; Freire, et al., 2005; Julien, et al., 2001; Sewell, et al., 2006; Whitehouse, et 
al., 1997). The most common tumor-associated glycan antigens are the O-linked blood group 
precursor structures Tn (GalNAc) and TF (Galβ1-3GalNAc), which have been recorded in 
several carcinoma entities and have been introduced in chapter 1.1.2 (Brockhausen, 1999; 
Ohtsubo and Marth, 2006).  
In normal epithelial cells of the breast O-glycan structures are mainly core 2-based, resulting 
from the activity of 2-β6-N-acetylglucosaminyltransferase (C2GnT1) on core 1 O-glycans. In 
contrast, in breast carcinoma cells shorter O-glycans are added. These result from chain 
termination by sialylation of GalNAc or core1 by α2,6-sialyltransferase (ST6GalNAc-I) or 
α2,3 sialyltransferase (ST3Gal-I), respectively (Fig. 1-6).  
Mechanistically, either C2GnT1 could be lost or the upregulation of ST6GalNAc-I/II and 
ST3Gal-I accounts for the switch from core 2 to sialylated core 1 O-glycans in breast cancer 
cells (Dalziel, et al., 2001; Julien, et al., 2007; Sewell, et al., 2006). Likewise, the 
downregulation of the core 1 enzyme β1,3galactosyltransferase (T-synthase) would lead to an 
accumulation of truncated Tn-glycans (Freire, et al., 2005). Recent reports provide evidence 
that T-synthase requires a unique molecular chaperone, Cosmc, which is an endoplasmic 
reticulum ER-localized adenosine triphosphate binding chaperone. In the ER this chaperone 
interacts with the nascent polypeptide of human T-synthase and assists its proper folding. 
Native T-synthase, which occurs mainly as a homodimer, then exits the ER. When Cosmc is 
mutated and dysfunctional, the nascent polypeptides of T-synthase form inactive aggregates or 




to the ERAD pathway. Here they are retrotranslocated from the ER to the cytosol, 
ubiquitinated, and finally degraded by the proteasome (Ju, et al., 2008). Accordingly, Ju and 
Cummings (2002) demonstrated that a mutated chaperone, Cosmc, accounts for the increased 
amount of inactive T-synthase in Jurkat cells. 
 
Fig. 1-6: Glycosylation and cancer. In breast cancer cells a switch from core 2 to core 1 O-glycans takes place 
(Sewell, et al., 2006). 
In general, alterations in glycan structures per se have numerous biological and pathological 
consequences in cancer, because potential ligands and receptors responsible for interactions 
between cancer cells and their microenvironment are changed. This influences the growth and 
survival of the cell, its ability to invade and metastasize, and its interactions with lectins and 
cell-surface receptors or cells of the immune system (Glinskii, et al., 2004; Hanahan and 
Weinberg, 2000; Springer, 1984; Tsuiji, et al., 2003). However, whereas the genetic dissection 
of pathogenetic events in tumor cell transformation has made tremendous progress, more 
complex traits of malignancy, including modulatory effects on the secretory pathway and 
glycosylation, have proven difficult to analyse (Schietinger, et al., 2006).  
 
1.5 Aims 
The tumor-associated antigen EBAG9 has been identified as a primary estrogen-responsive 




EBAG9 overexpression has been recorded in a multitude of human epithelial cancers and was 
shown to correlate with tumor progression (Akahira, et al., 2004; Ogushi, et al., 2005; Suzuki, 
et al., 2004; Takahashi, et al., 2003; Tsuneizumi, et al., 2001). Previously, it was demonstrated 
that EBAG9 induces the surface deposition of common tumor-associated glycan antigens, 
such as the O-linked blood group precursor structures Tn (GalNAc) and TF (Galβ1-3GalNAc) 
at the cell surface in non-secretory cells (Engelsberg, et al., 2003). Despite its putative role in 
tumor progression, the pathophysiological function of EBAG9 has not yet been well defined. 
In neuroendocrine PC12 cells, EBAG9 induces a downregulation of Ca
2+
 regulated secretion 
(Ruder, et al., 2005), but essentially no glycan alteration. However, modulation of 
neurotransmitter release in cells equipped with a regulated exocytosis machinery could not be 
reconciled with the effects observed in epithelial cell lines, including O-linked glycan 
generation.  
In this project, I aimed for elucidation of the functional role of EBAG9 within the Golgi 
apparatus and how this function might be correlated with glycome alteration and tumor 
progression in epithelial cells. First, I planned to examine the putative pathophysiological 
implications of EBAG9 for the biosynthetic pathway including constitutive and regulated 
exocytosis. Here, I wanted to use EBAG9 overexpression to mimic crucial events during 
tumor cell pathogenesis, since EBAG9 is overrepresented but not deleted in tumors. As a 
further assessment of the physiological role of EBAG9, I intended to apply siRNA-mediated 
depletion of EBAG9. Second, with regard to proteins associating with EBAG9, I meant to 






All enzymes, chemicals and materials not listed were purchased from Amersham Bioscience 
(Freiburg), BioRad (München), Boehringer (Mannheim), Clontech (Palo Alto, USA), Fluka 
(Neu-Ulm), Gibco/BRL (Eggenstein), Merck (Darmstadt), NEB (Schwalbach), NEN (Köln), 
Promega (Mannheim), Qiagen (Hilden), Roche (Mannheim), Roth (Karlsruhe), Serva 
(Heidelberg) or Sigma (Taufkirchen). 
 
2.1 Cells 
Cos-7  African green monkey kidney cells  ATCC CRL-1651  
Hek293  Human embryonic kidney cell  ATCC CRL-1573 
Hela   Human cervix carcinoma   ATCC CCL-2 
MCF-7  Human breast adenocarcinoma  ATCC HTB-22 
MDA-MB435 Human breast adenocarcinoma or  ATCC HTB-129 
   Human melanoma cells (under debate) 
MDCK  Madin Darby Canine kidney cells  ATCC CCL-34 
PC12   Rat adrenal pheochromocytoma  ATCC CRL-1721 
 
EBAG9 or GFP stably transfected MDA-MB435 cells were provided. Stably εCOPI-YFP, 
EBAG9-∆176-213-GFP and EBAG9-∆30-213GFP expressing MDA-MB435 cells were 
generated within this work as described in chapter 3.3.3.  
 
2.2 Viruses 
Adenovirus for human EBAG9 (Ad-EBAG9) or LacZ (Ad-LacZ) were provided by Dr. Arne 
Engelsberg (AG Dr. Armin Rehm). The plasmid contains a CMV promoter for efficient 




(Schuck, et al., 2007) and GST-rGH12 were provided by Dr. Sebastian Schuck (AG Prof. Kai 
Simons) as well as  fowl plaque virus (FPV) described in (Matlin and Simons, 1983). 
 
2.3 Bacterial strains 





), phoA, supE44, thi-1, gyrA96, relA1, λ- 





Z∆M15, Tn10(tetr)]  
 
2.4 Mice strains 
C57BL/6 and BALB/c mice were obtained from Charles River Laboratories (Sulzfeld). 
EBAG9-deficient mice were provided by Dr. Constantin Rüder (AG Dr. Armin Rehm). 
Severe Combined Immunodeficient (SCID) mice, strain B6.CB17-Prkdc
scid
 /SzJ, were 
purchased from Jackson Laboratory. 
 
2.5 Expression constructs 
Tab. 1: Vectors 
Vector Reference Description 























Tab. 2: Expression constructs 
Plasmid Reference Description 
C2GnT1 (Dalziel, et al., 2001) C2GnT1 in pcDNA Neo 
EBAG9-C-FLAG (Ruder, et al., 2005) Human EBAG9 in pFlag 
EBAG9-GFP (Engelsberg, et al., 2003) Human EBAG9 in pEGFP-N3 
EBAG9-∆1-27-GFP (Engelsberg, et al., 2003) Deletion mutant of EBAG9-GFP 
(AS 28-213) 
EBAG9-∆1-163-GFP (Engelsberg, et al., 2003) Deletion mutant of EBAG9-GFP 
(AS 164-213) 
EBAG9-∆30-213GFP (Engelsberg, et al., 2003) Deletion mutant of EBAG9-GFP 
(AS 1-29) 
EBAG9-∆176-213-GFP (Engelsberg, et al., 2003) Deletion mutant of EBAG9-GFP 
(AS 1-175) 
EBAG9-∆1-27/∆176-213-GFP (Ruder, et al., 2009) Deletion mutant of EBAG9-GFP 
(AS 28-175) 




Bovine εCOPI in pEYFP 
GalT-DsRed Clontech (Verviers, Belgium) Human GalT in DsRed 
GalNAcT2-CFP (White, et al., 1995) *
2
 Human GalNAcT2 in pECFP 
pHGHCMV5 (Khvotchev, et al., 2003) Human GH in pCMV5 
ST6GalNAcII-FLAG (Sewell, et al., 2006) *
3
 ST6GalNacII in pFLAG 
T-synthase-HPC4 (Ju and Cummings, 2002) *
4
 Human C1β3Gal-T HPC4 tagged 
in pcDNA4 
VSVG-TsO5-GFP (Cao, et al., 2000) *5 VSVG in pEGFP 
Expression plasmids generated within this work (as described in chapter 3.1.9): 
C2GnT1-DsRed2 C2GnT1 with DsRed-tag in pDsRed2-N1 
EBAG9-DsRed2 EBAG9 with DsRed-tag in pDsRed2-N1 
ST6GalNAcII-DsRed2 ST6GalNacII with DsRed-tag in pDsRed2-N1 
Kindly provided by: *1 Dr. Jennifer Lippincott-Schwartz 
*
2 
Dr. Sebastian Schuck 
*
3 
Dr. Joyce Taylor-Papadimitriou  
*
4 
Prof. Richard D. Cummings 
*
5 






All nucleotides were purchased from BioTeZ GmbH (Berlin-Buch). Underlined bases label 
restriction sites.  
Tab. 3: Primer for cloning of expression plasmids 











Tab. 4: Primary antibodies 
(anti -) Name (clone) Isotyp / specificity Source / reference 
ArfGAP1 (S17) Rabbit-anti-human Santa Cruz Biotechnology  
(Santa Cruz, CA) 
βCOPI (maD) Mouse Ascites Fluid, monoclonal Sigma (Deisenhofen, Germany) 
Calnexin Rabbit polyclonal; anti-human Stressgen (Ann Arbor, MI) 
Cathepsin D (1C11) Mouse IgG1 mAK; anti-human Zymed Laboratories 
Cosmc (P-14) Goat polyclonal; anti-human Santa Cruz Biotechnology  
EBAG9 serum Rabbit polyclonal; anti-human (Engelsberg, et al., 2003) 
EEA1 (14) Mouse IgG1 mAK; anti-human BD Bioscience  
(Heidelberg, Germany) 
ERGIC-53 Mouse IgG1; anti-human Alexis Biochemicals 
(San Diego, CA) 
FLAG-tag (M2) Mouse-IgG Sigma 
GalNAcT1 Mouse IgG1; anti-human (Rottger, et al., 1998) *
1
 




GAPDH Rabbit polyclonal; anti-human Biozol (Eching, Germany) 
GFP Mixture of two mouse IgG1κ 
monoclonal antibodies 
Roche (Basel, Switzerland) 
GFP-biotin Goat polyclonal Vector Laboratories 
(Burlingame, CA) 
GM130 Mouse IgG1; anti-human BD Bioscience 
Granzyme B-Alexa 
Fluor 647 (16G6) 
Rat IgG2b; anti-mouse eBioscience (San Diego, CA) 
KDELr Mouse monoclonal; anti-human Stressgen (Ann Arbor, MI) 
Lck Mouse IgG1; anti-human BD Bioscience 
Mannosidase II Rabbit polyclonal; anti-human Chemicon (Hampshire, UK) 
MHC-class I 
(W6/32HL) 
Mouse IgG2a; anti-human MHC 
class I heavy chain 
(Barnstable, et al., 1978) 
P230 (15) Mouse IgG1; anti-human BD Bioscience 






Protein C (HPC4) Rabbit IgG; anti-Protein C epitope 
tag peptide 
GenScript (Piscataway, NJ) 
Sec23 (E19) Goat IgG, anti-human Santa Cruz Biotechnology 
TF (5f4) Mouse-anti-human Donated by Dr. Uwe Karsten 
Tn (22.1.1) Mouse IgM; anti-human MBL (Naka-ku Nogoya, Japan) 
C1GALT1 (T-synthase) Rabbit, anti-human Sigma 
Vivia Villosa Lectin 
(VVA) 
Anti-GalNAc (Tn);           biotin 
linked 
Vector Laboratories 
VSVG (P5D4) Mouse IgG1 ; anti-human Sigma 
VSVG 
(TKG, clone 17.2.21.4) 
Mouse-anti-human (Goldenberg and Silverman, 2009)*
2
 
Kindly provided by: *1 Prof. Nilsson 




Appropriate isotype controls for flow cytometry were purchased from BD Biosciences or 





Tab. 5: Secondary antibodies and streptavidin conjugates 
Name  Isotyp / specificity Source / reference 
Anti-goat-Alexa Fluor 568 Donkey-anti-goat IgG Molecular Probes (Karlsruhe, 
Germany) 
Anti-goat-HRP Donkey-anti-goat IgG Southern Biotechnology 
(Birmingham, AL) 
Anti-mouse-Alexa Fluor 488 Goat-anti-mouse IgG Molecular Probes 
Anti-mouse-Alexa Fluor 568 Goat-anti-mouse IgG Molecular Probes 
Anti-mouse APC Goat anti-mouse IgG BioLegend (San Diego, CA) 
Anti-mouse-biotin Goat anti-mouse IgGs DakoCytomation 
(Glostrup, Denmark) 
Anti-mouse-cy5 Goat anti-mouse IgG + IgM (H+L) Jackson ImmunoResearch 
(West Grove, PA) 
Anti-mouse-HRP Goat anti-mouse IgG H+L) Southern Biotechnology  
Anti-rabbit-Alexa Fluor 488 Goat-anti-rabbit IgG Molecular Probes 
Anti-rabbit-Alexa Fluor 568 Goat anti-rabbit IgG H+L) Molecular Probes  
Anti-rabbit-biotin Goat anti-rabbit IgGs DakoCytomation 
Anti-rabbit-cy5 Goat-anti-rabbit IgG Jackson ImmunoResearch 
Anti-rabbit-HRP Goat anti-rabbit IgG H+L) Southern Biotechnology 
Anti-rat-Alexa Fluor 568 Goat-anti-rat IgG Molecular Probes 
Anti-rat-HRP Goat-anti-rat IgG Southern Biotechnology 
Anti-rat-cy5 Donkey-anti-rat-cy5 Jackson ImmunoResearch  
Streptavidin-Alexa Fluor 568 Streptavidin linked Molecular Probes 
Streptavidin-cy2 Streptavidin linked Jackson ImmunoResearch  
Streptavidin-cy5 Streptavidin linked Jackson ImmunoResearch 









Tab. 6: Fluorescently labeled proteins 
Name Source / reference 
BODIPY TR C5-Cermide Molecular Probes 
Shiga Toxin B subunit – cy3 *
1
 (Mallard, et al., 1998) 
Transferrin-Alexa Fluor 633 Molecular Probes 
Transferrin-Alexa Fluor 568 Molecular Probes 
Kindly provided by: *1 Prof. Ludger Johannes and Prof. Brian Storrie 
 
2.8 Reagents 
Cycloheximide (Sigma) was prepared as stock solution in DMSO (100 mg/ml). Nocodazole 
(Sigma) was prepared as stock solution in DMSO (5 mg/ml) and BFA (Sigma) in EtOH (5 
mg/ml). MG-132 (Calbiochem) was kindly provided by Dr. Stephan Matthas. Mannosidase II 
substrate p-nitrophenyl-alpha-D-mannopyranoside was from Sigma, Endoglycosidase H 
(EndoH) and neuraminidase (NANA) were from New England Biolabs (NEB, Frankfurt, 
Germany). Protein A- and G-Sepharose, and glutathione-Sepharose were purchased from 
Amersham Biosciences (Buckinghamshire, UK). 
 
2.9 Buffer and media 
Buffer and solutions not listed can be found within the respective method section. 
Adenovirus storage buffer: 15 mM Tris pH 8.0, 150 mM NaCl, 0.15 % BSA, 50% Glycerol 
DNA-Sample buffer (10×): 0,25 % Bromphenolblue, 0,25 % Xylene-Cyanole, 30 % 
Glycerin 
EB-buffer:    10 mM Tris/HCl, pH 7.5 
IEF sample buffer: 9.5M Urea, 2 % Ampholine, pH 3.5-10 (v/v), 2 % NP-40 (v/v),  
5 % β-Mercaptoethanol (v/v)   
LB-Medium (Agar): 10 g Baco-Trypton, 5 g Yeast-extract, 10 g NaCl, ad 1 l H2O,  




NET-buffer (10×): 0.5 M Tris/HCL pH 7.5, 1.5 mM NaCl, 50 mM EDTA,               
5 % NP-40 
NP-40 Lysisbuffer: 50 mM Tris/HCL pH 7.4, 5 mM Mg2Cl, 0.5 % NP-40 
(add before use: 1 mM PMSF, 5 µg/ml Aprotinin) 
PAA for IEF: 30% Acrylamid (v/v), 1.6% N,N-Methylenbisacrylamid (w/v), 
stir with active carbon overnight 4°C, filter 
PBS(T): 140 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4,                      
1.5 mM KH2PO4, ad 1 l H2O, pH 7.2 (0,05 % Tween-20) 
Protein-Sample buffer (2×): 125 mM Tris pH 6.8, 4 % SDS, 0,002% Bromphenolblue, 20 % 
Glycerin, 5 % β-Mercaptoethanol 
RIPA-Lysisbuffer: 50 mM Tris/HCL pH 7.5, 50 mM NaCl, 0.5 mM EDTA,          
0.5 % NP-40, 0.25 % Na-deoxycholate (add before use:               
1 mM PMSF, 5 µg/ml Aprotinin) 
Running buffer (Lämmli): 250 mM Tris, 2.5 M Glycin, 1 % SDS  
Stripping buffer: 0.1 M Glycin, 0.15 M NaCl, ad 1 l H2O pH 2.5 
TAE (50×):    2 M Tris, 5.71 % (v/v) Eisessig, 50 mM EDTA pH 8.0 
TBS(T): 50 mM Tris/HCL pH 7.4, 50 mM NaCl, (0,05 % Tween-20) 
TE: 10 mM Tris/HCL, 1 mM EDTA, ad 1 l H2O, pH 7.4 
TX-100-Lysisbuffer: 50 mM Hepes pH 7.4, 150 mM NaCl, 10 % Glycerin, 1 % Tri-
ton X-100 (add before use: 1 mM PMSF, 5 µg/ml Aprotinin) 
TX-100-buffer for IP: 20 mM Hepes pH 7.4, 140 mM KCl, 20 mM NaCl, 0.5 mM 
MgCl2, 0.5 % Triton X-100 (add before use: 1 mM PMSF, 5 
µg/ml Aprotinin) 







Medium for cell culture 
DMEM: 500 ml DMEM (PAA, Cölbe), 5 ml Penicillin/Streptomycin 
(10000 U/ml; PAA), 5 ml 200 mM Glutamin (PAA), 5 ml 100 
mM Sodium-Pyruvat (Gibco/BRL), 5 ml 100 mM non-essential 
aminoacids (Gibco/BRL) for some cell lines  
RPMI: 500 ml RPMI (PAA, Cölbe), 5 ml Penicillin/Streptomycin 
(10000 U/ml; PAA), 5 ml 200 mM Glutamin (PAA), 5 ml 100 
mM Sodium-Pyruvat (Gibco/BRL), 500 µl 50 mM β-
Mercaptoethanol (Gibco/BRL) 
Trypsin-solution: 0.05 % Trypsin, 0.02 % EDTA (PAA) 





3.1 Molecular biology 
3.1.1 Culture of bacteria 
To amplify plasmids LB-medium was inoculated with bacteria of E.coli strain E.coli DH5α or 
E.coli XL1-Blue or spread on LB-Agarplates and incubated overnight at 37 °C. Clones were 
selected by addition of 100 µg/ml Ampicillin (Roth, Karlsruhe) or 30 µg/ml Kanamycin 
(Roth). 
 
3.1.2 Transformation of E.coli 
For transformation an aliquot of chemo-competent E.coli bacteria was incubated with DNA 
(10 µl of ligation or 5-20 ng plasmid-DNA) for 20 min on ice. After heat shock of 30 s at  
42 °C the mixture was cooled on ice for 2 min. After adding 200 µl LB-Medium and 
incubation for 60 min at 37 °C, 50-200 µl of Bacteria suspension was distributed on LB-
agarplates supplemented with Ampicillin or Kanamycin. 
 
3.1.3 Isolation of plasmid DNA from E.coli cells 
Analytic preparation of small quantities of plasmid DNA was done using the principle of 
alkaline lysis and was done to test for designated product of ligation. Transformed E.coli 
bacteria were grown overnight and 1.5 ml centrifuged at 13000 rpm for 30 s. The pellet was 
resupended in 300 µl P1-buffer, 300 µl P2-buffer were added and cells were lysed for 5 min at 
RT. After addition of 300 µl P3-buffer the suspension was neutralized, incubated for 15 min 
on ice and centrifuged at 13000 rpm, 4 °C for 20 min. The plasmid DNA was precipitated 
from the supernatant by using 0.7 Vol Isopropanol for 5 min on ice. After centrifugation and 
washing with 70 % EtOH, the plasmid DNA was air dried and dissolved in 50 µl EB buffer. 
P1-buffer:  50 mM Tris/HCL pH 8.0, 10 mM EDTA pH 8.0, 100 µg/ml RNaseA 
P2-buffer:  200 mM NaOH, 1 % SDS 




The preparative isolation of plasmid DNA was done using DNA-affinity columns from 
JETSTAR (Genomed, Bad Oeynhausen, Germany) or QUIAGEN (Hilden, Germany) 
“Plasmid Maxi- Kit” according to manufacturer’s  instructions. 
 
3.1.4 Polymerase chain reaction (PCR) 
Polymerase chain reaction was used to amplify certain DNA sections and to introduce direct 
mutations. To ensure high fidelity of DNA polymerisation a polymerase with 3´-5´-proof-
reading activity (PFU; Roboklon, Berlin, Germany) was chosen and the PCR-reaction was 
performed according to manufacturer’s instructions using the buffer provided.  
 
3.1.5 Restriction digest 
Cleavage of DNA was carried out using restriction enzymes and buffer provided by New 
England Biolabs (NEB, Schwalbach). For 1 µg plasmid DNA 1-5 U restriction enzyme was 
used and incubated for at least 3 h or overnight. After linearization the vector was incubated 
with Calf Intestine Phosphatase (CIP) (1 U/5 µg DNA; NEB, Schwalbach) for 30 min at  
37 °C to dephosphorylate the 5´-end. This procedure inhibits re-ligation of the linearized 
vector without incorporation of a DNA fragment and enhances the efficiency of ligation. 
Afterwards the phosphatase was inactivated at 75 °C for 15 min. Finally, the cleavage 
products were isolated by agarose gel electrophoresis (chapter 3.1.6) and DNA was purified 
from the gel as described in chapter 3.1.7.   
 
3.1.6 Agarose gel electrophoresis 
Analysis and purification of DNA was performed by horizontal electrophoresis in an  
0.8 % - 2 % Agarosegel (0.8-2 g Agarose/100 ml 1x TAE, 0.5 µg/ml Ethidiumbromide). 
DNA-probes were mixed with 10x DNAsample buffer and the probe was separated by 
electrophoresis (4-8 V/cm) in 1x TAE buffer. Excitation of the intercalating dye 
Ethidiumbromide by UV-light (254-366 nm) allows the analysis of DNA bands. The size of 




Eggenstein). The amount of DNA was estimated by comparison with SmartLadder 
(Eurogentec, Seraing, Belgien). 
  
3.1.7 Isolation of DNA from agarose gels 
DNA separated by Agarose gel electrophoresis was quickly cut out under a UV-light using a 
scalpel. The DNA was isolated using the „QIAquickTM Gel-Extraction Kit“ (Qiagen) 
according to manufacturer’s instructions.  
 
3.1.8 Ligation of DNA 
Ligation of Vector and DNA to obtain the desired expression construct was performed in a 
total volume of 20 µl (1 U T4-DNA-Ligase, 2 µl 10x Ligationbuffer; Roche) overnight at  
16 °C for sticky ends. Vector and DNA were added in a molar ratio of 1:3, 1:1 and 3:1, 
whereas the amount of vector was 50-150 ng. 
 
3.1.9 Cloning 
EBAG9, C2GnT1 or ST6GalNAcII were amplified by PCR (chapter 3.1.4) using the primers 
shown in Tab. 3 and subcloned into KpnI and BamHI restriction sites of pDsRed2-N1 
(Clontech). All constructs generated were verified by sequencing. 
 
3.2 Protein biochemistry 
3.2.1 Protein isolation and determination of protein 
concentration 
Cells were trypsinized and counted using a Neubauer haemocytometer. After collecting the 
cells by centrifugation at 1100 rpm for 5 min, the pellet was washed twice with PBS and 
resuspended in the appropriate cold lysis buffer (NP40, RIPA or TX-100) to a final 
concentration of 4×10
6
/100 ml. This was followed by 30 min rotation at 4 °C. Finally, cell 
lysate was centrifuged at 13000 rpm for 10 min to pellet unsoluble cell material and nuclei. 




coimmuniprecipitation (chapter 3.3.6) or Mannosidase activity assay (chapter 3.3.13). If 
required, protein concentration was determined by Bradford assay using the „BIO-RAD 
Protein Assay“ (BioRad) according to manufacturer’s instructions. Bovine serum albumin 
(BSA) was used as standard to plot a calibration curve.    
 
3.2.2 SDS-polyacrylamide-gelelectrophoresis (SDS-PAGE) 
For protein separation by SDS-PAGE 2x protein sample buffer was added and probes were 
boiled for 5 min. Equal amounts of protein were loaded on 8 %, 10 % or 12 % reducing SDS-
polyacrylamide gel. A 4.5 % stacking gel served to focus the probes before separation. To 
determine the molecular weight of proteins „RainbowTM coloured protein molecular weight 
marker, high molecular weight range“ (Amersham) was separated on the same gel. 
Electrophoresis was carried out in 1x Laemmli-buffer at 5-8V/cm. Resolving gel (RG) and 
stacking gel (SG) were prepared according to the following recipe. 
 
Tab. 7: Composition of SDS-polyacrylamide gels 
Gel 12 % RG 10 % RG 8 % RG 4.5 % SG 
H2O 16.75 ml 19.80 ml 23.20 ml 7.5 ml 
Rotiphorese® Gel30 
(30 % Acrylamid, 0.8 % Bisacrylamid; Roth) 
20.75 ml 16.7 ml 13.30 ml 1.875 ml 
 
1.5 M Tris/HCl pH 8.8, 0.4 % SDS 12.5 ml 12.5 ml 12.5 ml - 
0.5 M Tris/HCl pH 6.8, 0.4 % SDS - - - 3.125 ml 
10 % APS 250 µl 250 µl 250 µl 90 µl 
TEMED (Roth) 25 µl 25 µl 25 µl 9 µl 
 
3.2.3 Immunoblot (westernblot analysis) 
After separation by SDS-PAGE proteins were transferred to nitrocellulose membranes 
(Schleicher & Schuell, Dassel, Germany) at 400 mA for 2-3 h in WBT using a „Trans-
Blot®SD“  westernblot chamber (BioRad).  
 The blots were blocked in 1× TBST with 5 % milk for 30 min to saturate unspecific protein 
binding and washed three times with 1× TBST, followed by incubation with primary antibody 
(Tab. 4) in 1× TBST with 2.5 % milk for 1-2 h at RT or overnight at 4 °C. After washing four 
times with 1× TBST for 5-10 min, the blots were probed with a secondary antibody 




and washed again four times with 1× TBST for 5-10 min. Protein bands were visualized by 
chemiluminescence (ECL kit, Amersham Biosciences, Braunschweig, Germany), exposed to 
an X-ray (Kodak X-OMAT LS) film and developed.  
For further analysis the membrane was incubated in stripping buffer (chapter 2.9) for 30 min 
to strip all bound antibody off the membrane. After washing twice with H2O the membrane 
could be re-probed again.  
 
3.2.4 One-dimensional (1d)-isoelectric focusing gel 
electrophoresis (IEF) 
Isoelectric focusing separates proteins according to their charge. Immunoprecipitates were 
dissolved in IEF sample buffer and loaded into gel pockets. Samples were overlaid with ~ 1:4 
diluted sample buffer, including Bromphenol blue, followed by adding Kathode buffer 
(50mM NaOH) into the upper chamber. Then, chambers were filled with Anode buffer  
(20 mM H3PO4) and electrophoresis was carried out at 1000 V for 12-13 h overnight. The IEF 
gel was prepared according to the following recipe.  
Tab. 8: Composition of 1d-isoelectric focusing gel 
 Gel 
H2O 16.5 ml 
Urea 41.25 g 
10 % NP-40 15 ml 
PAA 11.25 ml 
Dissolve slowly at 30 °C under frequent stirring 
Add ampholine: 
pH 5-7 3 ml 
pH 3.5-10 0.75 ml 
pH 7-9 0.75 ml 
10% APS 150 µl 
TEMED (Roth) 75 µl 
 
3.2.5 Autoradiography 
To enhance the detection of [
35
S]-labeled proteins, the SDS-PAGE gel was incubated twice 
with DMSO for 30 min to dehydrate the gel and then incubated in the scintillator 2,5-
Diphenyloxazol/DMSO (PPO; Roth) for 1 h. Afterwards the gel was washed in H2O for  




under vacuum. Finally, radioactive labeled proteins were visualized by exposure to an X-ray 
(Kodak X-OMAT AR) film at -80 °C. Sometimes, gels were exposed to a Phosphoimager-
Plate (Fuji), and analysis was done using a  „Fujix BAS 2000 Phospho-Imager“ (Fuji). 
 
3.2.6 Quantification of protein bands 
Band intensities were quantified by densitometry using the program „Tina 2.0“ (Raytest). The 
intensity values obtained were adjusted to background intensity values.  
 
3.3 Cell biology 
3.3.1 Cell culture and transfections 
HEK293, HeLa, MDA-MB435, and COS7 were grown in DMEM medium (chapter 2.9; PAA 
Laboratories, Cölbe, Germany) supplemented with 10 % FCS (Foetal Calf serum inactivated 
for 20 min at 55 °C; Biochrom, Berlin, Germany) in a humidified incubator at 37 °C and 5 % 
CO2. PC12 cells were grown on collagen coated plates [10 µg/ml Collagen Typ I (Sigma) in 
0.1 M acetic acid] in RPMI-medium supplemented with 10 % horse serum (Invitrogen, 
Carlsbad, CA) and 10 % FCS. MDCK cells strain II were maintained as described (Benting, 
et al., 1999). Cells were grown to confluency and generally passaged 1:3 to 1:6. They were 
washed with PBS, trypsinised and resuspended in fresh medium. For cryoconservation,  
5×10
6
 cells/ml were resuspended in freezing medium, followed by transfer to a -80 °C freezer 
and ultimately stored in liquid nitrogen one day later. 
 
3.3.2 Transfection of mammalian cells  
Cells were transfected with plasmid DNA by using LipofectAMINE 2000 (Invitrogen, 
Karlsruhe) or Fugene (Roche, Basel, Switzerland) according to manufacturer’s instructions by 
using generally a ratio 1:1 of DNA (µg) : Lipofectamine (µl). Transfection was done in 
OptiMEM (Gibco/BRL) for 5-6 h, then medium was changed to normal growth medium and 





3.3.3 Generation of stable cell lines 
After transfection of 2×10
6
 cells in a 10 cm dish with 15 µg of plasmid DNA as described 
above (chapter 3.3.1), cells were grown for 24 h at 37 °C in normal growth medium to allow 
expression of the plasmid. Then cells were split into five 24 well plates in normal growth 
medium. Medium was changed after 6 h to fresh medium containing 700 µg/ml geneticin-
sulphate (G-418; PAA, Pasching, Austria). Cells were fed with selective medium every 3-4 
days until untransfected control cells died. Finally, G418 resistant clones were picked, 
expanded and tested for gene-product expression by FACS analysis. Stable clones were 
maintained in the presence of 400 µg/ml G-418.  
   
3.3.4 Amplification and transduction of cell lines with 
adenovirus 
To amplify EBAG9-encoding adenovirus, HeK293A cells (~ 60-80 % confluent) were 
infected with purified virus in DMEM supplemented with 2 % FCS for 90 min at 37 °C. Cells 
were grown for 2-7 days in normal growth medium until they began to detach. Cells and 
supernatant were collected, centrifuged at 1500 rpm, and cell pellet was resuspended in 
DMEM supplemented with 2 % FCS, followed by three thaw (37 ºC) and freeze (-70 ºC) 
cycles. Then, cells were centrifuged at 3500 rpm at 4 °C for 20 min and the supernatant 
purified via a discontinuous CsCl-gradient consisting of CsCl 1.4 M solution (53 g CsCl,  
87 ml 10 mM Tris-HCl, pH 7.9) and CsCl 1.2 M solution (26.8 g CsCl, 92 ml 10 mM Tris-
HCl, pH 7.9). The first gradient was centrifuged for 90 min at 26.000rpm at 4 ºC (deceleration 
rate = 0) using a SW 28/Beckman swinging bucket rotor. Afterwards, the tube was punctured 
below the lowest bluish white band containing the virons using a 5 ml syringe with an 18G 
needle. The viral band was aspirated and loaded on a second discontinuous CsCL gradient, 
followed by centrifugation overnight at 28.000 rpm at 4 ºC (deceleration rate = 0) using a SW 
40/Beckman swinging bucket rotor. The purified virons were isolated as described above and 
diluted 1:1 with TE. To remove the CsCl, the purified virus was loaded on an equilibrated  
10 ml Sephadex G25 column in PBS and fractions (~ 0.5 ml) were collected. Virus 
concentration was determined by optical density analysis at 260 nm. Fractions with the 




infectivity was determined empirically and by titration as described previously (Cichon, et al., 
1999; Ruder, et al., 2005).  
 
3.3.5 Pulse-chase experiments 
Cells were incubated in methionine- and cysteine-free RPMI medium for 45 min at 37°C. 
After starvation, cells were centrifuged at 1100 rpm for 5 min and resuspended in 500 µl in 
methionine- and cysteine-free RPMI, followed by incubation with 500 µCi [35S]methionine-
cysteine (Expre labeling mix, Perkin Elmer, Waltham, MA) for 10 min to label the cells 
(Pulse). Then medium supplemented with excess of unlabeled methionine (1.5 mM) and 
cysteine (0.5 mM) was added and cells were chased at either 19.5 °C or 37 °C for various 
times. For each time point, 1 ml sample was taken, centrifuged and cells were lysed in NP-40 
buffer (chapter 3.2.1). After centrifugation, preclearing of the supernatant was done by 
addition of 80 µl Staph.A (Staphylococcus aureus, Pansorbin, Calbiochem) 5 µl rabbit serum. 
Then, the sample was centrifuged and MHC class I heavy chain was immunoprecipitated 
(chapter 3.3.6). To investigate the ER to Golgi transport, immunoprecipitates were digested 
with Endoglycosidase H (EndoHf, NEB) or  neuraminidase (NEB) as described elsewhere 
(Rehm, et al., 2001). Samples were analysed by SDS-PAGE (chapter 3.2.2) or 1d-IEF-gel 
(chapter 3.2.4). Gels were fixed and subjected to autoradiography (chapter 3.2.5). 
 
3.3.6 Immunoprecipitation (IP) and co-immunoprecipitation 
To isolate specific proteins from cell lysates (chapter 3.2.1), 5 µl antigen-specific antibody 
and 120 µl protein A-Sepharose (Amersham Biosciences) or protein G-Sepharose (Amersham 
Biosciences) were added and rotated for at least 2 h at 4 °C. After centrifugation at 13000 g 
for 1min and washing four times with 1× NET buffer (for pulse chase experiments), 
immunoprecipitates were analyzed as described in chapter 3.2.2.    
If the immunoprecipitated protein interacts with other proteins in vivo, these associated 
proteins might be co-immunoprecipitated. For coimmunoprecipitation, HeLa cells were 
transiently transfected with EBAG9-GFP or GFP. Cells were lysed in 0.5 % TX-100 lysis 




antibody and protein A- or G-Sepharose for 3 h at 4°C. Beads were washed 10 times with  
0.4 % TX-100 lysis buffer, and bound proteins were separated by SDS-PAGE (chapter 3.2.2) 
and analysed by immunoblotting (chapter 3.2.3). Primary antibodies used for blots were 
biotinylated anti GFP and anti-βCOP. 
 
3.3.7 Subcellular fractionation 
Hela cells transfected with T-synthase for 48 h (chapter 3.3.2) and infected with murine Ad-
EBAG9 or Ad-LacZ for 18 h (chapter 3.3.4) were resuspended in 1.5 ml homogenization 
buffer (HB). Resuspended cells were homogenized by 30 strokes in a glass-teflon 
homogenizer with a tight-fitting pestle (B. Braun, Melsungen). Afterwards, the homogenate 
was centrifuged at 3000 rpm for 7 min at 4 °C to remove nuclei and unbroken cells. Then the 
postnuclear supernatant (PNS) was centrifuged at 60.000 rpm for 50 min at 4 °C using a 
table-top ultra centrifuge to obtain microsomal membranes and cytosolic fractions.  
For investigation of ArfGAP1 or βCOP, the microsomal fraction was directly resuspended in 
sample buffer, whereas proteins of the cytosolic fraction were precipitated quantitatively with 
20 % TCA for 1-3 h, washed once with ice-cold EtOH before they were resuspended and 
finally analysed by SDS-PAGE and immunoblot (chapter 3.2.3). 
For analysis of T-synthase distribution, the microsomal fraction was homogenized in 850 µl 
HB and loaded on a discontinuous Optiprep (Axis-Shield, Po CAS, Oslo, Norway) gradient 
(bottom – 50, 40, 30, 20, 10 % - top) followed by centrifugation at 21.000 rpm at 4 °C 
overnight using a SW40 rotor. Fractions 1-14 (785 µl) were carefully removed from top to 
bottom, precipitated as described, washed once with ice cold acetone, once with EtOH and 
finally analysed as described before.  
 
Homogenizing buffer (HB):  10 mM Tris/HCl pH 7.4, 250 mM Sucrose, protease 





3.3.8 Fluorescence activated cell sorting (FACS)-analysis 
Cells for analysis were once washed with cold FACS-buffer, transferred into round-bottom 
microtiterplates and blocked for 20 min. After centrifugation at 1500 rpm for 1 min, cells 
were washed once with FACS-buffer, blocked with normal goat serum (NGS) for 20 min and 
then incubated with primary antibody for 30 min on ice. This was followed by two washing 
steps and incubation with the secondary antibody for 30 min on ice. For determination of cell 
death, one aliquot of cells was also stained with PI (Bender MedSystems, Vienna, Austria) 
according to manufacturer’s instructions. Finally, cells were washed three times and analysed 
on a FACSCalibur (Becton-Dickinson) or FACS Canto (Becton-Dickinson). Data were 
analysed using “Cell Quest” (BD Biosciences, Heidelberg) or FlowJo (BD Biosciences, 
Heidelberg) software. 
 





 (12 well) or 3.6×10
4
 (24 well) cells were grown on glass coverslips (Roth). 24 h later 
they were washed with PBS, fixed with 2-4 % PFA for 10 min on ice, washed twice and 
permeabilized for 5 min with 0.25 % Triton X-100 in PBS. Afterwards cells were washed 
twice for 5 min with PBS and blocked in 2.5 % milk powder in PBS for 30 min to avoid 
unspecific binding of antibodies. Slides were then incubated with primary antibodies (Tab. 4) 
in 2.5 % milk powder in PBS for 1-2 h at RT, washed twice for 5 min with PBS, followed by 
incubation with secondary antibody (Tab. 5Tab. 5) conjugated with fluorescence dye in 2.5 % 
milk powder in PBS for 45 min at RT. Finally, cells were washed twice for 5 min in PBS and 
covered with Mowiol on a microscope slide. Treatment with nocodazole (10 µM) or BFA 
(5 µg/ml) was carried out for 1 h prior to fixation of cells.  
 






3.3.10 Lectin staining 
Cells were fixed in cold acetone for 7 min on ice, washed twice with PBS, permeabilized with 
0.25% TritonX-100 for 10 min and blocked with 5% BSA for 60 min. Then, cells were 
washed in special washing medium (WM) and stained with VVA, PNA (Tab. 4) and GM130 
in special binding medium (BM) for 90 min. After washing twice for 5 min with WM the cells 
were incubated with secondary antibody in BM for 45 min. Finally, cells were washed twice 
for 5 min in WM, and covered with Mowiol on a microscope slide. 
 
Washing Medium (WM): 10 mM Hepes, pH 7,5; 0,15 M NaCl 
Binding Medium (BM): 10 mM Hepes, pH 7,5; 0,15 NaCl; 0,08 % NaN3; 0,1 mM CaCl2; 
0,01 mM MnCl2 
 
3.3.11 Confocal image acquisition and correlation analysis 
Images were acquired with a Zeiss LSM510Meta confocal setup on an Axiovert 200M 
inverted microscope (Zeiss, Göttingen, Germany) equipped with an argon and helium/neon I 
or II laser for double or triple fluorescence at 488 nm, 543 nm and 635 nm using a 63x or 
100x phase contrast plan-apochromat oil immersion objective. For double and triple staining 
GFP, Alexa Fluor 568 or 647, cy3, DsRed and cy5 signals were recorded sequentially (multi 
track) to minimize potential cross-talk between the fluorophores. Main beam splitter was HFT 
UV/488/543/633, HFT UV 488/543 or HFT UV 458/514 with following parameters for each 
fluorochrome: GFP, λexc = 488 nm and λem = BP500-530 nm or Metadetector 494.7-505.4 nm 
(double staining with DsRed); CFP, λexc = 458 nm and λem = Metadetector 462.6-473.3 nm; 
Alexa Fluor 568, Cy3 and DsRed, λexc = 543 nm and λem = LP560 nm (double staining with 
GFP) or λem = BP565-615 nm (triple staining); Cy5 and Alexa Fluor 647, λexc = 633 nm and 
λem = LP650 nm. All images were processed using LSM Examiner 3.2 and LSM Browser 
software (Zeiss) or ImageJ (open source). To better visualize colocalization of proteins, the 





Colocalization was quantified calculating the Pearson’s correlation coefficient (R) according 
to the following formula (Ch, channel; values are pixel intensities):  
    
The Golgi was marked as region of interest (ROI) using the LSM software. For each ROI the 
software calculated R. In all experiments the intensity of signals was kept equal. The 
Pearson’s correlation coefficient takes into consideration similarities between shapes, while 
ignoring the intensities of signals, and thus is applicable when fluorescence intensities are 
equal (Zinchuk and Zinchuk, 2008; Zinchuk, et al., 2007). For the calculation of the relative 
Golgi fluorescence (RGF) ImageJ software was used. The Golgi or whole cell was marked as 
ROI and the sum of the values of the pixels in the selection (Integrated Density) was 
quantified. RGF was calculated according to the following formula:     
 
Selective photobleaching of the Golgi complex was performed using 30-50 consecutive scans 
of the appropriate laser line at full power (Ward, et al., 2001). Recovery was then monitored 
by time-lapse imaging at low-intensity illumination. Images of cells were captured with a 
100x phase contrast plan-apochromat oil immersion objective using a pinhole diameter 
equivalent to 1 Airey unit. All figures were assembled with Corel Draw (Corel). 
 
3.3.11.1 Time-lapse imaging 
To observe live-cells, we used 15 µ-slides for live cell imaging (Ibidi). MDA-MB435 cells 
stably expressing EBAG9 were grown on these dishes for 24 h, then medium was changed to 
fresh complete medium with 5 µg/ml transferrin conjugated to Alexa Fluor 568 for 20 min at 
37 °C, washed once with medium without transferrin, followed by addition of fresh medium 
supplemented with 10 mM Hepes. The cells were viewed with a Zeiss LSM 5 Live confocal 
microscope equipped with a 63× objective lens (Plan-Apochromat; Carl Zeiss). GFP was 
excited by the 488 nm line of an Argon laser and detected through a BP500-525 nm band-pass 




long-pass filter. Cells were scanned with the multitrack mode with 5.2 or 5.0 s of interval 
time. 
 
3.3.12 Transport assays 
3.3.12.1 Human growth hormone release assay  
For detection of constitutive exocytosis 5x105 EBAG9-GFP and GFP stably transfected 
mamma carcinoma (MDA-MB435) cells or 3x106 PC12 cells were seeded in untreated or 
collagen coated wells, respectively. MDA-MB435-EBAG9 and MDA-MB435-GFP cells were 
transfected with human growth hormone (hGH) alone, whereas PC12 cells were transiently 
cotransfected with hGH and EBAG9-GFP or GFP using LipofectAMINE2000 (chapter 3.3.2). 
48 h after transfection, cells were stimulated with low KCl buffer or high KCl buffer for  
30 min (constitutive release) or 10 min (regulated secretion) at 37 °C. Cell culture supernatant 
and transfected cells were collected, and cells were broken in PBS by three cycles of freeze-
thawing. The resulting cell extracts were cleared by centrifugation at 13000 rpm for 10 min, 
and the amounts of hGH in the medium and in the cell extracts were quantified by hGH 
specific ELISA, according to the manufacturer's instructions (Biosource, Nivelles, Belgium). 
Regulated release of hGH from PC12 cells was effectuated with high KCl secretion buffer for 
10 min, essentially as described (Khvotchev, et al., 2003).  
 
Low KCL buffer:  140 mM NaCl, 5.6 mM KCl, 2.2 mM CaCl2,  0.5 mM MgCl2, 5.6 mM 
glucose, 15 mM Hepes, pH 7.4 
High KCL buffer:  95 mM NaCl, 56 mM KCl, 2.2 mM CaCl2,  0.5 mM MgCl2, 5.6 mM 
glucose, 15 mM Hepes, pH 7.4 
 
3.3.12.2 Polarized transport assay 
The VSVG transport assay was carried out as described (Schuck, et al., 2007). MDCKII cells 
grown to confluence on coverslips were infected with EBAG9 adenovirus (chapter 3.3.4) for 




and incubated at 39.5 °C for 6 h. Cells were then shifted to 32 °C, chased in the presence of 
40 µg/ml cycloheximide for the time intervals indicated and analysed by widefield 
microscopy (chapter 3.3.11). 
To monitor Golgi to plasma membrane transport of apical VSVG, cells were incubated at 
19.5 °C in CO2-independent medium containing 40 µg/ml cycloheximide. After 90 min the 
protein was allowed to exit the Golgi at 32 °C for the times indicated. 
 
3.3.12.3 rGH transport assay 
The rGH transport assay was modified after (Scheiffele, et al., 1995). MDCKII cells were 
seeded on 24-mm polycarbonate filters (Costar) and grown for 24 h (Fig. 3-1). Then cells 
were incubated in PBS without MgCl2 and CaCl2 (PBS-) for 15 min to open tight junctions 
and to facilitate virus infection, followed by cotransfection of control and GST-rGH12 
adenovirus or EBAG9 and GST-rGH12 adenovirus for 1 h. After 14 h incubation at 37 °C 
cells were washed in PBS with MgCl2 and CaCl2, radioactively labeled (chapter 3.3.5) and 
chased for the indicated times. Medium was harvested from the apical and basolateral side of 
the filter, cells were lysed in 0,5 % Triton-X-100 in PBS-containing 10× CLAP (NEB) for  
10 min at RT and the protein containing supernatant was collected. Finally, rGH12 was 
precipitated with glutathione beads, resolved by SDS-PAGE and analysed by phosphorimager 
(chapter 3.2.5).    
 
Fig. 3-1: Filter grown MDCK cells. Medium from 
apical and basolateral side is separated by filter. 
 
3.3.12.4 HA transport assay 
Influenza hemagglutinin transport in filter-grown MDCK cells was modified after (Schuck, et 
al., 2007). MDCKII cells were seeded on 24-mm polycarbonate filters (Costar) and grown for 
24 h. Then cells were incubated in PBS without MgCl2 and CaCl2 (PBS-) for 15 min to open 




adenovirus for 1 h at 37 °C. After 12 h incubation at 37 °C cells were washed in PBS with 
MgCl2 and CaCl2 (PBS+), infected with Fowl plaque virus [FPV; 0.45 ml virus / filter (about 
10-20 PFU/cell)] for 1 h and incubated in fresh infection medium for 3 h. Then, filters were 
washed in PBS+, radioactively labeled (chapter 3.3.5) for 8 min, washed in PBS+ and chased 
for the indicated times to measure ER to PM transport. After washing the filter with cold 
PBS+, cells were trypsinized from the apical and basolateral side so that the total surface 
delivery of hemagglutinin (HA) could be measured. Cells were lysed in 2 % NP-40 in PBS- 
containing 1× CLAP, 0,2 % SDS  for 10 min at RT and the protein containing supernatant was 
collected. Finally, HA was resolved by SDS-PAGE and analysed by phosphorimager (chapter 
3.2.5).    
  
3.3.12.5 VSVG transport assay 
For transport assays of VSVG-GFP, COS7 cells were transiently cotransfected using 
LipofectAMINE2000 or Fugene with VSVG-GFP and either EBAG9, EBAG9-DsRed2 or 
empty vectors pcDNA3.1 and pDsRed2, respectively (chapter 3.3.2). Cells were cultured for 
16-24 h at 40°C in a humidified atmosphere, 100 µg/µl cycloheximide were added, followed 
by incubation for 3 h at 15°C before shifting cells to 32°C to resume transport, as described 
(Rojo, et al., 1997). At defined time intervals, cells were processed for immunofluorescence 
as described in chapter 3.3.9.  
 
3.3.12.6 siRNA treatment and VSVG-transport analysis 
MDA-MB435 cells, stably expressing EBAG9, or MCF7 cells were transfected with Alexa 
Fluor 647 labeled siRNA against EBAG9 (3´-AAGATGCACCCACCAGTGTAA-5´) or 
Alexa Fluor 647 labeled “all star negative control” using Oligofectamin (Invitrogen) 
according to manufacturer’s instructions and incubated at 37 °C. After 24 h cells were 
retransfected with siRNA and cells were analysed for EBAG9-GFP expression by FACS 
analysis 24 h later. MCF7 cells were collected after 48 h of siRNA expression, and protein 
lysates (section 3.2.1) were analysed for EBAG9 expression by SDS-Page (chapter 3.2.2) and 




For VSVG-transport analysis cells were re- and co-transfected with siRNA and GFP-tagged 
VSVG-ts045 for 5 h at 37 °C, and finally incubated at 39.5 °C to accumulate VSVG in the 
ER. After 48 h siRNA expression, 100 µg/µl cycloheximide was added, followed by 
incubation for 30 min at 32 °C to allow ER export and subsequent transport beyond the Golgi. 
Cells were fixed in PFA at the times indicated, permeabilized and stained with an antibody 
against GM130. Colocalization was analysed by confocal microscopy (chapter 3.3.11). The 
kinetics of Golgi transition was quantitatively determined by measuring the ratio of 
fluorescence intensity in the Golgi versus the whole cell at 30 min as described in chapter 
3.3.11. 
 
3.3.12.7 Shiga toxin transport assay 
HeLa cells were transiently transfected with EBAG9-GFP or GFP. After 24 h cells were 
incubated with media containing Cy3-Shiga toxin B-fragment (1:1000 dilution of 
concentrated stock) for 45 min on ice as described (Yoshino, et al., 2005). Cells were washed 
twice with cold PBS to remove unbound STB. Warm medium was added, followed by a chase 
at 37 °C. Cells were fixed and processed for immunofluorescence as described in chapter 
3.3.9 and analysed by confocal microscopy (chapter 3.3.11).  
 
3.3.13 Mannosidase activity assay 
Stable EBAG9-GFP or GFP expressing MDA-MB435 cells were lysed in 10 mM KH2PO4 
buffer, pH 6.8, containing 0.5 % Triton X-100 and 1 mM NaN3 for 30 min at 4 °C. After 
centrifugation, protein concentration of the lysate was determined by Bradford assay (chapter 
3.2.1). For the Mannosidase activity assay (Jelinek-Kelly, et al., 1985), 1 mg of protein lysate 
was incubated with 0, 2, 4, 6, 8, 10 or 12 mM p-nitrophenyl-alpha-D-mannopyranoside at  
37 °C. After 0, 30, 60, 90 and 120 min aliquots were taken and mixed with an equal volume 
of 0.5 M Na2CO3 buffer to terminate the enzymatic reaction. Optical density of reaction 
products was measured at 405 nm in a plate reader. To plot enzyme activity as Michaelis-
Menten kinetics, the optical density was plotted against time and the velocity of the reaction 




3.3.14 Lymphocyte activation 
Cytotoxic T lymphocytes (CTL) were derived by activation of 4×10
6
 splenocytes/ml from 








 irradiated (3,000 
rads) splenocytes/ml as stimulators from BALB/c (H-2
d
 haplotype) mice in complete RPMI 
medium supplemented with β-mercaptoethanol. For confocal microscopy analysis, naive 
CD8
+
 T cells were stimulated by culturing cells for 3-4 days with plate-bound anti-CD3ε mAb 
(3 µg/ml) and anti-CD28 mAb (2 µg/ml) in the presence of 50 U/ml IL-2. CD8+ cells were 
purified by negative selection with magnetic beads (Miltenyi Biotec or Dynal), followed by 1-
2 days of culture in the presence of IL-2 and IL-7 (Peprotech; 50 U/ml). Purity of CD8
+
 cells 
was usually greater than 90 %. 
 
3.3.15 Immunological synapse formation 
Dynabeads (4.5 µm) precoated with CD3/CD28 antibodies (Invitrogen) were used to initiate 
synapse formation. 5×10
5
 CTLs were mixed with 5×10
5
 coated beads and incubated for 5 min 
at 37 °C in complete RPMI, allowing the formation of conjugates. After centrifugation for  
4 min at 2000 rpm (Eppendorf-centrifuge), the pellet was responded in RPMI without FCS 
and distributed into wells of collagen coated plates followed by 30 min incubation at 37 °C. 
Next, cells were fixed in either acetone or 2 % PFA and subjected to immunofluorescence 
staining as described in chapter 3.3.9, except that cells were blocked with 5 % BSA. 
Antibodies were incubated in 1 % BSA in PBS and the second antibody was pre-absorbed 
with hamster serum for 30 min at RT.  
 
3.3.16 In vivo tumor growth  
Immunodeficient B6.CB17-Prkdc
scid
 /SzJ homozygous mice (Charles River, Sulzfeld, 
Germany) were transiently anesthetized. Then 2x10
6
 MDA-MB435-GFP or MDA-MB435-
EBAG9-GFP cells in 100 µl PBS were injected into the mammary fat pad. Tumor volume was 
frequently monitored and followed up to 92 days or till a maximum tumor size of 15 mm 
(measured in two rectangular dimensions) was reached. Tumor volume was calculated 






3.4 Statistical analysis 
Results are expressed as mean ± S.D or SEM, as indicated. Data were considered statistically 
significant for p < 0.05, which was determined using the two-tailed unpaired Student’s t test 





To investigate the physiological role of the tumor-associated antigen EBAG9 in epithelial 
cells, mamma carcinoma cells that stably express EBAG9-GFP (MDA-MB435-EBAG9-GFP) 
were used. This situation is analogous to EBAG9 overexpression in tumor cells. In general, 
EBAG9 protein expression levels vary strongly in diverse cancer cells and tissues (Akahira, et 
al., 2004; Reimer, et al., 2005; Takahashi, et al., 2003; Tsuchiya, et al., 2001). This is also 
reflected in a broad range of native EBAG9 protein expression levels in diverse epithelial cell 
lines (Fig. 4-1A). 
 
Fig. 4-1: EBAG9 overexpression in different cell lines. Indicated cell lines either expressing endogenous 
EBAG9 only (A) or stably expressing GFP and EBAG9-GFP (B) were lysed in a buffer containing 25 mM 
Hepes, pH 7.4, 140 mM KCl, 20 mM NaCl, 0.5 mM MgCl2, 0.8 mM PMSF, aprotinin 5 µg/ml, 0.5 % TX-100 
for 30 min at 4 °C. Lysates were spun to deplete nuclei and insoluble material, and 100 µg of each probe was 
resolved by SDS-PAGE and analysed by immunoblotting using rabbit-anti-EBAG9 serum or rabbit-anti-GAPDH 
(loading control). (C) Densitometry analysis of (B) showing the amount of EBAG9 relative to endogenous 
EBAG9 in MDA-MB435 cells normalized to GAPDH. Black bars, endogenous EBAG9; grey bar, overexpressed 
EBAG9-GFP. 
Here, westernblot analysis demonstrated that the expression level of stably transfected 
EBAG9 was 1.7× fold higher than endogenous EBAG9, but still in the range of endogenous 




endogenous EBAG9 expression in MCF-7 cells, EBAG9-GFP stably expressing MDA-
MB435 cells mimic EBAG9 expression in a range similar to primary human tumors. 
 
4.1 Golgi association of EBAG9 
4.1.1 Subcellular localization and morphology of EBAG9 
Since a detailed understanding of the subcellular localization of a protein should provide an 
indication of the physiological process it might be involved in, the localization and dynamics 
of EBAG9 were thoroughly analysed. First, a subcellular localization analysis of EBAG9 by 
confocal microscopy revealed a strong colocalization of EBAG9 with the cis-Golgi marker 
GM130 and with the IC marker ERGIC-53 (Fig. 4-2). The latter was identified as a cargo-
specific transport receptor for ER-to-Golgi traffic known to continuously cycle between these 
two compartments (Appenzeller-Herzog and Hauri, 2006). 
 
Fig. 4-2: EBAG9 localizes to the Golgi as 
well as to the intermediate compartment. 
MDA-MB435 cells stably expressing 
EBAG9-GFP were fixed in PFA, 
permeabilized and stained with antibodies 
against GM130 or ERGIC-53. The 
subcellular distribution of EBAG9-GFP 
(green) and GM130 or ERGIC-53 (red) was 
analysed by confocal microscopy. Merged 
images are shown on the right. Scale bars, 
10 µm.  
 
In the overlay images, it could be seen that cis-Golgi (GM130
+
) and IC (ERGIC-53
+
) were 
not resolved sufficiently as separated compartments. A more detailed analysis, using an 
EBAG9 construct that exhibits a substantially smaller epitope tag (FLAG-tag, 12 aa), 
demonstrated that EBAG9 stronger colocalized with ERGIC-53 ( at 37 °C, mean R = 0,60; at 
15 °C, mean R = 0,57) than with GM130 ( at 37 °C, mean R = 0,28; at 15 °C, mean R = 0,18) 
as quantified by the Pearson`s correlation coefficient (R) (Fig. 4-3). This is consistent with 
earlier studies demonstrating that ERGIC-53 is present in tubulo-vesiclular membrane profiles 
predominantly near the cis-side of the Golgi stack at 37 °C. Theses ERGIC clusters have been 




Schweizer, et al., 1988). Furthermore, it was noted that the morphological integrity of the 
Golgi was not altered by EBAG9 overexpression. 
 
Fig. 4-3: EBAG9 colocalizes stronger with 
ERGIC-53 than GM130. HeLa cells were 
transiently transfected with EBAG9-C-Flag. 
After 24 h, cells were either chased at 15 °C for 
3 h, or directly fixed and stained with antibodies 
against EBAG9, ERGIC-53 and GM130. 
Colocalization of EBAG9 with ERGIC-53 and 
GM130 was assessed by determining the 
Pearson`s correlation coefficient. Data represent 
mean values ± SEM of 16 cells. 
 
4.1.2 Dynamic redistribution of EBAG9 in epithelial cells 
Dynamic molecular interactions are fundamental for many cellular processes. To address 
whether EBAG9 is permanently or dynamically associated with Golgi membranes, 
fluorescence recovery after photobleaching (FRAP) analysis was applied. In FRAP, 
fluorescent molecules are permanently bleached at a region of interest. The rate of 
fluorescence recovery provides a measure of how fast fluorescent molecules move into the 
bleached region and depends on the rates of passive diffusion and active transport of the 
fluorescent molecule through the cell. Secondly, mobility is also influenced by binding 
interactions, which prevent molecules from free diffusion (Sprague and McNally, 2005).  
 
Fig. 4-4: Dynamic association of 
EBAG9 with Golgi membranes. 
MDA-MB435-EBAG9-GFP stably 
transfected cells were 
photobleached in the Golgi area, 
and the recovery of fluorescence in 
the selected area was monitored. 
Images show representative time 
points postbleach. Recovery of 
EBAG9 fluorescence can be 
readily seen after 15-25 min. Insets 
show a higher magnification of the 




After photobleaching of Golgi located EBAG9-GFP, full fluorescence recovery was obtained 
within 15 to 20 min (Fig. 4-4). These data were comparable to those obtained in published 
experiments using tagged p58/ERGIC-53 protein (Tisdale, et al., 1997; Ward, et al., 2001), 
and clearly differed from the much slower transport of a Golgi-resident (GalT) molecule or 
the extremely fast transport of a cytoplasmic protein (εCOPI) (Presley, et al., 1998). These 
results indicated that EBAG9 could traffic between the ER and the Golgi apparatus like 
ERGIC-53, continuously cycling between these two compartments. 
Additionally, the behaviour of EBAG9 was investigated by live cell imaging of MDA-MB435 
cells stably expressing EBAG9-GFP. Many cells exhibited a perinuclear staining pattern 
corresponding to the Golgi, and in some cells budding and fusion reactions of vesicular and 
tubular structures could be observed (indicated by an arrow) (Fig. 4-5). 
 
Fig. 4-5: Vesicular and tubular structures in EBAG9-overexpressing cells. Representative pictures from a 
time-lapse sequence showing movement of EBAG9 containing structures. MDA-MB435 cells stably expressing 
EBAG9-GFP were imaged in Hepes buffered medium with a confocal microscope with a stage heated to 37 °C 
using a 488 nm laser excitation. Sixty frames were collected. Insets show higher magnification of the area 
indicated by a square. Budding and fusion reactions of vesicular and tubular structures are indicated by an arrow. 
Scale bar, 10 µm. 
This demonstrated that EBAG9 moves with vesicles involved in protein trafficking, in which 




three major classes of coated vesicles: COPI, COPII or Clathrin coated vesicles. Clathrin-
coated vesicles can be distinguished from other vesicle populations, since transferrin is 
specifically endocytosed by clathrin-coated endosomal vesicles (Hanover, et al., 1984; 
Kirchhausen, et al., 2005). Time-lapse imaging of EBAG9 and transferring-containing 
vesicles showed that transferrin-labeled endosomal carriers were clearly separate from 
EBAG9-GFP stained vesicles (Fig. 4-6A).     
 
Fig. 4-6: EBAG9 localizes to DND99 positive compartments, but not to clathrin-coated vesicles containing 
transferrin. (A) Representative images of a time-lapse sequence showing movement of EBAG9-GFP and 
transferring-containing vesicles. MDA-MB435 cells stable expressing EBAG9-GFP were imaged in Hepes 
buffered medium with a confocal microscope with a stage heated to 37 °C using a 488 nm and 532 nm laser 
excitation. 40 frames were collected. Insets show higher magnification of the area indicated by a square. Scale 
bar, 5 µm. (B) Representative images of a time-lapse sequence showing movement of EBAG9-GFP and DND99 
containing vesicles. MDA-MB435 cells stably expressing EBAG9-GFP were imaged in Hepes buffered medium 
with a confocal microscope with a stage heated to 37 °C using a 488 nm and 532 nm laser excitation. 20 frames 




In contrast, a strong overlap of EBAG9 with DND99 was found (Fig. 4-6B). DND99 consists 
of a fluorophore linked to a weak base that is only partially protonated at neutral pH and thus 
freely permeate to cell membranes, whereas in cellular compartments with low internal pH, 
such as lysosomes, it accumulates selectively.   
Taken together, these results indicated that EBAG9 moves with non-clathrin coated vesicles 
within the cell and is only transiently associated with the Golgi, presumably shuttling between 
the ER and the Golgi. Furthermore, EBAG9 might associate with lysosomes. 
 
4.2 EBAG9 associates with coatomer complex I 
To obtain mechanistical insight into the cellular function of EBAG9 within the secretory 
pathway, I searched for interaction partners. A former interaction screen employing an 
EBAG9-GST fusion protein pull-down assay, which used a bait different from that previously 
used for a yeast-two hybrid screen (Ruder, et al., 2005), pointed towards a possible interaction 
with COPI. In this screen, COPI complex subunits δCOP, γ2COP, γCOP, β2COP, βCOP, 
β´COP and αCOP were identified by mass spectrometry (data generated by Dr. Tatjana A. 
Reimer, AG Dr. A. Rehm).  
To confirm that EBAG9 and COPI can associate in epithelial cells, coimmunoprecipitation 
studies in EBAG9-GFP expressing HeLa cells were performed (Fig. 4-7).  
 
Fig. 4-7: EBAG9 associates with βCOP. HeLa cells were 
transiently transfected with EBAG9-GFP or GFP. After 24 
h, EBAG9-GFP or GFP were immunoprecipitated from 
TX-100 lysates with an anti-GFP antibody (IP). Samples 
were washed and analysed by SDS-PAGE and 





An association between full length EBAG9-GFP and endogenous βCOP could be detected in 
those cells, but not in GFP control cells.  
To map a possible interaction site, stable MDA-MB435 cell lines expressing mutant EBAG9 
(∆176-213 or ∆30-213) were generated and used for coimmunoprecipitation experiments. 
Additionally, transiently overexpressed, truncated forms of EBAG9 (∆1-27, ∆1-163 and ∆1-
27/∆176-213) were employed as a bait to capture interacting endogenous βCOP. However, 
none of these EBAG9 mutants coimmunoprecipitated with endogenous βCOP (Fig. 4-8). 
 
Fig. 4-8: Only full length EBAG9 interacts with βCOP. MDA-MB435 cells stably expressing EBAG9-GFP 
(Wt), GFP, EBAG9-∆176-213-GFP, EBAG9-∆30-213-GFP or MDA-MB435 cells transiently transfected with 
EBAG9-GFP, GFP, EBAG9-∆1-27-GFP, EBAG9-∆1-163-GFP, EBAG9-∆1-27/∆176-213-GFP were used. After 
24 h, GFP constructs were immunoprecipitated from TX-100 lysates with an anti-GFP antibody (IP). Samples 
were washed and analysed by SDS-PAGE and immunoblotting (WB) using anti-βCOP or biotinylated anti-GFP 
antibodies.  
Next, the presence of EBAG9 on COPI transport carriers was tested by immunofluorescence. 
MDA-MB435 cells stably expressing EBAG9 were treated with nocodazole to better visualize 
a possible colocalization. Nocodazole is a microtubule depolymerising agent which causes the 
Golgi apparatus to break down into functional ministacks (Dinter and Berger, 1998). Here, 





Fig. 4-9: EBAG9 is localized on COPI transport carriers. MDA-MB435 cells stably expressing EBAG9-GFP 
were treated with nocodazole for 2 h, fixed in PFA, permeabilized and stained with an antibody against γCOPI. 
Subcellular distribution of EBAG9-GFP (green) and γCOPI (red) was analysed by confocal microscopy. Merged 
images are shown on the right. Scale bars, 5 µm.  
This observation suggested that COPI-coated transport carriers were also positive for EBAG9. 
In summary, these data indicated that EBAG9 associates with COPI coats in vitro and in vivo.  
 
4.3 EBAG9 impairs the anterograde transport route 
The dynamic redistribution of EBAG9 within the ER-cis-Golgi trafficking route and the 
identified COPI association pointed towards a potential function of EBAG9 in biosynthetic 
cargo transport. Thus, constitutive and regulated secretion as well the anterograde transport 
between the ER and the Golgi were thoroughly investigated.  
 
4.3.1 EBAG9 inhibits protein transport before the medial Golgi 
in a cell-type dependent manner 
4.3.1.1 EBAG9 affects regulated secretion in secretory as well as 
constitutive secretion in epithelial cells 
To see whether EBAG9 might influence cargo delivery, epithelial non-secretory MDA-
MB435-EBAG9-GFP cells, equipped only with a constitutive pathway, were transfected with 
a reporter vector encoding human growth hormone (hGH). Then the secretion of hGH into 
cell culture supernatant was measured over 30 min. In EBAG9-GFP transfectants, constitutive 





Fig. 4-10: EBAG9 decreases constitutive release of hGH in epithelial cells. (A, B) MDA-MB435-EBAG9-
GFP, -GFP or -EBAG9-∆30-213-GFP stably transfected mamma carcinoma cells were transfected with human 
growth hormone (hGH). hGH secretion was stimulated by incubation in low KCl (5.6 mM) containing secretion 
buffer for 30 min. Release of hGH into culture supernatant and total cell lysate associated hGH was determined 
by ELISA. All data are means ± S.D. of three independent experiments, performed in triplicate and normalized 
to total hGH. *** p≤ 0,0005; ** p≤ 0,005; Student's unpaired t test; n.s., non significant. 
Furthermore, a hGH release assay was carried out in PC12 cells, to reconcile the finding that 
EBAG9 controls regulated synaptic-like vesicle release in neuroendocrine PC12 cells (Fig. 
4-11). This neuroendocrine cell line is equipped with a regulated as well as a constitutive 
pathway. The assay applied here induces [Ca
2+
] regulated secretion of hGH by high [K+] 





] channels (Khvotchev, et al., 2003).  
 
Fig. 4-11: EBAG9 impairs the regulated, but not the constitutive release of hGH in neuroendocrine cells. 
(A, B) PC12 cells were transiently cotransfected with hGH and EBAG9-GFP or GFP. After 48-72 h, hGH 
secretion was stimulated with low KCl solution for 30 min (constitutive secretion) (A), or for 10 min in high KCl 
solution (56 mM, regulated secretion) (B). Release of hGH was measured as described in Fig. 4-10. All data are 
means ± S.D. of three independent experiments, performed in triplicate and normalized to total hGH. 





In contrast to non-secretory cells, the constitutive pathway was unaltered, whereas regulated 
secretion upon transient EBAG9 transfection was inhibited as shown before (Ruder, et al., 
2005).  
As an additional control, a truncated variant of EBAG9, the EBAG9-∆30-213-GFP mutant 
was used to rule out that the inhibition of secretion results from local overloading with 
transfected EBAG9-GFP (Fig. 4-10B). However, although still attached to Golgi membranes 
due to a membrane anchor, this mutant behaved essentially as it did in GFP control cells. In 
agreement, EBAG9-∆30-213-GFP also failed to cause a significant increase of the Tn- and 
TF-epitope (Fig. 4-12), whereas full length EBAG9 overexpression in epithelial cell lines 
generated cell surface deposition of Tn- and TF-glycans (Engelsberg, et al., 2003).  
 
Fig. 4-12: Aberrant expression of cell surface glycans caused by EBAG9 overexpression. HEK 293 cells 
were transfected with EBAG9-GFP, EBAG9-∆30-213-GFP, or GFP as a control. After 48 h cells were processed 
for immunofluorescence staining. Cells were incubated with primary antibodies including mouse IgM (isotype 
control), anti 22.1.1 Ab (A) and anti TF mAb (B) on ice.  After 30 min, cells were washed and incubated with 
goat-anti-mouse-IgG/IgM-APC (FL4) for 30 min on ice. Cells were analysed by flow cytometry. To exclude 
damaged cells from evaluation, cells were costained with propidium iodide. Background staining for isotype 
controls was always in the same range between differently transfected cells. Tn and TF cell surface expression 
was significantly upregulated in EBAG9-GFP expressing cells, compared to control GFP transfected cells or 
truncated mutant EBAG9-∆30-213-GFP transfected cells. Data represent the mean values ± S.D. of three 
independent experiments. * p≤ 0,05; Student’s unpaired t Test. 
To revisit this antibody based assay, specific lectins were applied. Lectins are proteins able to 
bind specifically and reversibly to mono- or oligosaccharides. Confocal microscopy 







structures. These structures were reminiscent of the ER and mostly separated from EBAG9-
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glycan structures within the cell in stably transfected mamma carcinoma cells. 
 
Fig. 4-13 Truncated O-glycan structures accumulate within the cell by EBAG9 overexpression. (A, B) 
MDA-MB435 cells stably expressing EBAG9-GFP (white) or GFP were fixed in cold acetone for 7 min, 
permeabilized with 0.25 % TritonX-100 and blocked with 5 % BSA for 60 min. Cells were washed in special 
washing medium (10 mM Hepes, pH 7,5; 0,15 M NaCl) and stained with lectins against VVA (A), PNA (B) and 
GM130 in special binding medium (10 mM Hepes, pH 7,5; 0,15 M NaCl; 0,08 % NaAzide; 0,1 mM CaCl2; 0,01 
mM MnCl2). Scale bars, 5 µm.  
These results suggested that EBAG9 modulates the secretory pathway in a cell-type-specific 
manner depending on the unique molecular composition of the cell. Furthermore, they 
indicated that the aberrant expression of glycans in EBAG9-overexpressing cells could be 




4.3.1.2 Transport polarity of apical and basolateral cargo is 
unaltered 
Loss of polarity is a hallmark of tumorigenesis in epithelial cells. N-linked glycans as well as 
O-linked glycans have been shown to provide sorting signals for apical protein transport in 
polarized Madin-Darby canine kidney (MDCK) and Caco-2 cells (Benting, et al., 1999; 
Monlauzeur, et al., 1998). To investigate the late stages of membrane glycoprotein transport 
and sorting between plasma membrane domains, the MDCK cell line is a useful model 
system. MDCK cells exhibit the properties of a polarized transporting epithelium (Matlin and 
Simons, 1983). Since EBAG9 is overexpressed in several tumors of epithelial origin and 
induces the expression of tumor-associated glycans, the question of whether EBAG9 might 
influence polarized transport in MDCK cells was addressed. First, two variants of the 
temperature-sensitive O45 strain of vesicular stomatitis virus glycoprotein (VSVG-tsO45) 
coupled to GFP were used to monitor basolateral and apical transport. The apical VSVG 
(aVSVG) mutant travels selectively to the apical surface, whereas the basolateral VSVG 
(bVSVG) mutant is transported to the basolateral surface (Keller, et al., 2001). Both 
glycoproteins have a reversible folding defect at 39.5 °C, causing them to accumulate in the 
ER. Shifting to the permissive temperature of 32 °C induces rapid folding, export from the ER 
and delivery to the corresponding plasma membrane. If the temperature shift is combined 
with cycloheximide treatment to block protein biosynthesis, ER-accumulated VSVG can be 
chased through the secretory pathway as a synchronous wave. Polarized MDCK cells infected 
with EBAG9-encoding adenovirus sorted VSVG to the basolateral (Fig. 4-14A) or apical 
(Fig. 4-14B) membrane, but transport was strongly delayed. In control cells, most of the 
bVSVG was delivered to the basolateral membrane within 40 min after the temperature shift. 
In contrast, in EBAG9-overexpressing cells, even after 90 min the majority of bVSVG was 
still intracellular and only a small fraction was found at the basolateral membrane (Fig. 
4-14A). To investigate the transport between Golgi and plasma membrane in more detail, cells 
were incubated for 90 min at 19.5 °C to accumulate aVSVG in the Golgi before chasing it at 
the transport permissive temperature. At 45 min, significant levels of aVSVG signals were 
still associated with the Golgi area. This clearly visible difference as compared to control cells 






Fig. 4-14: EBAG9 delays surface transport of basolateral and apical VSVG in polarized MDCK cells. (A, 
B) Coverslip-grown MDCK cells expressing adenovirally-encoded EBAG9 were infected with a second 
adenovirus encoding GFP-tagged (A) basolateral or (B) apical VSVG-ts045. Cells were incubated at 39.5 °C to 
accumulate VSVG in the ER (0 min panel A) or, if further incubated for 90 min at 19.5 °C, in the Golgi (0 min 
panel B). Subsequently, cells were shifted to the transport-permissive temperature of 32 °C, and transport 
kinetics of VSVG-GFP from the ER to the basolateral (A) or from the Golgi to the apical (B) surface was 
followed for different time intervals. Cells were fixed in PFA, and analysed by widefield microscopy.  
Additionally, a GST-coupled, glycosylated variant of rat growth hormone (rGH) that is 
secreted mostly from the apical membrane was investigated (Guan, et al., 1985). Here, 
MDCK cells were grown on filters to separately collect apical and basolateral medium 
containing radioactively labeled rGH. Consistent with the results above, polarized MDCK 
cells overexpressing EBAG9 sorted rGH correctly, but secretion was decreased (Fig. 4-15). 
Within an observation period of 60 min, only approximately 20 % of the rGH was secreted, 
73 % of it into the apical medium, when EBAG9 was overexpressed (Fig. 4-15B). Whereas in 
control cells, approximately 70 % (apical and basolateral) of the rGH was secreted, 77 % of it 





Fig. 4-15: EBAG9 decreases surface transport of rGH in polarized MDCK cells. (A, B) Filter-grown MDCK 
cells expressing adenovirally-encoded EBAG9 or control cells were infected with a second adenovirus encoding 
GST-tagged rat growth hormone (rGH). Newly synthesized protein was radiolabeled. After the time intervals 
indicated, apical and basolateral media as well as total cell lysates were collected, the amount of labeled rGH in 
all three fractions was determined by pull-down of rGH with gluthathione beads, SDS-PAGE and 
autoradiography. The percent transport to the apical and basolateral side is calculated and shown for control and 
EBAG9, respectively. 
In agreement with these findings, a strong delay in ER-to-plasma-membrane transport in 
EBAG9-overexpressing MDCK cells was also observed for influenza hemagglutinin, another 
marker for biosynthetic surface transport (Fig. 4-16). When MDCK cells are infected with 
influenza A viruses, the spike glycoproteins are inserted predominantly in the apical cell 
surface, leading to virus assembly at the apical plasma membrane domain. The cell surface 
transport of hemagglutinin can be easily measured by a sensitive tryptic assay (Matlin and 
Simons, 1983; Rodriguez Boulan and Sabatini, 1978). After a chase for 60 min of infected 
pulse-labeled cells, the amount of hemagglutinin precursor (HA, HA0) was diminished. 
Instead, the polypeptides HA1 and HA2 appeared (Fig. 4-16A). These are formed by a cell-
dependent cleavage during transport of the precursor to the plasma membrane and remain 
associated by disulfide bonding. The HA1 harbours the original amino terminus of the 
hemagglutinin precursor and is a peripheral membrane protein, localized on the outside of the 
infected cell. The HA2 is a transmembrane polypeptide with about 11 amino acid residues 
exposed on the cytoplasmic membrane face. Both HA1 and HA2 are glycosylated (Matlin and 
Simons, 1983). After 60 min chase, 73,7 % of the hemagglutinin A had reached the plasma 
membrane in control cells, whereas in EBAG9-overexpressing cells only 7,6 % were 





Fig. 4-16: EBAG9 overexpression blocks transport of hemagglutinin and VSVG-GFP. (A) Influenza 
hemagglutinin transport in filter-grown MDCK cells was assayed as described (Schuck, et al., 2007), except that 
trypsin was applied from both the apical and the basolateral side so that the total surface delivery of 
hemagglutinin was measured. HA = full-length hemagglutinin, HA0 = unglycosylated HA, HA1 and HA2 = 
trypsin cleavage products of HA. In control cells, HA became accessible to trypsin cleavage within 40 min, 
whereas even after 60 min almost no HA had reached the cell surface in EBAG9-overexpressing cells, as shown 
by lack of HA1 and HA2 cleavage products. (B) Quantification of hemagglutinin surface transport shown in (A). 
EBAG9 (), and control cells (▲). 
Taken together, this provided evidence, that EBAG9 overexpression inhibits protein transport 
but does not influence biosynthetic sorting routes at the TGN. However, this transport block 
might result in a short-term alteration of cell surface protein composition caused by EBAG9 
overexpression.  
To analyse the kinetics of the EBAG9-imposed transport block, the refill of anterograde 
transported VSVG-GFP into the Golgi region after photobleaching was determined (Fig. 
4-17). 
 
Fig. 4-17: EBAG9 overexpression inhibits 
transport of VSVG-GFP. COS7 cells were 
cotransfected with VSVG-GFP and EBAG9-DsRed2 
or empty vector. After 48 h at 40 °C, 20 mM Hepes 
was added and cells were moved to a confocal 
microscope, equipped with a stage heated to 32°C. 
Using the 488 nm laser line at full power, selective 
photobleaching of GFP within the Golgi was 
performed and the recovery monitored by time lapse 
imaging at 30 s intervals at low intensity 
illumination. Fluorescence quantification was done 
using Zeiss LSM software. The recovery of VSVG-
GFP Golgi fluorescence was twofold faster in control 
than in EBAG9 expressing cells. Data represent 
mean values ± SEM of a total of 6 cells from three 
independent experiments, *** p≤ 0,0005; Student’s 




In accordance with previous results, VSVG transport into the Golgi area exhibited a 
substantially faster kinetics in control cells than in EBAG9-overexpressing cells. Here, 2.5 
times less VSVG reached the Golgi within a 15 min observation period.  
 
4.3.1.3 Anterograde transport is accelerated by EBAG9 
downregulation  
To analyse the physiological role of EBAG9 in epithelial cells and to confirm the observed 
transport block, siRNA mediated depletion of EBAG9 was applied. Efficiency of siRNA-
mediated downregulation was verified in EBAG9-GFP transfected cells by loss of GFP-
fluorescence intensity, which was about 50% (Fig. 4-18).  
 
Fig. 4-18: Downregulation of overexpressed EBAG9-GFP by EBAG9 specific siRNA. MDA-MB435 cells 
stably transfected with EBAG9-GFP were transfected with Alexa Fluor 647 labeled siRNA against EBAG9 or 
Alexa Fluor 647 labeled “all star negative control” (Quiagen) using Oligofectamin (Invitrogen) according to the 
manufacturer’s instructions. After 24 h cells were re-transfected and incubated again for 24 h. Cells were 
collected, washed, and levels of EBAG9-GFP expression in cells were analysed by flow cytometry on a 
FACSCalibur
TM
 flow cytometer (BD Biosciences), using CellQuest analysis software. Representative graphs 
from the three experiments that were performed are shown. Blue curves, EBAG9-GFP (siRNA control or siRNA 
EBAG9 as indicated); red curves, EBAG9-GFP (isotyp control). 
In addition, immunoblotting followed by densitometry analysis revealed a reduced expression 





Fig. 4-19: Downregulation of endogenous EBAG9 by EBAG9 specific siRNA. (A) HeLa cells were 
transfected with siRNA EBAG9-Alexa Fluor 647, siRNA Control-Alexa Fluor 647 and mock control as 
described in Fig. 4-18. Cells were lysed for 30 min at 4°C. Lysates were spun to deplete nuclei and insoluble 
material, and 100 µg of each probe was resolved by SDS-PAGE and analysed by immunoblotting using rabbit-
anti-EBAG9 serum or rabbit-anti-Calnexin. Protein bands were quantified by densitometric scanning and are 
shown in (B).  
Next, it was tested whether the delivery of VSVG-GFP to the plasma membrane (PM) might 
be accelerated in EBAG9-specific siRNA treated MDA-MB435 cells. After release of the 
temperature block, VSVG was chased until all cargo had reached the Golgi (10 min), 
followed by emergence of cargo carriers at the PM (30 min). At 30 min, more VSVG 
containing vesicles moving towards the plasma membrane could be seen in siRNA EBAG9 
transfected cells than in control cells (Fig. 4-20A). To quantitatively measure the kinetics of 
Golgi transition, the ratio of fluorescence intensity in the Golgi versus the whole cell was 
determined at 30 min (Fig. 4-20B; chapter 3.3.11). This was consistent with the assumption 
that VSVG was transported through the Golgi significantly faster in EBAG9 siRNA treated 
than control cells.  
Additionally, effectiveness of VSVG delivery to the plasma membrane was determined by 
using an antibody against an extracellular epitope of VSVG. The percentage of cells with 





Fig. 4-20: VSVG transport 
is accelerated by EBAG9 
downregulation. (A) 
MDA-MB435 cells were 
transfected with 
fluorescently labeled siRNA 
and incubated at 37 °C. 
After 24 h cells were re- 
and co-transfected with 
siRNA and GFP-tagged 
VSVG-ts045 (green) for 5 h 
and finally incubated at 
39.5 °C to accumulate 
VSVG in the ER (0 min). 
After 48 h siRNA 
expression, 100 µg/µl 
cycloheximide was added 
and cells were shifted to 32 
°C for up to 30 min to allow 
ER export and subsequent 
transport beyond the Golgi. 
Cells were fixed in PFA, 
permeabilized and stained 
with an antibody against 
GM130 (red) and analysed 
by widefield microscopy. 
(B) Shown is the number of 
cells (frequency) for each 
group of Golgi versus total 
cell fluorescence (Relative 
Golgi fluorescence). Data 
are means ± S.D. 60 cells 
each of two independent 
experiments; ***p≤ 0,0005; 
Student's unpaired t test; 







Fig. 4-21: Surface 
transport of VSVG is 
accelerated in EBAG9 
depleted cells. (A) Hela 
cells were transfected with 
fluorescently labeled siRNA 
and 24 h later co-
transfected with siRNA and 
GFP-tagged VSVG-ts045 
(green) for 4 h. Then, cells 
were shifted to 39.5 °C to 
accumulate VSVG in the 
ER (0 min). After 48 h, 50 
µg/µl cycloheximide was 
added and cells were shifted 
to 32 °C for up to 45 min to 
allow ER to Golgi transport 
(15 min), and subsequent 
transport beyond the Golgi 
(30 min). Cells were placed 
on ice at the times 
indicated, stained with anti-
VSVG antibody (TKG) 
directed against an 
extracellular epitope of 
VSVG to label VSVG 
protein at the cell surface 
(red), fixed and followed by 
widefield microscopy 
analysis. (B) Quantification 
of cells chased for 30 min. 
Shown is the percentage of 
cells with VSVG surface 
staining. Data are means ± 
S.D. from n = 18 or 12 cells 
in each group (n = two 
independent experiments), 
*p≤0,05; Student's unpaired 
t test; Scale bars, 5 µm. 
In cells treated with siRNA EBAG9, essentially all cells expressed VSVG on the plasma 
membrane within 30 min. In contrast, only 16,7 % of control cells showed cell-surface 
deposited VSVG at 30 min. In control cells, it took even 45 min till all VSVG molecules had 
reached the plasma membrane (Fig. 4-21). Thus, it can be concluded that EBAG9 impairs the 





4.3.2 EBAG9 inhibits the biosynthetic transport at a step 
between the IC and medial-Golgi  
4.3.2.1 EBAG9 affects transport of a membrane glycoprotein at a 
pre-medial Golgi step 
To further localize the EBAG9-imposed transport block in epithelial cells, the sensitivity of 
major histocompatibility complex (MHC) class I antigen to Endoglycosidase H (EndoH) 
digestion was examined (Fig. 4-22).  
 
Fig. 4-22: MHC class I transport is inhibited in a pre-medial Golgi compartment by EBAG9 
overexpression. (A) HeLa cells were infected with EBAG9- or LacZ-encoding adenovirus (MOI 5-20) for 14-16 
h. Cells were labeled with [
35
S]-methionine/cysteine for 10 min at 37 °C, followed by a chase at 19.5 °C for the 
times indicated. MHC class I was immunoprecipitated from NP-40 lysates with W6/32 antibody which 
recognizes properly folded MHC class I complexes, samples were treated (+/-) with EndoH and analysed by 
SDS-PAGE. HCR = Endo H resistant heavy chain, HCS = Endo H sensitive heavy chain. Light chain, β2m, was 
omitted from the gel. (B) An aliquot of the immunoprecipitates was subjected to neuraminidase treatment or was 
mock treated (NANA), followed by 1-d isoelectric focusing gel analysis (*sialylated forms). 
HeLa cells were transduced with EBAG9- or β-galactosidase encoding adenovirus, followed 
by metabolic labelling for 10 min, and chased up to 180 min at 19.5 °C. At 19.5 °C, transport 
processes within the Golgi are significantly delayed and allow a higher resolution of glycan-
modifying enzyme activities. MHC class I molecules were recovered from cell lysates using 




neuraminidase, followed by SDS-PAGE (Fig. 4-22A) and 1d-isoelectric focusing gel (1d-IEF) 
analysis (Fig. 4-22B). In control cells, the acquisition of EndoH resistance was detected after 
60 min and finally, after 180 min all molecules had passed the medial Golgi. In EBAG9 
transduced HeLa cells Endo H resistant forms were not detected until 120 min. Even after 180 
min only 1/3 of MHC class I molecules had acquired Endo H resistance and substantial 
amounts of EndoH-sensitive heavy chains persisted (Fig. 4-22A). This suggested that the 
EBAG9-imposed transport block must occur before the medial Golgi. In contrast, the addition 
of sialic acids occurs within the trans-Golgi and leads to a negative charge shift. This can be 
visualized by treatment of the samples with neuraminidase (NANA), since the enzyme 
cleaves sialic acids of branched glycans. In agreement with a transport block at a level prior to 
the medial Golgi, 1-d isoelectric focusing gel analysis revealed a transfer of sialic acids in Ad-
EBAG9 transduced cells only at 120 and 180 min of chase (indicated by * Fig. 4-22B).  
In summary, it can be inferred that MHC class I molecules that pass the EBAG9-induced 
transport block in a pre-medial Golgi compartment finally undergo sialylation in the trans-
Golgi compartment.  
 
4.3.2.2 The delivery of anterograde cargo from the ER to the IC is 
not delayed by EBAG9 
To address whether the ER exit of cargo protein is already disturbed by EBAG9 
overexpression, a transport assay with VSVG-GFP on a short time scale was performed. 
Transiently transfected COS7 cells were rapidly shifted from 40 °C to 32 °C for 3 min to 
allow release of newly folded VSVG from ER exit sites. After 3 min, VSVG was already 
clearly separated from Sec23 positive vesicles in all cells. Thus in EBAG9-overexpressing 
cells, cargo loading and the budding and scission of VSVG-containing COPII vesicles had 
occurred in a proper sequence (Fig. 4-23A, B top row). Additionally, a partial overlap of 
VSVG with γCOPI and ERGIC-53 was observed in most cells. This pointed toward an 
accurately accomplished coat switch between COPII and COPI carriers. VSVG entered the IC 
at a similar rate in all cells. However, VSVG-containing transport intermediates often 
appeared densely clustered in the presence of EBAG9, whereas in control cells smaller 






Fig. 4-23: EBAG9 targets the 
delivery of anterograde cargo from 
the intermediate compartment to 
the cis-Golgi. COS7 cells were 
transiently cotransfected with VSVG-
GFP (green) and empty vector (A), or 
EBAG9-dsRed (blue) (B). To 
accumulate VSVG-GFP in the ER, 
cells were incubated at 40 °C. After 24 
h the temperature was shifted to 32 °C 
for exactly 3 min to release the cargo. 
Cells were immediately fixed in PFA, 
permeabilized and stained with 
antibodies against Sec23, γCOP, 
ERGIC-53 or GM130 (red), as 
indicated. Images were acquired using 
confocal microscopy. Merged images 
are on the right. Insets show a higher 
magnification of the area indicated by 





These structures resemble pleiomorphic tubulovesicular ER-to-Golgi carriers (EGCs) (Marra, 
et al., 2007; Polishchuk, et al., 2009; Presley, et al., 1997), which appeared significantly 
expanded in EBAG9-overexpressing cells compared to controls.  
In agreement with these results, EBAG9 overexpression itself had no effect on the recruitment 
of εCOP-YFP onto Golgi membranes, as shown by FRAP analysis of double transfected 
MDA-MB435 cell lines (Fig. 4-24).  
 
Fig. 4-24: Recruitment of coatomer subunits to Golgi membranes remains unaltered in the presence of 
EBAG9. MDA-MB435 cells stably expressing εCOPI-YFP were transfected with EBAG9-DsRed2 or empty 
vector. After 24 h cells were imaged in Hepes buffered medium with a confocal microscope, equipped with a 
stage heated to 37 °C. Excitation of YFP was done with a 514 nm laser excitation wavelength, and 543 nm 
excitation wavelength was used for DsRed2. Selective photobleaching of YFP within the Golgi was performed 
using the appropriate laser line at full power. Recovery was then monitored by time lapse imaging at 15 s 
intervals at low intensity illumination. Fluorescence quantification was done using Zeiss LSM software. Data 
represent mean values ± SEM of a total of 26 cells from three independent experiments.  
Here, the εCOP-YFP fluorescence signal within the Golgi region was selectively bleached 
and recovery was measured over time in EBAG9 or control transfected cells. However, this 
assay measures only the recruitment of cytoplasmic coatomer components, but not the fusion 
of COPI coated carriers with target membranes.  
Taken together, the results suggested that EBAG9 is present on COPI-coated carriers that 





4.3.2.3 Priming and docking of vesicles is undisturbed by EBAG9 
According to Ruder et al. (2005) and confirmed by the EBAG9-imposed inhibition of hGH 
secretion in neuroendocrine PC12 cells, EBAG9 also delays regulated secretion. Most recent 
literature has shown that COPI components are involved in the maintenance of 
endosomal/lysosomal sorting (Razi, et al., 2009). Hence, another system of regulated 
cytotoxic secretion, the response of cytotoxic T-cells (CTL), was investigated to gain more 
mechanistic insight into EBAG9 function.  
Ruder et al. (2009) demonstrated in EBAG9 KO mice that the loss of EBAG9 confers an 
enhanced cytolytic capacity on CTLs. The transfer of cytolytic agents from secretory 
lysosomes in CTLs is critically dependent on the cell’s capacity to form a so-called 
immunological synapse. The immunological synapse is a stable region of contact between a T 
cell and an antigen-presenting cell that forms through cell–cell interactions of adhesion 
molecules. The mature immunological synapse contains two distinct, stable membrane 
domains: a central cluster of TCRs, known as the central supramolecular activation cluster 
(cSMAC), and a surrounding ring of adhesion molecules known as the peripheral 
supramolecular activation cluster (pSMAC). In turn, this polarization of the T cell allows 
effector molecules to be focused directly toward the antigen-bearing target cell (Montoya, et 
al., 2002; Reichardt, et al., 2007). To address a potential influence of EBAG9 on the 
formation of the immunological synapse, an immunofluorescence staining of CTLs 
conjugated with anti-CD3/CD28-conjugate microbeads was performed. These beads engage 
the T cell receptor and induce the regulated secretion of lytic granule content. A simultaneous 
detection of lytic granule reorientation and localization of the signalling zone molecule Lck 
was performed. CTLs were allowed to form conjugates with anti-CD3/CD28 mAb-coated 
microbeads, which acted as surrogate APCs, for 15 min, followed by anti-granzyme B and 
anti-Lck staining. Synapse formation for bead-conjugated T cells was assessed by the 
reorientation of both markers. Clusters of coalesced Granzyme B-stained lytic granules could 
be identified exclusively in conjugated T cells, surrounded by Lck staining (Fig. 4-25B). This 
pattern differed markedly from unconjugated, nonpolarized T cells in which granules were 
scattered at the cell periphery (Fig. 4-25A). Consistent with the short duration of conjugate 




Among the conjugates analysed (n = 10 for each group), similar numbers of granules in Wt 
and KO CTLs showed a tight polarization of the majority of granules at the synapse.  
 
Fig. 4-25: Immunological synapse formation is indistinguishable between Wt and EBAG9-/- CTLs. CTLs 
from EBAG9 Wt and KO mice were generated and purified as described in methods. CTLs were mixed in a 1:1 
ratio with CD3/CD28 precoated Dynabeads, centrifuged for 5 min, and incubated for another 5 min at 37 °C. 
Conjugates were plated on poly-L-lysine coated coverslips, and incubated for additional 15 min before fixation 
with PFA and permeabilization. Granules were visualized by intracellular staining with the secretory lysosome 
marker Granzyme B-Alexa Fluor 647 (reassigned to red), and the signaling zone molecule Lck (green). 
Representative images are shown. At the 15 min time point, unconjugated T cells could be easily identified and 
exhibited a scattered, non-polarized distribution of lytic granules at the cell periphery (A). In T cells conjugated 
with microbeads, in both genotypes a clearly visible focusing of lytic granules toward the T cell-microbead 
interface occurred. In this polarized cluster of granules, substantial accumulation of Lck-positive structures was 
visible (B, Merged images). Data are representative of one experiment with CTLs from n = 3 animals per 
genotype, with at least 20 conjugates analysed. Polarization was identified in 6 synapses per group. Bar 5µm.  
These data indicate that EBAG9 is not involved in the secretion process at the plasma 
membrane itself, but rather acts upstream through regulation of trafficking steps toward the 
maturation of secretory lysosomes. 
In addition, the redistribution of EBAG9-GFP upon the formation of the immunological 




and CD3/CD28-coated microbeads was assessed by anti-cathepsin D staining. Whereas in 
nonpolarized CTLs cathepsin D-positive organelles were distributed clearly separately from 
the perinuclear staining pattern of EBAG9-GFP, upon polarization EBAG9-GFP was 
relocated towards the synapse. The EBAG9-GFP-positive organelles surrounded the cathepsin 
D-containing granules, but a fusion between both compartments was rarely seen (Pearson’s 
correlation coefficient r = -0.10 ± 0.18).  
 
Fig. 4-26: EBAG9 moves to the immunological synapse upon polarized stimulation of CTLs. CTLs were 
generated and transfected with EBAG9-GFP (green) as described in Methods. CTLs were mixed with 
CD3/CD28-precoated Dynabeads, incubated for 5 min at 37 °C, plated on coverslips, and incubated for another 
30 min before fixation and permeabilization. Lytic granules were stained with anti-cathepsin D antibody (red). 
Representative images of non-conjugated and non-polarized T cells are shown in the top row. Polarized T cells 
with conjugated beads is shown below. Data are from one experiment with CTLs from n = 3 animals. At least 20 
conjugates were analysed (r =-0.10 ± 0,18). Scale bars: 5 µm. Insets have additional magnifications of 2- to 3-
fold. 
Taken together, this provides evidence that EBAG9 is not involved in priming and docking of 
vesicles before fusion and release. Therefore the underlying cause must lie within a process 
further upstream, either within the Golgi or the endosomal transport.  
 
4.4 Lack of tumor-promoting effect of EBAG9 in 
immunodeficient mice 
To investigate a putative role of EBAG9 overexpression in tumor pathogenesis in further 
detail, the influence of EBAG9 on in vivo tumor growth of mamma carcinoma cells in severe 
combined immunodeficiency (SCID) mice was analysed. In this T- and B-lymphocyte 
deficient model, no significant difference in tumor growth kinetics between control and 
MDA-MB435-EBAG9-overexpressing tumor cells was seen until day 35. However, at later 




control tumors (Fig. 4-27). These data were in accordance with the cell biological data on a 
disturbed biosynthetic transport pathway.  
 
Fig. 4-27: EBAG9 delays tumor growth in SCID mice. B6.CB17-Prkdcscid /SzJ homozygous mice were 
temporarily anesthetized and 2x106 MDA-MB435 cells, stably transfected with GFP or EBAG9-GFP, in 100µl 
PBS injected into the mammary fat pad. EBAG9-overexpressing tumors grew much slower than control tumors. 
One representative experiment out of two experiments that were performed. Data are mean tumor volumes ± 
SEM from n = 8 animals per group. Control () and EBAG9 (▲). 
 
4.5 EBAG9 targets selectively COPI-dependent ER-to-Golgi 
transport 
The data obtained thus far in epithelial cells suggested an inhibitory role of EBAG9 in a 
COPI-dependent, ER-to-Golgi trafficking route. However, since the anterograde and 
retrograde transport route are closely connected, Golgi-to-ER transport was investigated as 
well. Trafficking and distribution of KDELr is recognized as a function of a COPI-dependent 
retrograde trafficking route. 
 
4.5.1 KDEL-receptor redistributes towards the ER 
EBAG9-GFP or GFP transiently transfected HeLa cells were incubated for various times at 15 
°C. At this temperature, protein is expected to accumulate in the intermediate compartment 
(Hauri, et al., 2000) and thus also in the ER (Luna, et al., 2002) permitting an investigation of 
retrograde transport only. Cells were fixed and the kinetics of Golgi to ER/IC transport of 
KDELr were monitored by immunofluorescence staining with antibodies against KDELr and 





Fig. 4-28: EBAG9 shifts the steady-state distribution of KDELr towards the ER. (A, B) HeLa cells were 
transiently transfected with EBAG9-GFP or GFP. After 24 h, cells were chased at 15 °C for the times indicated, 
fixed in PFA, permeabilized and stained with antibodies against KDELr (green) and Calnexin (red). (B) Kinetics 
of retrograde transport via COPI vesicles was assessed by determining the Pearson`s correlation coefficient of 
KDELr and Calnexin. Data represent the mean values ± S.D. of 30 cells from three independent experiments. 
Black bars, GFP control; grey bars, EBAG9-GFP. The steady-state level of KDELr in the ER was significantly 
higher in EBAG9 expressing than in control cells. ***p≤ 0,0005; **p≤ 0,05; Student's unpaired t Test. Scale 
bars, 10 µm. 
As expected, KDELr distribution in control cells changed from a predominant Golgi steady-
state distribution (0 min) to a peripheral punctuate staining pattern after a 2 h incubation at  
15 °C. In contrast, in EBAG9-overexpressing cells the steady-state distribution of KDELr was 
already found to be redistributed into punctuate peripheral structures at 0 min (Fig. 4-28 A). 
The Pearson’s correlation coefficient (R) of KDELr and Calnexin was calculated for different 
time points for each cell analysed. This quantitative evaluation revealed increasing R values 
over time in control cells (R = 0.28 at 0 min to R = 0.53 at 120 min), indicating a slow 
accumulation of KDELr in the ER (Fig. 4-28 B), as expected. However, in EBAG9-
overexpressing cells high R values (R = 0.55) at the steady-state level at 0 min pointed 
towards the presence of significant quantities of KDELr in the ER at the beginning of the 
chase. No further increase of ER colocalization was observed, thus precluding an acceleration 
of the retrograde trafficking route. Therefore it could be concluded that KDELr distribution is 
affected by an EBAG9-induced disturbance of the anterograde transport between ER and 
Golgi, rather than by enhanced retrograde transport.  
Additionally, EBAG9 exhibited a compact perinuclear localization corresponding to the Golgi 
apparatus with some surrounding vesicular structures at 0 min (Fig. 4-29). After a temperature 
switch (120 min) to 15 °C, the localization of EBAG9 changed to an intensely dotted Golgi-




proteins that normally recycle between the ER, IC and the Golgi, such as ERGIC or the 
KDELr, accumulate in the IC. These results supported the view that EBAG9 shuttles between 
the ER and the Golgi. 
 
Fig. 4-29: EBAG9 redistributes towards 
the IC at 15°C. HeLa cells were transiently 
transfected with EBAG9-GFP. After 24 h, 
cells were incubated at 15 °C for the 
indicated times, fixed and stained for 
KDELr. Merged images are shown on the 
right, EBAG9 (green) and KDELr (red). 
Scale bars, 10 µm.  
 
4.5.2 Retrograde transport of Shiga-toxin B subunit is not 
disturbed 
To substantiate the specificity and topology of this block, a second retrograde transport route 
was analysed. Transport of Shiga toxin B-fragment (STB), which enters the cell through 
clathrin-independent endocytosis, was shown to reach the ER via a Rab6-dependent pathway 
that appears to be separate from those employed by classic recycling markers, such as the 
KDELr and COPI coated carriers (Girod, et al., 1999; Johannes, 2002). Using confocal 
microscopy and colocalization analysis, kinetics of retrograde transport of STB was found to 
be similar in EBAG9 expressing and control cells (Fig. 4-30). In control as well as in 
EBAG9-overexpressing cells vesicles, containing STB, had entered the cell within 20 min. 
Then, after 60 min STB had reached the Golgi, colocalizing with cis-Golgi marker GM130. 
After 90 min, the toxin had been transported to the IC as indicated by the colocalization with 
ERGIC-53. Finally, at 180 min, STB distributed in a ER like pattern (Calnexin
+
). Thus, 





Fig. 4-30: EBAG9 does not affect retrograde transport of Shiga-toxin B fragment. (A - C) HeLa cells were 
transiently transfected with EBAG9-GFP () or GFP (▲). After 24 h, cells were incubated with cy3-coupled 
Shiga-toxin B-fragment (STB) (red) for 45 min on ice, followed by a chase at 37 °C for the times indicated. 
Cells were fixed in PFA, permeabilized and stained with antibodies against EEA1, GM130, ERGIC-53 or 
Calnexin (blue). Retrograde transport was followed by confocal microscopy analysis. (B, C) Colocalization of 
STB with the markers indicated was determined by calculating the Pearson`s correlation coefficient (data shown 
for GM130 and ERGIC-53). Data represent the mean values ± S.D. of 12 cells from two independent 
experiments. Differences were not significant between EBAG9 and control cells. Scale bars, 10 µm. 
The conserved oligomeric Golgi (COG) complex is thought to function in retrograde vesicular 
trafficking and to influence the expression levels of Golgi resident integral membrane proteins 
(Ungar, et al., 2006). COG-deficient cells have multiple glycosylation defects, similar to 
EBAG9-overexpressing cells. Thus, based on this phenotypic similarity, it was interesting to 
see whether EBAG9 also affected expression levels of proteins that were shown to be COG 
sensitive markers, among them ERGIC-53, or COG insensitive marker proteins. The latter 
included Calnexin, PDI (ER), GM130, P230 (Golgi), and vesicle markers (SNARE molecule 
GS27). In immunoblot analysis, differences between EBAG9-overexpressing and control cells 





Fig. 4-31: Expression levels 
of proteins involved in 
secretory pathway 
functions are undisturbed 
in EBAG9-overexpressing 
cells. (A) Protein lysates 
from equal numbers of 
EBAG9-GFP or control 
stably transfected MDA-
MB435 cells were analysed 
by SDS-PAGE, followed by 
immunoblotting with the 
indicated antibodies. 
Expression levels of ER 
(Calnexin, PDI), IC 
(ERGIC-53), Golgi 
(GM130, P230) and SNARE 
proteins (GS27) were 
indistinguishable between 
EBAG9-overexpressing and 
control cells. Protein bands 
were quantified by 
densitometric scanning and 
are depicted in (B). Data 
represent mean values ± 






4.5.3 Enzymatic processing of ceramide and endosomal uptake 
of transferrin remain unaffected by EBAG9 overexpression 
To strengthen the specificity of the inhibition of COPI-dependent transport by EBAG9 that 
has been observed, the endosomal transport route as well as the transport of ceramide were 
analysed. Cell-surface transferrin receptors deliver transferrin with its bound iron to early 
endosomes by receptor-mediated endocytosis. The low pH in the endosome induces 
transferrin to release its bound iron, but the iron-free transferrin itself (apotransferrin) remains 
bound to its receptor. The receptor-apotransferrin complex enters the tubular extensions of the 
early endosome and from there it is recycled back to the plasma membrane. Here, the 




MB435 cells were incubated with fluorescently labeled transferrin and the uptake was 
followed by FACS for 1 h. After the removal of labeled transferrin and competition with the 
unlabeled version, the recycling of labeled transferrin was retraced and measured as loss of 
cell-associated fluorescence (Fig. 4-32). No difference in the uptake and recycling of 
transferrin was seen between low- and high-EBAG9 expressing cells. 
 
Fig. 4-32: Transferrin uptake and recycling is not impaired upon EBAG9 overexpression. (A) HeLa cells 
were transiently transfected with EBAG9-GFP and incubated with 10 µg/ml Alexa Fluor-633-labeled transferrin 
at 37 °C for 60 min. The recycling phase was induced by briefly washing the cells, followed by competition with 
excessive unlabeled transferrin (10x excess molar ratio). Cells were fixed in 1 % glutaraldehyde/PBS at various 
time points, followed by flow cytometry analysis to determine cell-associated fluorescence activity. Transiently 
transfected HeLa cells were grouped according to their GFP intensity (FL1), and uptake (0-60 min) versus 
recycling values (> 60-120 min) for fluorescently labeled transferrin (FL4) are given according to low, 
intermediate and high EBAG9-GFP levels. Data represent the mean values ± S.D. of five independent 
experiments. No difference in the uptake and recycling of transferrin was seen between low- and high-EBAG9 
expressing cells. Thus, endosomal uptake and recycling are not compromised in the presence of EBAG9. (B) 
EBAG9-GFP and GFP stably transfected MDA-MB435 cells were labeled and analysed as described above. 
Data represent the mean values ± S.D. from three independent experiments. 
From theses data the possibility was excluded that the endosomal uptake and recycling route 
of transferrin was influenced by EBAG9 in epithelial cell lines.  
Similarly, the transport route taken by the fluorescently labeled ceramide analogue BODIPY 
TR C5-ceramide, which is used as a marker for a post-medial Golgi processing, was not 
impaired (Fig. 4-33) (Ktistakis, et al., 1995; Martin and Pagano, 1994). BODIPY TR C5-
ceramide molecules combine an endogenous lipid, ceramide, with a fluorophore moiety 
(BODIPY). Like their cellular counterparts, these molecules are metabolized intracellular to 
fluorescent sphingomyelin and glycosylceramide. Both metabolites are then transported from 




C5-ceramide to the cell surface and its subsequent loss from the cell is a time-dependent 
process which was measured as loss of cell-associated fluorescence by FACS. In both stably 
transfected control and EBAG9-overexpressing cells BODIPY TR C5-ceramide was 
transported at the same rate (Fig. 4-33). 
 
Fig. 4-33: Ceramide transport is not affected by 
EBAG9 overexpression. EBAG9-GFP and GFP 
stably transfected MDA-MB435 cells were 
incubated with BODIPY-TR-C5-ceramide in serum-
free DMEM for 30 min, washed and incubated for 
the indicated time points at 37 °C. Loss of 
fluorescence intensity was measured by FACS. 
There was no difference in kinetics of ceramide 
transport between EBAG9-overexpressing and 
control cells. Data represent mean values ± S.D. of 
three independent experiments.  
Taken together, these data further support the specificity of the EBAG9-imposed transport 
block, which has to occur upstream of ceramide processing and transferrin recycling.  
 
4.6 EBAG9 controls the spatial distribution and function of a 
cis-Golgi localized enzyme 
Subsequently, the spatial distributions of different Golgi enzymes were analysed. Proper 
spatial and functional arrangement of Golgi glycan-modifying enzymes is most important for 
the function of the Golgi complex and the subsequent formation of mature glycoconjugates. 
Mannosidase II (Man II), mainly localized within the cis-Golgi, and β-1-4 
Galactosyltransferase (GalT), a marker for the trans-Golgi, were explored (Brockhausen, 
2006). Both enzymes are involved in N-glycosylation. In contrast, the UDP-N-acetyl-α-D-
galactosamine: polypeptide N Acetyl-galactosaminyl-transferase (GalNAc-T2), located 
predominantly in the medial-Golgi complex (Storrie and Nilsson, 2002), and the UDP-
galactose:glycoprotein-N-acetyl-D-galactosamine 3-β-D-galactosyltransferase (core 1 β3-
Gal-T or T-synthase), localized between the cis-medial Golgi compartment (Brockhausen, 




The T-synthase generates the core 1 disaccharide O-glycan Galβ1-3GalNAcα1-Ser/Thr (T-
antigen, Thomson-Friedenreich antigen), which is a precursor for many extended O-Glycans 
(Ju and Cummings, 2002; Ju, et al., 2002). Loss or downregulation of this protein would 
favour the generation of the Tn-antigen (Ju, et al., 2008; Sewell, et al., 2006). However, this is 
not the only pathway for Tn formation. The human lymphoblastoid T cell line Jurkat has been 
demonstrated to contain higher amounts of inactive T-synthase, which is subject to quick 
ubiquitination and a subsequent degradation by the proteasome (Ju and Cummings, 2002). 
These cells lack T-synthase activity and express the Tn antigen, although they contain a 
normal gene and mRNA encoding the enzyme. Ju and Cummings (2002) demonstrated that a 
mutated chaperone, Cosmc, accounts for the increased amount of inactive T-synthase.   
Hence, the expression of Cosmc was investigated by confocal microscopy. However, no 
difference in the amount or distribution of Cosmc could be found between EBAG9-
overexpressing MDA-MB435 and control cells (Fig. 4-34). 
 
Fig. 4-34: Cosmc expression and distribution is not altered by EBAG9 expression. MDA-MB435 cells 
stably expressing EBAG9-GFP (white) or GFP (not shown) were fixed in cold methanol, permeabilized and 
stained with antibodies against Cosmc (red) and Calnexin (green). Analysis was done by confocal microscopy 
analysis. Scale bars, 5 µm. 
Furthermore, the expression and distribution of either transfected or endogenous T-synthase 
was analysed first by confocal microscopy and subsequently by subcellular fractionation. 
Confocal microscopy revealed no difference in the Golgi distribution of T-synthase in stably 





Fig. 4-35: Distribution of endogenous T-synthase is not affected by EBAG9 overexpression. MDA-MB435 
cells stably expressing EBAG9-GFP (white) or GFP (not shown) were fixed in cold 2 % PFA, permeabilized and 
stained with antibodies against T-synthase (red) and GM130 (green). Analysis was done by confocal microscopy. 
Insets show a higher magnification of the indicated area. Scale bar, 5 µm. 
 
Additionally, the spatial distribution of T-synthase was analysed after 1 h of nocodazole and 
Brefeldin A (BFA) treatment, respectively. After 1 h of nocodazole treatment, T-synthase did 
not colocalize with either the cis-Golgi marker GM130 or the trans-Golgi marker P230 (data 
not shown), but was rather localized throughout the ER, including the nuclear envelope. In 
contrast, EBAG9 had already accumulated in numerous discrete structures distributed 
throughout the cell (Fig. 4-36A). Thus, EBAG9 overexpression had no affect on T-synthase 
redistribution. However, the data also demonstrated that EBAG9 and GM130 redistributed to 
peripheral sites at a much faster rate than the Golgi resident T-synthase. This agrees with Cole 
et al. (1996) showing that itinerant (ERGIC-53) and resident (GalT) Golgi markers 
redistribute at distinct rates and supports our previous results that EBAG9 only transiently 
associated with the Golgi. Similarly, after 1 h of BFA treatment, T-synthase also redistributed 
towards ER-like structures, whereas EBAG9 colocalized with GM130 in non-ER discrete 





Fig. 4-36: Nocodazole or BFA treatment do not reveal an affect of EBAG9 overexpression on T-synthase 
localization. (A, B) MDA-MB435 cells stably expressing EBAG9-GFP (green) or GFP (not shown) were 
transfected with T-synthase-HPC4 (red) and after 48 h of expression nocodazole (10 µM) (B) or BFA (5 µg/ml) 
(B) was added for 1 h. Cells were permeabilized and stained with antibodies against HPC4 and GM130 (blue). 




To test whether active T-synthase might be partially mislocalized, subcellular fractionation of 
T-synthase was applied to separate ER from Golgi membranes (Fig. 4-37A).  
 
Fig. 4-37: Subcellular 
fractionation of T-
synthase transiently 
expressed in Hela cells. 
(A) Hela cells were 
transfected with T-
synthase-HPC4 for 48 h 
and infected with 
adenovirus LacZ 
(control) or EBAG9 for 
18 h. Then the 
postnuclear supernatant 
was fractionated using a 
discontinuous iodixanol 
density gradient. 
Fractions were analysed 
by immunoblot using 
antibodies against 
HPC4, PDI and 
EBAG9. (B) 
Distribution of T-
synthase and PDI in 
adenovirus LacZ or 
EBAG9 infected cells in 
percent. Protein bands 
were quantified by 
densitometric scanning. 
 
The postnuclear supernatant of Hela cells, transfected with T-synthase-HPC4 and infected 
with either EBAG9 or control adenovirus, was fractionated using a discontinuous iodixanol 
density gradient. Due to different densities, cellular components sediment at a position where 
the density of the solution is equal to their own. The buoyant density of subcellular 
membranes in iodixanol gradients increases in the following order: PM < early endosomes < 
Golgi < ERGIC < ER. The fractions collected were then analysed by immunoblot to detect the 
distribution of T-synthase, PDI as an ER marker, and the distribution of EBAG9. However, 




the second corresponding to the ER fraction (higher density, fraction 7-9) (Fig. 4-37B). 
Densitometry analysis showed that the distribution was similar in both LacZ and EBAG9-
overexpressing cells. Recent literature gives evidence that PDI is also found in the rest of the 
endomembrane system, including the Golgi, secretory vesicles, plasma membrane and 
mitochondria (Sun, et al., 2006; Turano, et al., 2002). Separate from the fractionation profile 
of PDI, T-synthase distributed in one main peak corresponding to an ER localization (fraction 
7-9) in both cell lines explored (Fig. 4-37B). However, this distribution might be an artefact of 
T-synthase overexpression, since endogenous T-synthase was predominantly localized to the 
Golgi as shown before (Fig. 4-36A). Furthermore, EBAG9 was found in two major peaks 
(fraction 2-4 and fraction 7-9), which might indicate Golgi/IC and ER localization. This 
agrees with previous results suggesting that EBAG9 shuttles between the ER and the Golgi. 
These results suggested that the function of T-synthase is not influenced by EBAG9 
expression. Currently, it is unknown whether T-synthase is subject to anterograde COPI-
dependent transport processes. 
Likewise, confocal microscopy analysis revealed no difference in the Golgi localization of 
GalT and GalNAc-T2 in EBAG9 expressing and control MDA-MB435 cells (Fig. 4-38A, B).  
 
Fig. 4-38: EBAG9 overexpression affects distribution of mannosidase II, whereas GalT and ppGalNacT2 
remain unaffected. (A) EBAG9-GFP and GFP stably transfected MDA-MB435 cells were transfected with 
GalT-dsRed or GalNacT2-CFP. After 24 h, cells were fixed in PFA and permeabilized, and untransfected cells 
stained with an antibody against mannosidase II (Man II). All cells were costained with GM130 antibody, and  
the distribution of enzymes was analysed by confocal microscopy. Shown is the distribution of the indicated 
enzyme in white. (B) Quantitative analysis of the percentage of cells with predominant ER or Golgi-like staining 
pattern. Data represent the mean values ± S.D. of two (GalT, GalNacT2) or three (Man II) independent 
experiments, in which 50 cells were counted for each experiment. ***p≤ 0,0005; Student's unpaired t Test. Scale 




In contrast, the distribution of the endogenous cis/medial Golgi marker Mannosidase II (Man 
II) (Cole, et al., 1996; Pernet-Gallay, et al., 2002), changed from a Golgi staining pattern 
(GM130
+
) in control cells to a predominant ER-like staining pattern in about 50 % of 
EBAG9-overexpressing cells, indicating a redistribution of Man II towards the ER (Fig. 
4-38A, B). 
Since a correct Golgi localization is indispensable for proper enzymatic activity of these 
enzymes, the consequences of Man II relocalization were investigated in an enzyme assay 
using 4-nitrophenyl-alpha-D-mannopyranoside as substrate. The amount of the enzymatic 
cleavage product 4-Nitrophenol can be determined by spectral absorption at 405 nm. The 
velocity of each reaction was calculated and expressed as Michaelis-Menten-Kinetics. In 
EBAG9-expressing cells, the enzymatic activity of Man II was decreased by 60 % compared 
to control cells (Fig. 4-39).  
 
Fig. 4-39: Mannosidase II activity is reduced in EBAG9-overexpressing cells.  (A) Equal amounts of lysate 
from EBAG9-GFP () and GFP (▲) stably transfected MDA-MB435 cells were incubated with 0, 2, 4, 6, 8, 10 
or 12 mM p-nitrophenyl-alpha-D-mannopyranoside at 37 °C for 0, 30, 60, 90 and 120 min, and the optical 
density of the reaction product was determined at 405 nm. Data show a representative Michaelis-Menten-
Kinetics, determined from the velocity of each reaction and calculated for each concentration over time. Data 
represent the mean values ± SEM of three independent experiments. * p≤ 0,05; Student's unpaired t Test. (B) 
Equal amounts of lysate from EBAG9-GFP () and GFP (▲) stably transfected MDA-MB435 cells were 
incubated with 6 mM p-nitrophenyl-alpha-D-mannopyranoside at 37 °C for 0, 30, 60, 90 and 120 min, and the 
optical density of the reaction product was determined at 405 nm. Data represent the mean values ± SEM of 
three independent experiments. 
Consistently, treatment with siRNA EBAG9 resulted in a significantly increased Man II 
activity. Thus, Man II converted its substrate about 33% faster in siRNA EBAG9 treated cells 





Fig. 4-40: Mannosidase II activity is enhanced by 
EBAG9 depletion. MDA-MB435 were transfected 
with fluorescently labeled siRNA EBAG9 () and 
control siRNA (▲) for 48 h.  Then, MDA-MB435 
cells were lysed in 10 mM KH2PO4 buffer, pH 6.8, 
containing 0.5 % Triton X-100 and 1 mM NaN3 for 
30 min at 4 °C. Protein concentration was 
determined by Bradford assay. For the Mannosidase 
activity assay, 1 mg of protein lysate was incubated 
with 6 mM 4-nitrophenyl-alpha-D-manno-
pyranoside at 37 °C. After 0, 60, 90 and 120 min, 
aliquots were taken and mixed with an equal 
volume of 0.5 M Na2CO3 buffer to terminate the 
enzymatic reaction. Optical density of reaction 
products was measured at 405 nm in a plate reader. 
Shown is the mean of three independent 
experiments. Gradient between 60 and 120 min is 
significantly different. * p≤ 0,05; Student's unpaired 
t Test. 
In summary, these results suggested that EBAG9 shuttles between the ER and the Golgi and 
specifically targets anterograde COPI-dependent processes.  
 
4.7 EBAG9 impairs recruitment of cytosolic GAP to 
membranes 
Mechanistically, the data generated suggested that EBAG9 inhibits anterograde transport by 
interfering with a process prior to fusion and release of vesicles.  
The disassembly of the coatomer complex occurs prior to vesicle tethering and is an essential 
step in the final fusion of Golgi vesicles with target membranes. Disassembly in turn, depends 
on ArfGAP1 which is thought to catalyze Arf1 GTP hydrolysis (Beck, et al., 2009; Liu, et al., 
2005; Spang, 2002). The binding of ArfGAP1 to Golgi membranes is mediated through 
interactions between its noncatalytic domain and the KDELr (Aoe, et al., 1997). Since a 
redistribution of KDELr toward the ER was seen, the distribution of ArfGAP1 by subcellular 
fractionation was determined. The ratio of cytosolic and membrane-bound ArfGAP1 shifted 
toward the cytosol upon EBAG9 overexpression (Fig. 4-41A, B). The increased ArfGAP1 in 
the cytosol reflects its impaired recruitment from the cytosol to membranes and not its 
increased synthesis, since the total pool of ArfGAP did not change upon EBAG9 
overexpression (Fig. 4-41A). In confocal microscopy, an enhanced cytosolic and decreased 





Fig. 4-41: EBAG9 affects the recruitment of cytosolic GAP to membranes. (A, B) Hela cells infected with 
adenovirus EBAG9 or control were analysed for the distribution of ArfGAP1 to membranes or cytosol by 
subcellular fractionation. Cellular fractions (total, cytosolic, membrane) were immunoblotted for ArfGAP1, and 
also for Calnexin as loading control. (B) Quantification was done by densitometric scanning of bands. Shown is 
the ratio of cytosolic and membrane-bound ArfGAP1 of four independent experiments. * p≤ 0,05; Mann-
Whitney U test. A representative blot is shown in (A). (C) Hela cells infected with adenovirus EBAG9 or control 
were fixed after 18 h in methanol, permeabilized, stained with an antibody against ArfGAP1 and analysed by 
confocal microscopy. Shown is the representative distribution of ArfGAP1 in white, n = 30 cells analysed. Scale 
bars, 5 µm. 
Since ArfGAP1 relocalization could impair coat disassembly, the amount of βCOP on 
microsomal membranes was determined. In fact, subcellular fractionation of ΕΒAG9 
expressing cells confirmed a higher amount of βCOP associated with microsomal membranes 
(Fig. 4-42). The increased βCOP represents its impaired dissociation from the microsomal 
membranes and not its increased synthesis, since the total pool of βCOP did not change upon 
EBAG9 overexpression. Both observations, ArfGAP1 and βCOP localization, implicate a 
direct effect of EBAG9 overexpression on the uncoating reaction of COPI vesicles, which is a 






Fig. 4-42: EBAG9 impairs βCOP release from 
microsomal membranes. HeLa cells infected 
with adenovirus EBAG9 or control were 
analysed for the localization of βCOP to 
microsomal membranes or cytosol. Cellular 
fractions (total, cytosolic, microsomal 
membranes) were immunoblotted for βCOP, and 
for Calnexin as loading control. A representative 
blot of two independent experiments performed 
is shown.  
In summary, these results suggested that EBAG9 overexpression, by interfering with the 
distribution of KDELr, impairs GAP recruitment to membranes and thus inhibits the 
dissociation of coat proteins from Golgi structures. This in turn inhibits the fusion of IC-
derived Golgi vesicles with cis-Golgi membranes, a process that results in a delay of COPI-






To gain insight into the pathophysiological function of EBAG9 in view of its role in glycome 
alteration in epithelial cells, the role of EBAG9 in vesicular trafficking was investigated.  
In this work, COPI-dependent vesicular transport processes were identified as a target for 
EBAG9 activity. This interaction resulted in the mislocalization of components of the ER 
quality control and glycosylation machinery in epithelial cell lines. The observations do not 
only add a new molecule involved in the regulation of the secretory pathway in epithelial cell 
types, but also links the modulation of exocytosis with tumor pathogenesis. In several primary 
tumors and tumor cell lines, defects for specific steps in the sequential order of glycosylation 
have been found (Brockhausen, 2006; Whitehouse, et al., 1997). However, these mechanisms 
apply to single, specific tumor entities, and not to others. In contrast, EBAG9 has a 3-to-5-
fold increased level of expression in a multitude of human epithelial cancers compared to 
benign tissues (Akahira, et al., 2004; Ogushi, et al., 2005; Takahashi, et al., 2003; Tsuneizumi, 
et al., 2001). An overexpression model such as that used in the current work could be a 
concern since the transfected gene product might titrate out interacting factors required for the 
activity or transport of other proteins. However, the application of such a system seems 
appropriate to mimic crucial events during tumor cell pathogenesis, since EBAG9 is 
overrepresented but not deleted in tumors. Secondly, from this epidemiological survey it can 
be inferred that EBAG9 overexpression defines a broadly applicable pathogenic principle. 
 
5.1 Characterisation of EBAG9-COPI association 
To address the molecular pathways of by which EBAG9 modulates essential trafficking steps 
in epithelial cell lines, a biochemical interaction screen that had been previously carried out 
was confirmed by co-immunoprecipitation experiments. From several COPI-coat components 
retrieved by the former screen, which included αCOP, γCOP, βCOP, β´COP and δCOP, 
endogenous βCOP was demonstrated to co-immunoprecipitate with EBAG9. This result is 
consistent with a recent proteomics approach where EBAG9 was found in purified COPI 
vesicles (Gilchrist, et al., 2006). The exact contribution of COPI to intra Golgi transport is still 




coated vesicles involved in bidirectional transport, but also in post-Golgi trafficking steps. 
Regarding ER to Golgi trafficking, Scales et al. (1997) and Stephens et al. (2000) have 
demonstrated that after COPII mediated ER exit, subsequent transport is carried out by 
tubulovesicular intermediates that stained also for the COPI coat. In this thesis, EBAG9 has 
been observed in such vesiclular-tubular structures as well, which points towards a function of 
EBAG9 in ER to Golgi transport. Currently, compelling evidence for an important function of 
COPI in ER to Golgi transport exists (Duden, et al., 1994; Hosobuchi, et al., 1992; Pepperkok, 
et al., 1993; Peter, et al., 1993). These authors showed that VSVG transport to the Golgi is 
inhibited by antibodies directed against the βCOP subunit of coatomer. The relation to my 
work on EBAG9 could lie in an association of EBAG9 with βCOP, which has an impact on 
anterograde COPI-dependent transport. This is supported by the fact that EBAG9 colocalizes 
with γCOP on transport vesicles, suggesting that COPI-coated transport carriers are also 
positive for EBAG9. Furthermore, this vesicle population was clearly separate from another 
class of coated vesicles, CCV. On the other hand, EBAG9 was also found on lysosome-like 
vesicles. Most interestingly, Aniento et al. (1996) implicated COPI in transport events into 
and through early endosomes and the maintenance of lysosomal function. This raises the 
question of whether EBAG9 might play a role in post-Golgi trafficking steps as well. In this 
view, EBAG9 would be able to associate with different COPI sub-populations.  
To map a possible interaction site of EBAG9 with endogenous COPI, the association of 
EBAG9 truncation mutants with COPI was investigated. Only the full length protein but none 
of the mutants coimmunoprecipitated with endogenous βCOP. This implies that more than 
one interaction site for EBAG9-βCOP interaction exists or that a certain conformation is 
required for successful interaction. Alternatively, EBAG9 might associate with βCOP via an 
indirect protein-protein interaction or EBAG9 interacts with the assembled COPI coat only. In 
summary, these data indicated that full-length EBAG9 associates with COPI coats in vitro and 






5.2 EBAG9 dynamically associates with the Golgi 
To address the molecular function of EBAG9, its localization and dynamic behaviour was 
investigated in more detail. To this end, pharmacological agents, such as BFA or nocodazole, 
have proven to be powerful tools. The fungal metabolite BFA triggers rapid COPI dissociation 
and reversible redistribution of Golgi enzymes into the ER by inhibiting a guanine nucleotide 
exchange factor (GEF) of ARF-1. On the other hand, matrix proteins, like GM130 or 
GRASP65, are forced to disperse throughout the cytoplasm without merging with the ER 
(Dinter and Berger, 1998). In contrast, nocodazole, a microtubule depolymerising agent, 
causes the Golgi apparatus to break down into functional ministacks that become redistributed 
from the juxtanuclear region to random sites throughout the cytoplasm. Secretory and 
biosynthetic activities of the Golgi apparatus remain remarkably unaffected upon nocodazole 
treatment (Dinter and Berger, 1998). Cole et al. (1996) showed that this is a two-step process. 
First, Golgi membrane components gradually redistribute to ER exit sites upon microtubule 
disruption accompanied by a significant block in secretory trafficking. Subsequently, a 
regeneration of small Golgi stacks in these peripheral sites re-establishes secretory flow from 
the ER to the Golgi and result in “Golgi fragmentation" (Cole, et al., 1996).  
As seen before, EBAG9 colocalized with the cis-Golgi marker GM130 even when the Golgi 
complex was disassembled with nocodazole or BFA (Engelsberg, et al., 2003; Reimer, et al., 
2005). At the same time after treatment, when T-synthase was rather localized throughout the 
ER, including the nuclear envelope, EBAG9 had already accumulated in numerous discrete 
GM130
+
 structures distributed throughout the cell. These data also demonstrated that EBAG9 
and GM130 redistributed to peripheral sites at a much faster rate than the Golgi resident T-
synthase. This agrees with Cole et al (1996) showing that itinerant (ERGIC-53) and resident 
(GalT) Golgi markers redistribute at distinct rates that are comparable to those of EBAG9 and 
T-synthase. Thus, it can be inferred that EBAG9 only transiently associates with the Golgi 
complex. In conclusion, EBAG9 behaves in a way similar to ERGIC-53, which was shown to 
recycle constitutively between the IC and ER (Aridor, et al., 1995; Itin, et al., 1995; 
Lippincott-Schwartz, et al., 1990; Saraste and Svensson, 1991).  
In support of this conclusion, strong colocalization was also obtained with proteins cycling 
between the ER and the Golgi complex, such as ERGIC-53 and KDELr. This observation was 




shown by FRAP analysis, EBAG9 is not stably associated with the Golgi, but rather traffics 
between the ER and the Golgi apparatus. The kinetic behaviour of EBAG9 is similar to 
tagged p58/ERGIC-53 protein (Tisdale, et al., 1997; Ward, et al., 2001). By way of 
comparison, Ward et al. (2001) showed that GalT recovers much slower (50 min) after 
selective photobleaching of the Golgi area, as expected for a Golgi resident protein. In 
contrast, εCOPI recovery was very rapid within 20 s. COPI components are known for their 
binding and release from Golgi membranes. They are recruited from a cytoplasmic pool, a 
process which is very rapid since it does not require any transport intermediates (Presley, et 
al., 1998). This comparison suggests that EBAG9 behaves like ERGIC-53, which was shown 
to reside only transiently at the Golgi complex and recovers within 15 min. Based on the very 
distinct recovery times after photobleaching of Golgi resident, cytoplasmic and cycling 
molecules, it can be inferred that EBAG9 traffics between the ER/IC and the Golgi system.  
This fine-tuned localization analysis under dynamic conditions and the association between 
EBAG9 and COPI, prompted me to explore transport processes between the ER and the Golgi 
complex in more detail.  
 
5.3 EBAG9 is a regulator of the biosynthetic pathway 
5.3.1 EBAG9 influences the anterograde secretory pathway 
While a significant inhibition of constitutive hGH release was found in EBAG9-GFP 
transfectants, this was not the case in neurosecretory PC12 cells. In agreement with a previous 
study (Ruder, et al., 2005), only the regulated release was decreased in these cells. Consistent 
with this observation, the regulated secretion of Granzyme B and A from secretory lysosomes 
was strongly enhanced in EBAG9-deleted cytotoxic T lymphocytes, whereas the constitutive 
pathway remained unaltered (Ruder, et al., 2009). These results implied that EBAG9 
modulates the secretory pathway in a cell type-specific manner, depending on the unique 
composition of the exocytosis machinery. Such promiscuous binding and trafficking 
behaviour was also shown for syntaxin 6 which was found to associate with different partners 
depending on the intracellular compartment and the cell line explored (Wendler and Tooze, 




to function as a GTP-dependent switch between regulated and constitutive secretory pathways 
in neuronal, but not in non-neuronal cell lines (Khvotchev, et al., 2003).  
To exclude the possibility that EBAG9 transfection might cause antigen overload at the Golgi 
complex with subsequent artefacts on cellular transport assays, a Golgi-localized truncation 
mutant was employed. Consistent with its inability to induce truncated O-linked glycan 
formation, this mutant failed to inhibit hGH secretion in mamma carcinoma cells. These 
observations imply that the aberrant expression and intracellular accumulation of glycans in 
EBAG9-overexpressing cells might be related to disturbances within the biosynthetic 
secretory pathway.  
In general, EBAG9 imposed a transport block which exhibited a two-fold decreased in 
kinetics in VSVG Golgi accumulation. Despite the significant delay of apical and basolateral 
targeting of VSVG, rGH and HA in EBAG9-overexpressing polarized cells, no disturbance of 
polarity was detected. Polarized transport mainly diverges at the TGN (Ikonen and Simons, 
1998; Nelson and Yeaman, 2001) and is apparently unaffected by EBAG9. Failure to cause 
alterations in transferrin recycling or transport and the metabolism of BODIPY TR C5-
ceramide supports our contention that EBAG9 overexpression does not impose nonselective 
effects on the secretory or endocytic pathway in epithelial cell lines (Koval and Pagano, 1991; 
Ktistakis, et al., 1995; Martin and Pagano, 1994). However, a delay, but not the complete 
abolishment of transport, might be of functional relevance for short-lived cell surface 
proteins, proteins to be replaced, or proteins to be secreted, such as cytokines and growth 
factors, and also gap junctional proteins and plaques (Berthoud, et al., 2004).  
In support of this functional specificity, siRNA-mediated downregulation of EBAG9 
expression accelerated VSVG transport along the secretory transport route. Hence, EBAG9 
behaves physiologically as a negative regulator of the constitutive secretory pathway in 
epithelial cells. However, the secretion block in EBAG9-overexpressing tumor cells seems to 
be contradictory to the observed accelerated growth kinetics of EBAG9
+
 tumors when 
transplanted into immunocompetent mice. In general, solid tumor progression requires 
secretion of matrix-degrading enzymes, cytokines, and angiogenetic factors for rapid 
expansion (Bergers and Coussens, 2000; Coussens and Werb, 1996; Coussens and Werb, 
2002; Hong, et al., 2009; Johnsen, et al., 1998; Ogushi, et al., 2005; Rak, et al., 1995). 




deficient SCID mice. This is in accordance with the report of Ogushi, Takahashi et al. (2005) 
on the growth kinetics of transfected renal cell carcinoma cells in immunodeficient BALB/c 
nude mice. In this thesis, the growth of EBAG9-overexpressing tumors was retarded, which is 
consistent with the protein transport block that was observed in EBAG9-overexpressing cells 
in vitro. Thus, it can be concluded that the tumor-promoting effect of EBAG9 does not rely on 
autonomy in growth signals, insensitivity to growth-inhibitory signals, evasion of apoptosis or 
a limitless replicative potential typical for many carcinomas (Hanahan and Weinberg, 2000), 
but rather on the suppression of antitumor immunity. In agreement with several reports on a 
modulatory function of altered glycan antigens during T cell recognition or activation (Cudic, 
et al., 2002; Jensen, et al., 2001; Marth and Grewal, 2008; Rubinstein, et al., 2004; Rudd, et 
al., 2001; Tsuboi and Fukuda, 1997; van Kooyk and Rabinovich, 2008), it might be 
hypothesized that EBAG9 modulates the recognition of tumor cells by T lymphocytes that 
attack, most likely by tuning the secretory pathway and subsequently altering the cellular 
glycome, a process commonly referred to as immune evasion.  
.  
5.3.2 EBAG9 selectively affects IC-to-cis Golgi transport 
The delayed acquisition of EndoH resistance of MHC class I molecules revealed the topology 
of the EBAG9-associated transport inhibition. EndoH resistance is acquired as a function of 
enzymes located in the cis-medial Golgi compartment (Tarentino, et al., 1978), thus it can be 
concluded that EBAG9 acts prior to this step. Consistent with a selective effect of EBAG9 on 
an earlier Golgi route, but not on overall Golgi integrity, the TGN- associated sialylation of 
MHC class I heavy chains occurred in the proper manner. The phenotype that was observed 
might be caused either by a direct interaction of EBAG9 with MHC class I-loaded COPI 
vesicles, or alternatively, indirectly by the partial relocalization of Man II, which contributes 
to the synthesis of EndoH resistant glycoproteins. Currently, neither possibility can be 
discounted. However, regarding the interaction of EBAG9 and βCOP, it is interesting to note 
that the injection of βCOP specific antibodies induces VSVG arrest at the interface ER/Golgi 
stack and the inhibition of the acquisition of EndoH resistance, a phenotype comparable to the 




To further dissect the topology of the EBAG9-associated transport block, VSVG transport 
steps between the ER and the IC were analysed. As mentioned before, ER export is mediated 
by vesicles coated with COPII coatamer, which is lost before fusion with the IC. Subsequent 
transport events between the IC and the cis-Golgi are likely to be mediated by a COPI-
dependent step (Bannykh and Balch, 1997; Presley, et al., 1997; Scales, et al., 1997; Stephens, 
et al., 2000). In EBAG9-overexpressing cells, the loading of VSVG-containing cargo and the 
formation of COPII coated vesicles occurred properly. Thus, processes at ER exit sites appear 
to remain unaffected, including vesicle budding and scission. Subsequently, VSVG was found 
in COPI and ERGIC-53 positive structures, which implies that the switch between COPII and 
COPI coat components was undisturbed and the transport of anterograde cargo from the ER 
towards the IC was not inhibited by EBAG9. Therefore, the function of EBAG9 is separate 
from p53/58, which had been proposed to function in the coupled exchange of COPII for 
COPI (Tisdale, et al., 1997). Furthermore, as shown by FRAP analysis, EBAG9 did not 
interfere with the recruitment of cytosolic coatomer components onto Golgi membranes. 
Thus, inhibition of coat assembly seems unlikely, including inhibitory functions on GEFs, as 
has been shown for the enterovirus 3A protein (Wessels, et al., 2006). 
On the other hand, the formation of densely clustered, COPI and VSVG double-positive 
carriers that were still separated from the cis-Golgi marker GM130 suggest that EBAG9 
targets a step in cargo delivery immediately prior to fusion with the cis-Golgi. These 
structures resemble pleiomorphic, tubulo-vesicular ER-to-Golgi carriers (EGCs) or vesicular-
tubular-clusters (VTC), respectively (Marra, et al., 2007; Polishchuk, et al., 2009; Presley, et 
al., 1997). EGCs mature into larger and more homogeneous membrane units, and are destined 
for the incorporation into the cis-Golgi, a process controlled by GM130. It has been shown 
that inhibition of the tethering molecule GM130 delayed anterograde transport of VSVG and 
caused KDELr accumulation in peripheral structures, a phenotype also observed for EBAG9 
overexpression. In contrast to the loss of GM130 function, EBAG9 overexpression does not 
cause a gross modification of Golgi biogenesis. Interestingly, partially uncoated vesicles tend 
to form large aggregates (Rutz, et al., 2009), which is consistent with what can be seen for 
VSVG carriers in the presence of EBAG9.  
Additional insight into EBAG9 behaviour was gained from the regulated cytotoxic response 
of CTLs. As shown by TCR-induced relocalization toward the immunological synapse, the 




with the colocalization between EBAG9 and GM130 and the known polarization of the 
microtubule-organizing center and associated organelles toward the signaling platform at the 
T cell–target cell contact site (Kupfer and Singer, 1989; Stinchcombe, et al., 2001). 
Interestingly, EBAG9 positive organelles surrounded cathepsin D-containing granules. Since 
both compartments did not fuse and the polarization of lytic granules toward the 
immunological synapse was unaltered in Ebag9–/– mice, it appears that vesicle docking and 
tethering are not influenced in CTLs. Provided that similar mechanisms of EBAG9 function 
apply in CTLs and epithelial cells, it can be inferred from these observations that EBAG9 
regulates trafficking steps further upstream in both model systems.  
Taken together, the data presented here suggest that EBAG9 overexpression blocks VSVG 
transport at a step between the IC/ERGIC and cis-Golgi. More specifically, EBAG9 might 
target a step in cargo delivery immediately prior to fusion with the cis-Golgi complex. 
Furthermore, it seems likely that EBAG9 exists in a macromolecular complex with COPI on 
coated carriers. On these carriers, the molecule might interfere with essential COPI 
interactions required for the uncoating reaction and subsequent vesicle tethering and docking. 
 
5.4 Aberrant expression of EBAG9 mislocalizes components of 
the ER quality control and glycosylation machinery in a 
COPI-dependent manner 
In principle, the inhibition of anterograde transport could depend on a disturbance of the 
retrograde route (Bannykh and Balch, 1997; Luna, et al., 2002; Pernet-Gallay, et al., 2002). In 
yeast, defects in anterograde transport due to COPI mutations are thought to be an indirect 
effect of the failure to retrieve an anterograde machinery (Lee, et al., 2004). In the present 
work, the trafficking of two substrates of the retrograde pathway, STB and the KDELr, were 
addressed. While there were no differences in the dynamics of the retrograde transport of the 
STB subunit towards the Golgi and ER in EBAG9-overexpressing and control cells, a 
disturbance of the steady state distribution of KDELr was seen. This difference is best 
explained by a selective effect of EBAG9 on a COPI-dependent transport route. KDELr is 
known to be transported within COPI vesicles (Capitani and Sallese, 2009; Martinez-
Menarguez, et al., 2001) In contrast, STB employs an alternative, Rab6-dependent pathway 




distribution at steady-state conditions was already shifted towards a predominant ER 
localization and was not subject to further relocalization might imply that EBAG9 affects the 
COPI-dependent transport between the ER and Golgi rather than the reverse route. The 
overexpression of the Golgi Microtubule-Associated Protein-210 (GMAP-210) leads to a 
transport phenotype similar to that seen for EBAG9, but an important distinction remains the 
combined effect of GMAP-210 on the anterograde and retrograde route (Pernet-Gallay, et al., 
2002). Alternatively, KDELr is involved in ER quality control through the retrieval of KDEL-
tagged proteins from the IC or cis-Golgi back into the ER. This mechanism ensures that only 
correctly folded proteins are exported from the ER, whereas misfolded proteins are degraded 
by the ERAD pathway (Beck, et al., 2009; Capitani and Sallese, 2009; Yamamoto, et al., 
2001). Yamamoto et al. (2001) demonstrated that a significant amount of unassembled TCR α 
chain is exported from the ER and then returned to the ER from the post-ER compartments by 
retrograde transport. This recycling is mediated by the KDELr, and when interrupted, a high 
amount of TCRα was found to escape ERAD. Thus, retrieval by the KDEL receptor 
contributes to mechanisms by which the ER monitors newly synthesized proteins for their 
proper disposal. In view of the EBAG9-induced accumulation and prolonged resident time of 
premature proteins at the IC/cis-Golgi interface, with a subsequent inhibition of N-linked 
glycan maturation functioning as quality-control tags (Daniels, et al., 2004; Hebert, et al., 
2005; Helenius and Aebi, 2001), it might be possible that by retrieving many of these 
proteins, KDELr itself accumulates in the ER. However, this hypothesis seems unlikely, since 
no degradation of premature MHC class I molecules, uncovered by EndoH treatment, was 
observed over time in EBAG9-overexpressing cells. 
An additional function of KDELr was demonstrated by Aoe et al. (1999). This study showed 
that ligand binding on the luminal side of the KDELr also induces its interaction with 
ARFGAP1 on the cytoplasmic side of the receptor. As a result, ARFGAP1 is recruited from 
the cytosol to the membranes to activate GAP activity on ARF1. Currently, the role of 
ARFGAP1 in COPI vesicle biogenesis is still under debate. On the on hand, it has been 
demonstrated that coat disassembly depends on GTP hydrolysis by ARF1, catalyzed by ARF1 
GTPase-activating proteins (ArfGAPs) (Tanigawa, et al., 1993). This uncoating reaction is a 
prerequisite for vesicle fusion. Reinhard, Schweikert et al. (2003) found that vesicles can be 
formed when liposomes are incubated with ARF1 and coatomer in the presence of GTP only. 




vesicle formation (Reinhard, et al., 2003). Another study reported that GAP activity triggers 
the release of coatomer from liposomal membranes by sensing membrane curvature (Bigay, et 
al., 2003). In contrast to this view, studies from Hsu et al. (2009) have proposed the 
involvement of ArfGAP1 in multiple stages of COPI vesicle formation, including budding, 
cargo selection and fission (Hsu, et al., 2009). Based on in vitro budding assays, Yang, Lee et 
al. (2002) have suggested that ArfGAP1 is an essential and stoichiometric component of the 
coat of Golgi-derived COPI vesicles (Yang, et al., 2002). This role is contrary to reports 
defining the minimal machinery for the formation of COPI vesicles from liposomal 
membranes (Bremser, et al., 1999; Spang, et al., 1998), or from Golgi membranes in the 
absence of cytosol (Beck, et al., 2009; Beck, et al., 2008; Malsam, et al., 2005; Weimer, et al., 
2008). Furthermore, the study of Yang et al. (2002) disagrees that ARFGAP1 acts as an 
uncoating enzyme (Bigay and Antonny, 2005; Reinhard, et al., 2003). In fact, the use of GTP-
γS to block GAP activity in early studies resulted in the stabilization of coatomer on the Golgi 
membrane (Donaldson, et al., 1992; Palmer, et al., 1993). In addition, ArfGAP2/3, but not 
ArfGAP1, was detected on reconstituted COPI vesicles (Frigerio, et al., 2007). Finally, 
individual ArfGAPs, including ArfGAP1, can be depleted from cells without compromising 
cell viability, suggesting that none of these GAPs is an essential coat component (Frigerio, et 
al., 2007; Saitoh, et al., 2009). 
Within this work the recruitment of ArfGAP1 but not COPI onto Golgi membranes was found 
to be impaired by EBAG9 overexpression, arguing against ArfGAP1 as an essential 
component of COPI vesicles. Instead, an increase of the amount of βCOP on microsomal 
membranes points toward an essential function of ArfGAP1 in the disassembly of the coat 
lattice as demonstrated before (Aoe, et al., 1999; Liu, et al., 2005). In this thesis, KDELr 
relocalization had profound consequences, since KDELr regulates ArfGAP1 recruitment onto 
Golgi membranes through interaction with GAP1. Thus, the EBAG9 imposed relocalization 
of KDELr interferes with ArfGAP1 recruitment and subsequently, the lack of ArfGAP1 
activity delays COPI lattice disassembly on membranes, and carriers fail to fuse with their 
target membrane (Fig. 5-1). In agreement, densely clustered VSVG carriers were observed in 
EBAG9-overexpressing cells, resembling large aggregates of partially uncoated vesicles as 
described Rutz et al. (2009).  
At present we cannot definitively say whether KDELr redistribution is the cause or 




scenarios could be envisioned. In the first, KDELr accumulates in the ER by retrieving 
premature proteins as already discussed; in the second overexpressed EBAG9 replaces 
KDELr as a vesicle constituent because of its stoichiometric advantage and KDELr stays 
behind in the ER; in the third, EBAG9 facilitates phosphorylation of KDELr by protein kinase 
A (PKA), which is required for receptor-mediated trafficking from the Golgi to the ER 
(Cabrera, et al., 2003). EBAG9 itself is predicted to exhibit six phosphorylation sites 
(PhosphoSitePlus, 6 predicted phosphorylation sites). Hence, it can be hypothesised that 
EBAG9 might recruit kinases which subsequently phosphorylate KDELr. 
 
Fig. 5-1: EBAG9 impairs ARFGAP1 recruitment to membranes, subsequently interfering with uncoating 
of COPI. Recruitment of coat proteins is initiated by ARF-GDP binding to p23 (1). Upon nucleotide exchange, ARF-
GTP dissociates from p23, resulting in its stable association with the membrane (2). Multiple cycles of GTP hydrolysis and 
GDP to GTP exchange are likely to occur (grey box), possibly causing rearrangements of p23/p24 oligomers (3). The 
products of these processes are ARF-GTP and presumably a p23/p24 heterooligomer, which triggers coatomer binding and 
coat polymerization (4). Following budding (5), the catalytic domain of ARF-GAP is sufficient to trigger uncoating; the 
recruitment of ARFGAP1 to membranes mediated through KDELr is impaired by EBAG9 overexpression (6). Active 
components are shown in green; inactive components are shown in red [modified after (Nickel, et al., 2002)]. 
Furthermore, KDELr exhibits features of a G protein-coupled receptor with some 
characteristics of signalling receptors and was shown to activate a phosphorylation cascade 
that controls intra-Golgi trafficking (Capitani and Sallese, 2009; Pulvirenti, et al., 2008). The 
signal generated by the incoming traffic at the cis-Golgi complex is provided by the 
chaperones that exit the ER during the secretory process, as has been demonstrated for the 
immunoglobulin-binding protein BiP (Yamamoto, et al., 2003). KDELr binding of these 




the Golgi complex, as has been demonstrated by Pulvirenti et al. (2008). These kinases 
positively regulate the intra-Golgi transport machinery. More specifically, it was demonstrated 
that inhibition of Src kinases by chemical agents or siRNA impaired intra-Golgi trafficking. 
The inhibition of KDELr itself had the same impact (Pulvirenti, et al., 2008; Sallese, et al., 
2009). Accordingly, KDELr redistribution to the ER imposed by EBAG9 could provide a 
signal to decelerate the biosynthetic pathway and might amplify the phenotype of constitutive 
transport inhibition.  
Consistent with the suggestion that EBAG9 influences a COPI-dependent transport route, a 
diminished Golgi localization, activity, and redistribution towards the ER was observed for 
the cis/medial Golgi marker Man II in EBAG9-overexpressing epithelial cells. In agreement, 
EBAG9 knockdown increased Man II activity. Since COPI-dependent transport is likely to 
play a role in the correct steady-state distribution of proteins within the Golgi stack (Rabouille 
and Klumperman, 2005; Schmitz, et al., 2008; Tu, et al., 2008), EBAG9 might have a direct 
impact on enzyme localization and activity by interfering with COPI-dependent transport 
processes. 
A shift in distribution was not observed for GalT and GalNAc-T2, which were hypothesized 
to recycle via a COPI-independent pathway (Girod, et al., 1999; Storrie, et al., 1998). In 
contrast, it is largely accepted that Man II employs a COPI-dependent transport route 
(Martinez-Menarguez2001, Lanoix2001). Another O-glycosylating enzyme, T-synthase, and 
its chaperone Cosmc were found to be unaffected by EBAG9 overexpression. However, this 
analysis is not complete. Different mechanisms involving other enzymes may account for 
aberrant gylcosylation in cancer cells (Brockhausen, et al., 1998; Brockhausen, et al., 1995; 
Julien, et al., 2007; Sewell, et al., 2006); therefore a disturbance of O-glycosylating enzymes 
by EBAG9 overexpression could be induced. Glycosylation is a very complex process 
involving dynamically changing pathways whose control mechanisms are poorly understood 
(Brockhausen, 2006). On the other hand, it is not known whether O-glycosylating enzymes 
such as T-synthase are transported via a COPI-dependent anterograde transport route, or what 
amount of time they spend at the Golgi complex. 
These data indicate that EBAG9 overexpression causes a severe interference with the highly 
ordered sequence of enzymatic reactions necessary to catalyze glycan modifications. In spite 




synthesis (Dennis, et al., 1999; Hakomori, 1996; Whitehouse, et al., 1997; Zhang, 2006), to 
my knowledge EBAG9 is the first example of a tumor-associated antigen that interferes with 
the topological hierarchy of glycan-modifying enzymes. Consequently, the spatial 
rearrangement of enzymes may lead to a failure to synthesize essential intermediates, or may 
block further conversions through the premature synthesis of terminal glycan structures. A 
relocalization of a cis-Golgi protein (GM130), as well as the Tn antigen from the Golgi to the 
ER has been observed in human colon cancer cells. It has been suggested that these alterations 
induce abnormal protein or lipid glycosylation (Egea, et al., 1993). 
 
Fig. 5-2: Model of EBAG9 action within the secretory pathway. (A) The involvement of EBAG9 within the 
biosynthetic secretory pathway based on the stable compartment model (Appenzeller-Herzog and Hauri, 2006). 
Newly synthesized proteins, such as VSVG, MHC class I, growth hormone (GH), or Golgi resident proteins, like 
Mannosidase II, undergo anterograde transport and are incorporated into COPII vesicles which bud from the ER 
and move towards the IC, where a switch from COPII to COPI vesicles takes place. From here, tubulo-vesicular 
ER-to-Golgi carriers (EGCs) move toward the cis Golgi in a COPI-dependent manner. The sorting of mature 
proteins destined for lysosomes (Ly), constitutive or signal mediated regulated secretion takes place at the trans-
Golgi-Network (TGN). In the retrograde direction, Golgi resident and pre-mature proteins that possess the C-
terminal signal KDEL are retrieved from the IC/cis-Golgi by the KDEL-Receptor (KDELr), recycling back to 
the ER via retrograde COPI vesicles. The dual functions of COPI might be possible because of the existence of 
different COPI vesicle sub-populations. (B) EBAG9 associates with COPI on anterograde-moving vesicles, fine-
tuning the secretory pathway between the IC and cis-Golgi by negative regulation. Here, it might interfere with 
ArfGAP1 recruitment required for the uncoating reaction and subsequent vesicle tethering and docking. EBAG9 
overexpression, which is likely in some tumors, inhibits the transport of biosynthetic cargoes such as (VSVG), 
(MHCI), growth hormone (GH) or Golgi resident protein Mannosidase II (Man II) at the level of IC/cis-Golgi. 
Thus, Man II is redistributed towards the ER, disturbing the glycosylation of proteins and delaying protein 
maturation. This might also contribute to a block of anterograde cargo transport. Transport inhibition, on the 
other hand, causes proteins to accumulate and prolongs the resident time of premature proteins. Here, KDELr 
functions in retrieving proteins with the KDEL signal as a quality-control mechanism of the secretory pathway 
and might accumulate itself in the ER. Finally, the transport block has global effects on the glycosylation of 
proteins which might cause changes in the migratory, adhesive or invasive behaviour of cells and which might 
suppress anti-tumor immunity, leading to tumor progression.       
In summary (Fig. 5-2), the data in this thesis are in agreement with reports demonstrating that 




(Bannykh and Balch, 1997; Presley, et al., 1997; Scales, et al., 1997). Upon EBAG9 
overexpression in experimental cell lines and potentially in tumor tissues as well, the 
molecule causes the relocalization of KDELr towards the ER. It follows that ArfGAP1 
recruitment to COPI
+
 vesicles is diminished, which leads to partially uncoated vesicles. These 
vesicles tend to form aggregates and are unable to fuse with the cis-Golgi. Subsequently, 
anterograde transport through the Golgi is downregulated. As a result, COPI-dependent cargo, 
including enzymes such as Man II, is strongly affected in localization and activity. This 
relocalization has tremendous consequences for the glycosylation of a wide range of proteins 
and lipids with diverse functions and destinations.   
 
5.5 The evolving understanding of EBAG9 function 
– current views and future prospects 
In recent years EBAG9 has been implicated in several functions, as described in chapter 1.1.3. 
Within this work, novel mechanistic insight into EBAG9 function in epithelial cells is 
provided, since it could be shown that this molecule acts as a negative regulator of the COPI-
dependent anterograde transport pathway (Tab. 9). How does this fit into current concepts on 
EBAG9 function in mammalian cells and in tumor tissues? 
COPI, as one of three known coatamer protein complexes involved in vesicle transport, has 
been shown to play a role not only within the biosynthetic secretory pathway but also within 
the endosomal transport route towards the plasma membrane. Thus, COPI-coated vesicles 
might be as diverse as CCV, where each subpopulation is specialized for a different transport 
step (Boehm and Bonifacino, 2001). Regarding COPI-mediated transport, such diversity 
could arise from different coatomer subcomplexes (Bednarek, et al., 1996; Orci, et al., 1997). 
Since EBAG9 was shown to associate with COPI, which is known to play a role in transport 
steps beyond the Golgi as well, EBAG9 might not only have an impact on COPI-dependent 
biosynthetic transport as demonstrated in this work, but also in post-Golgi trafficking. In fact, 
live-cell imaging of EBAG9-GFP in epithelial cells shows a predominant Golgi staining, but 
also EBAG9 positive vesicles moving throughout the cytoplasm, including even including 
areas close to the plasma membrane. There is evidence for a promiscuous behaviour on the 
part of other proteins of the secretory pathway as well. Syntaxin 6, for example, is found in 




cell lines, secretory granules in PC12 cells, and locations at the plasma membrane in 
neutrophiles, and can associate with multiple partners (Wendler and Tooze, 2001). 
Tab. 9: Recent studies on EBAG9 regarding its cellular function 
Cell type EBAG9 Interaction 
partner 
Phenotype 




overexpression  Accelerated EBAG9 tumor growth; number of 
infiltrating CD8
+
 T lymphocytes was 





Overexpression Snapin Inhibition of regulated, but not constitutive 
secretion; EBAG9 inhibits Snapin 
phosphorylation and subsequently binding to 
SNAP25 








 Suppression of tumor growth and metastasis; 
Strong specific cytotoxic T lymphocyte 
activity and enhanced γ-interferon and 
interleukin-2 production; induction of 
intensive infiltration of CD8
+
 T cells in tumor 
mass 
4T1 cells in Balb/c Overexpression  Faster tumor growth and metastasis 
4T1/T-lymphocyte 
co-culture 
Overexpression  Induction of T cell apoptosis, enhancement of 
glycogen synthase kinase 3" phosphorylation; 
Inhibition of γ-interferon production of T cells; 





Ebag9 KO mice γ2Adaptin Enhanced cytolytic capacity of CTLs; 
enhanced cytolytic primary and memory T cell 
response; EBAG9 involvement in endosomal-
lysosomal biogenesis and membrane fusion 
Epithelial cells *
5
 Overexpression COPI Cell surface expression of truncated O-linked-
glycans Tn and TF; EBAG9 shuttles between 
the ER and cis-Golgi; Delay of constitutive 
ER-to-Golgi transport; regulated secretion 
unaffected; mislocalisation of KDELr and 
ArfGAP1 disturbs COPI uncoating; altered 
distribution and decreased activity of Man II 
 Downregulation 
by siRNA 
 Acceleration of ER-to-Golgi transport, 
increased activity of Man II 
*
1
Ogushi et al. (2005), *
2 
Rüder et al. (2005), *
3
 Hong et al. (2009), *
4
 Rüder et al. (2009), *
5
 Wolf et al. (in 
press) 
 
For this versatility two main properties are necessary: mobility and the ability to bind and 
regulate different proteins. In the case of EBAG9, the dynamic behaviour was not only 




Golgi in epithelial cells, but also during relocalization toward the immunological synapse in 
CTLs upon polarized stimulation. Furthermore, EBAG9 was shown to redistribute toward 
secretory vesicles in nerve growth factor (NGF)-activated neuroendocrine cells in the vicinity 
of the plasma membrane (Ruder, et al., 2005). In support of this flexibility, redistribution of 
EBAG9 in CTLs towards the plasma membrane was demonstrated (Ruder, et al., 2009). The 
mobility of proteins can be achieved by diverse posttranslational modifications, including 
acetylation, methylation and palmitoylation (Bijlmakers, 2009; Zhang and Wang, 2008). The 
latter is a lipid anchor by which proteins are attached to the inner surface of membranes, 
allowing them to become recruited to membranes only when necessary. More specifically, it 
has been demonstrated that the dynamic turnover of palmitate regulates the intracellular 
trafficking of Ras to and from the Golgi (Baekkeskov and Kanaani, 2009; Goodwin, et al., 
2005). Since EBAG9 exhibits a palmitoylation anchor and is subject to phosphorylation, it 
can be suggested that these modifications contribute to EBAG9 relocalization in epithelial as 
well as in T cells. Such a relocalization would also be consistent with the colocalization 
between EBAG9 and GM130, on the one hand, and the polarization of the microtubule-
organizing centre including associated organelles toward the T cell synapse (Ruder, et al., 
2009).  
However, dynamic and promiscuous behaviour could not only be explained by 
posttranslational protein modifications but also by different interaction partners which might 
be similar in sequence and structural motifs. Since the molecular equipment of a cell differs 
depending on its specialized functions, regulatory proteins such as EBAG9 might associate 
with diverse partners in different cell types. EBAG9 has been suggested to play a role in both 
the regulated and constitutive secretion pathways. Similarly, Rab11b has been suggested to 
have diverse functions in neuronal and non-neuronal cells and was shown to function as a 
GTP-dependent switch between the regulated and constitutive secretory pathways 
(Khvotchev, et al., 2003). For EBAG9, different interaction partners involved in different 
transport pathways have been identified. Rüder et al. (2005) have shown that in 
neuroendocrine cells EBAG9 negatively modulated regulated secretion by interacting with 
Snapin. For CTLs it has been suggested that EBAG9 is involved in the endosomal-lysosomal 
transport route (Ruder, et al., 2009). In this cell type, EBAG9 exerted its effects through 
interaction with the adaptor molecule γ2-adaptin, which is normally localized to the cis-Golgi 




enhanced cytolytic capacity through improved Granzyme release, another example of 
regulated secretion. In contrast, in epithelial cells equipped only with a constitutive secretory 
machinery, this pathway was negatively regulated by EBAG9 via COPI association. 
Interestingly, γ2-adaptin and βCOP share structural similarities. Adaptins and COPI are 
distantly related and share 16-21 % identity at the amino acid level (Boehm and Bonifacino, 
2001). The large AP subunits are related to the βCOP and γCOP subunits of COPI, while the 
medium and small AP subunits are related to the δCOP and ζCOP subunits of COPI, 
respectively. γ2-adaptin belongs to the large AP subunits and has been identified as a homolog 
of γ1-adaptin, a constituent of the AP1 complex, which mediates sorting events at the TGN 
and/or endosomes (Boehm and Bonifacino, 2001). However, γ2-adaptin appears to function 
independently of AP1 and γ1-adaptin. Major differences include subcellular localization, a 
lack of dependency on the GTPase ARF1 for recruitment onto TGN membranes (Fig. 5-3), 
and the inability of γ2-adaptin to substitute for the loss of γ1-adaptin in gene-deleted mice. 
Thus, γ2-adaptin may not act as a typical vesicle-forming adaptor, and γ2-adaptin–containing 
AP complexes have not yet been identified (Boehm and Bonifacino, 2001; Bonifacino and 
Lippincott-Schwartz, 2003; Hirst, et al., 2003; McMahon and Mills, 2004; Takatsu, et al., 
1998; Zizioli, et al., 1999). Instead, a sorting function of γ2-adaptin within the endosomal-
lysosomal compartment has been suggested (Rost, et al., 2006). From these publications, it 
might be inferred that the structural similarities between βCOP and the large AP subunits or 
γ2-adaptin, respectively, favour the promiscuous behaviour of EBAG9. However, whether the 
regulatory mechanisms are the same remains to be investigated Whereas BFA treatment 
resulted in impaired recruitment and dissociation of γ1-adaptin (AP1) from TGN, γ2-adaptin 
recruitment to membranes was not inhibited. Thus, the membrane association of γ2-adaptin 
appears to be regulated in a manner different from that of AP-1 and COPI (Takatsu, et al., 
1998). Since EBAG9 affected COPI membrane association through the inhibition of 
ArfGAP1 recruitment, a similar mechanism of EBAG9 on γ2-adaptin-dependent transport 
processes seems unlikely. However, it might be envisioned that EBAG9 influences AP1-
dependent transport processes as well (Fig. 5-3).  
Mechanistically, EBAG9 is not involved in the secretion process at the plasma membrane of 
CTLs itself, but rather acts upstream through the regulation of trafficking steps and the 




EBAG9 will reduce cytolytic capacity by acting at different sites. First, EBAG9 affects the 
efficiency of transport of effector molecules through the secretory pathway at the cis-Golgi 
level. In this context, Vollenweider et al. (1998) demonstrated that the disturbance of ER-
Golgi trafficking had an impact on the targeting of cathepsin C, which is normally destined 
for lysosomes. Alternatively, it has been suggested that EBAG9 acts as a negative regulator of 
vesicle secretion by suppressing cargo transfer, as well as fusion/exocytosis of these vesicles, 
by targeting their partner molecules at the post-Golgi level (Kino and Chrousos, 2009).  
 
Fig. 5-3:  Role of ARF1 for AP1 assembly at the 
TGN. Whereas COP1 and AP1 membrane association 
depends on ArfGAP1, γ2-adaptin recruitment seems to 
be independent of Arf1. Subsequently, EBAG9 might 
influence AP1 mediate transport processes via 
inhibition of KDELr dependent ArfGAP1 recruitment 
and impaired uncoating, as well. For EBAG9 action 
on γ2-adaptin mediated transport processes a different 
mechanism must be supposed. CGN = cis-Golgi 
network, TGN = trans-Golgi network. 
In the concept that has emerged from this thesis, EBAG9 influences the secretory pathway in 
a cell-type-dependent manner. The capacity to shuttle between the ER and the Golgi might 
specifically enable the molecule to act on the COPI-dependent anterograde transport route 
between the IC and the Golgi. In this scenario, EBAG9 targets a step prior to the priming and 
docking of vesicles, and thus prevents fusion and release in epithelial cells. Mechanistically, 
EBAG9 interferes with the uncoating reaction of COPI vesicles prior to fusion with the cis-
Golgi by impairing the recruitment of ArfGAP1 to Golgi membranes (chapter 5.4), which is a 
prerequisite for vesicle docking and finally fusion. Consequently, this activity inhibits not 
only the transport of proteins to be secreted, but leads also to a mislocalization of 
factors/components necessary for ER quality control and glycosylation.  
In order to gain more insight into the molecular processes in which EBAG9 is involved in 
epithelial cells, it might be interesting to investigate whether γ2-adaptin, its interaction partner 
in T cells, influences the constitutive secretory pathway as well. Additionally, the association 
of COPI and EBAG9 could be reconfirmed by applying fluorescence resonance energy 





How can the regulatory role of EBAG9 within the secretory pathway be reconciled with its 
association with tumors?  
Malignant transformation is accompanied by a modulation of the secretory pathway in a 
manner which promotes the development and proliferation of tumors as well as metastasis. 
Thereby, the expression of cell surface molecules is disturbed as well as the synthesis and 
release of a diverse range of growth factors and cytokines. Subsequently, responses to 
apoptotic signals and growth control are lost (Chan and Weber, 2002).  
As has been demonstrated in this study, the deregulation of a transport pathway can have 
extensive consequences. This disturbance can cause the deposition of aberrant glycans on the 
plasma membrane (chapter 1.4); functionally, this alteration may impose a failure of a 
protective T cell immune response. As has been described in chapter 1.1.2, EBAG9 has been 
correlated with tumor progression. In immunocompetent BALB/c mice, EBAG9 
overexpression promoted tumor growth (Hong, et al., 2009; Ogushi, et al., 2005). In this 
thesis, it was shown that in immunodeficient SCID mice, EBAG9 impaired the growth of 
tumor cells, which is in agreement with the observed secretion block. These results in animal 
models raise the question as to why EBAG9 expression significantly correlates with the 
progression of malignant tumors, including breast (Suzuki, et al., 2001), ovarian (Akahira, et 
al., 2004), prostate (Takahashi, et al., 2003), hepatocellular (Aoki, et al., 2003) and renal cell 
carcinomas (Ogushi, et al., 2005). Since it has been shown in immunocompetent BALB/c 
mice that Renca-EBAG9-transfected tumors or bladder cancer EJ-EBAG9 grew significantly 
larger compared to control tumors, it is reasonable to suggest that the tumor-promoting effect 
of EBAG9 might rely on the suppression of or an escape from antitumor immunity (Kumagai, 
et al., 2009; Ogushi, et al., 2005). This hypothesis warrants further verification in 
experimental animal models. Mechanistically, the tumor-promoting effects of EBAG9 might 
rely on tumor suppression caused by modulating cells of the immune system. This modulation 
is putatively linked to altered glycosylation, which itself is caused by an EBAG9-imposed 
inhibition of the biosynthetic transport route. O- and N-glycosylation have been implicated in 
immune system function and diseases (Lowe, 2001; Zhang, 2006) (chapter 1.3.2). More 
specifically, the inactivation of FucT-VII (a1-3-fucosyl-transferase) leads to defects in 
leukocyte trafficking, but to moderate increases in peripheral T cell numbers (Maly, et al., 




activity of E- and P-selectin ligands on neutrophils (Ellies, et al., 1998) and Mgat5 (N-
acetylglucosaminyltransferase V)-null mice exhibit a glomerulonephritis characteristic of 
autoimmune syndromes, and an exaggerated cellular immune response (Granovsky, et al., 
2000). Most strikingly, Rüder et al. (2009) showed that Ebag9–/– mice exhibit a substantially 
stronger cytolytic memory T cell response compared with Ebag9+/+ or naive mice, which 
points towards a modulation of CD8 memory pool by EBAG9. Referring to this observation, 
it was noted that ST3Gal-I-deficient mice show a reduced CTL activity and impaired CD8
+
 
memory T cell formation (Priatel, et al., 2000). Galvan et al. (1998) demonstrated that the 
differentiation of activated effector CD8
+
 T cells occurs with a significant resialylation of core 
1 O-glycans mediated by ST3Gal-I (Galvan, et al., 1998). Furthermore, Hong et al (2009) 
showed that EBAG9 knockdown prolonged the survival of tumor-bearing mice and induced 
more intensive infiltration of CD8
+
 T cells in the tumor. This demonstrates that EBAG9 
facilitates tumor growth the metastasis of experimental murine mammary carcinoma by 
suppressing cytotoxic T cell activity (Hong, et al., 2009). From these studies it might be 
inferred that by interfering with the secretory pathway and consequently glycosylation, 
EBAG9 impairs CD8
+
 T cell function, which contributes to tumor escape.  
In conclusion, EBAG9 interference with the secretory pathway and subsequently 
glycosylation might not only alter the surface of tumor cells, but might also impair T cell 
function at the same time. Both processes could be linked mechanistically through estrogen-
dependent expression of EBAG9 in tumor cells, and in T cells as well. This strategy would 
potentiate the tumor-promoting effect of EBAG9 (Fig. 5-4).  
 
Fig. 5-4: Effect of EBAG9 on 
tumor progression. The impact of 
EBAG9 on glycosylation of on the 
one hand epithelial tumor cells and 
on the other hand cytotoxic T cells, 
would finally potentiate the tumor-




Finally, since tumor cells overexpressing EBAG9 seem to be able to evade the immune 
system, they are more difficult to treat. There is now growing evidence indicating that several 
chemotherapeutic agents as well as radiotherapy are more efficient against tumors that grow 
in immunocompetent hosts as compared to the same tumors growing in immunodeficient 
mice. This might imply that the immune system plays a pivotal role in combating tumors 
(Finn, 2007; Ryan, et al., 2007), and many therapeutic strategies rely on the activation of the 
immune system (Apetoh, et al., 2007; Panaretakis, et al., 2009). Regarding EBAG9 as an 
estrogen-inducible gene (chapter 1.1.2) and its possible impact on the immune system, 
EBAG9 could be particularly important for the development of malignancies under estrogen 
regulation and consequent treatment. EBAG9 expressed in response to elevated levels of 
estrogens in cytotoxic CTLs would provide an essential advantage to the development of 
these tumors, since elevated EBAG9 in these immune cells impairs their cytotoxic activity by 
reducing the formation/exocytosis of secretory lysosomes. In fact, anti-estrogens, such as 
tamoxifen and toremifene, have been demonstrated to augment immune oncolysis by CTLs 
(Baral, et al., 1994). 
 
5.6 Outlook 
In the past, EBAG9 has been used as an independent prognostic marker for disease-specific 
survival, since EBAG9 overexpression significantly correlated with tumor progression in 
several epithelial cancers (Akahira, et al., 2004; Ogushi, et al., 2005; Suzuki, et al., 2004; 
Takahashi, et al., 2003; Tsuneizumi, et al., 2001). Here, the deposition of common tumor-
associated glycan antigens has been demonstrated (Engelsberg, et al., 2003). Functionally, 
those sugars were suggested to contribute to the pathogenesis of tumors through mediation of 
adhesion, invasion and metastasis (Baldus, et al., 2000; Cavallaro and Christofori, 2001; 
Hakomori, 2002; Tsuiji, et al., 2003). Despite its putative role in tumor progression, the 
pathophysiological function of EBAG9 has not yet been well defined. Recently, EBAG9 has 
been introduced as a negative regulator of regulated secretion (Ruder, et al., 2005) and 
implicated in endosomal-lysosomal biogenesis and membrane fusion (Ruder, et al., 2009). 
However, data obtained in these studies could not be reconciled with the effects observed in 
epithelial cell lines, including O-linked glycan generation. So far, little if any attention has 




pathogenesis of tumors. However, the importance of new avenues for cancer treatment by 
discovering novel pathways of tumor progression cannot be overestimated.  
This thesis focuses on the secretory transport pathway, and thereby contributes essential 
insights into human diseases that arise from deregulation of this pathway. Within this work, 
EBAG9 is introduced as a negative regulator involved in COPI-dependent ER-to-Golgi 
transport in epithelial cells. This represents a novel pathogenetic principle which integrates 
hormone-dependent gene expression, the generation of tumor-associated marker molecules, 
vesicle transport and the immune system. So far, the molecular principle of EBAG9 function 
in epithelial cells is understood to some degree, except for the exact molecular mechanism of 
EBAG9 function on COPI vesicles. However, regarding cancer research, the most promising 
direction for future research is to investigate the impact of EBAG9 on the immune system. 
The data presented in this thesis strongly suggest that EBAG9 contributes to tumor escape by 
interfering with the secretory pathway. It is suggested that by interfering with the secretory 
pathway and consequently glycosylation, EBAG9 impairs CD8
+
 T cell functions which 
contributes to tumor escape. However, this hypothesis has to be proved using animal models, 
in studies such as investigations into the phenotype of an EBAG9-overexpressing transgenic 
mouse. In this in vivo approach, the tissue-specific overexpression of EBAG9 in T 
lymphocytes, epithelial colon or mamma cells would be of intense interest. Finally, a detailed 
analysis of N- and O-glycosylating enzymes and changes in surface glycosylation patterns, 
which could be expected to be altered in these mice, would be beneficial. Since the immune 
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